<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN""http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html><head><title>Patent US7307148 - Method for purification of albumin conjugates - Google Patents</title><script>(function(){(function(){function e(a){this.t={};this.tick=function(a,c,b){var d=void 0!=b?b:(new Date).getTime();this.t[a]=[d,c];if(void 0==b)try{window.console.timeStamp("CSI/"+a)}catch(e){}};this.tick("start",null,a)}var a;window.performance&&(a=window.performance.timing);var f=a?new e(a.responseStart):new e;window.jstiming={Timer:e,load:f};if(a){var c=a.navigationStart,d=a.responseStart;0<c&&d>=c&&(window.jstiming.srt=d-c)}if(a){var b=window.jstiming.load;0<c&&d>=c&&(b.tick("_wtsrt",void 0,c),b.tick("wtsrt_",
"_wtsrt",d),b.tick("tbsd_","wtsrt_"))}try{a=null,window.chrome&&window.chrome.csi&&(a=Math.floor(window.chrome.csi().pageT),b&&0<c&&(b.tick("_tbnd",void 0,window.chrome.csi().startE),b.tick("tbnd_","_tbnd",c))),null==a&&window.gtbExternal&&(a=window.gtbExternal.pageT()),null==a&&window.external&&(a=window.external.pageT,b&&0<c&&(b.tick("_tbnd",void 0,window.external.startE),b.tick("tbnd_","_tbnd",c))),a&&(window.jstiming.pt=a)}catch(g){}})();})();
</script><link rel="stylesheet" href="/patents/css/_8a2b04e7bf975d5171d8e4c0b6365c7a/kl_intl_patents_bundle.css" type="text/css" /><script src="/books/javascript/atb_8a2b04e7bf975d5171d8e4c0b6365c7a__en.js"></script><script>function googleTranslateElementInit() {new google.translate.TranslateElement({pageLanguage: "en",gaTrack: true,gaId: "UA-27188110-1",multilanguagePage: true});}</script><script src="//translate.google.com/translate_a/element.js?cb=googleTranslateElementInit"></script><meta name="DC.type" content="Patent"><meta name="DC.title" content="Method for purification of albumin conjugates"><meta name="DC.contributor" content="Nathalie Bousquet-Gagnon" scheme="inventor"><meta name="DC.contributor" content="Omar Quraishi" scheme="inventor"><meta name="DC.contributor" content="Dominique P. Bridon" scheme="inventor"><meta name="DC.contributor" content="Conjuchem Biotechnologies Inc." scheme="assignee"><meta name="DC.date" content="2005-4-22" scheme="dateSubmitted"><meta name="DC.description" content="The present invention relates to a method for separating albumin conjugate from unconjugated albumin in a solution comprising albumin conjugate and unconjugated albumin by loading the solution onto a hydrophobic support equilibrated in aqueous buffer having a high salt content; applying to the support a gradient of decreasing salt concentration; and collecting the eluted albumin conjugate."><meta name="DC.date" content="2007-12-11" scheme="issued"><meta name="DC.relation" content="US:20010018421:A1" scheme="references"><meta name="DC.relation" content="US:20010047084:A1" scheme="references"><meta name="DC.relation" content="US:20020009441:A1" scheme="references"><meta name="DC.relation" content="US:20020018751:A1" scheme="references"><meta name="DC.relation" content="US:20020039999:A1" scheme="references"><meta name="DC.relation" content="US:20020049153:A1" scheme="references"><meta name="DC.relation" content="US:20030073630:A1" scheme="references"><meta name="DC.relation" content="US:20030108567:A1" scheme="references"><meta name="DC.relation" content="US:20030108568:A1" scheme="references"><meta name="DC.relation" content="US:20030170250:A1" scheme="references"><meta name="DC.relation" content="US:20030232754:A1" scheme="references"><meta name="DC.relation" content="US:20040053819:A1" scheme="references"><meta name="DC.relation" content="US:20040127398:A1" scheme="references"><meta name="DC.relation" content="US:20040138100:A1" scheme="references"><meta name="DC.relation" content="US:20040156859:A1" scheme="references"><meta name="DC.relation" content="US:20040248782:A1" scheme="references"><meta name="DC.relation" content="US:20040266673:A1" scheme="references"><meta name="DC.relation" content="US:20050037974:A1" scheme="references"><meta name="DC.relation" content="US:20050065075:A1" scheme="references"><meta name="DC.relation" content="US:4206199" scheme="references"><meta name="DC.relation" content="US:4251631" scheme="references"><meta name="DC.relation" content="US:4423034" scheme="references"><meta name="DC.relation" content="US:4462941" scheme="references"><meta name="DC.relation" content="US:4678671" scheme="references"><meta name="DC.relation" content="US:4745100" scheme="references"><meta name="DC.relation" content="US:4766106" scheme="references"><meta name="DC.relation" content="US:4859604" scheme="references"><meta name="DC.relation" content="US:4902505" scheme="references"><meta name="DC.relation" content="US:5103233" scheme="references"><meta name="DC.relation" content="US:5118666" scheme="references"><meta name="DC.relation" content="US:5120712" scheme="references"><meta name="DC.relation" content="US:5424286" scheme="references"><meta name="DC.relation" content="US:5493007" scheme="references"><meta name="DC.relation" content="US:5545618" scheme="references"><meta name="DC.relation" content="US:5574008" scheme="references"><meta name="DC.relation" content="US:5580853" scheme="references"><meta name="DC.relation" content="US:5612034" scheme="references"><meta name="DC.relation" content="US:5612458" scheme="references"><meta name="DC.relation" content="US:5614487" scheme="references"><meta name="DC.relation" content="US:5614492" scheme="references"><meta name="DC.relation" content="US:5654276" scheme="references"><meta name="DC.relation" content="US:5705483" scheme="references"><meta name="DC.relation" content="US:5725804" scheme="references"><meta name="DC.relation" content="US:5770570" scheme="references"><meta name="DC.relation" content="US:5807827" scheme="references"><meta name="DC.relation" content="US:5840733" scheme="references"><meta name="DC.relation" content="US:5843440" scheme="references"><meta name="DC.relation" content="US:5855866" scheme="references"><meta name="DC.relation" content="US:5869602" scheme="references"><meta name="DC.relation" content="US:5874408" scheme="references"><meta name="DC.relation" content="US:5939390" scheme="references"><meta name="DC.relation" content="US:5942620" scheme="references"><meta name="DC.relation" content="US:5958909" scheme="references"><meta name="DC.relation" content="US:5981488" scheme="references"><meta name="DC.relation" content="US:6005081" scheme="references"><meta name="DC.relation" content="US:6006753" scheme="references"><meta name="DC.relation" content="US:6087375" scheme="references"><meta name="DC.relation" content="US:6103233" scheme="references"><meta name="DC.relation" content="US:6107489" scheme="references"><meta name="DC.relation" content="US:6133235" scheme="references"><meta name="DC.relation" content="US:6191102" scheme="references"><meta name="DC.relation" content="US:6268343" scheme="references"><meta name="DC.relation" content="US:6277583" scheme="references"><meta name="DC.relation" content="US:6277819" scheme="references"><meta name="DC.relation" content="US:6277863" scheme="references"><meta name="DC.relation" content="US:6284725" scheme="references"><meta name="DC.relation" content="US:6329336" scheme="references"><meta name="DC.relation" content="US:6403324" scheme="references"><meta name="DC.relation" content="US:6437092" scheme="references"><meta name="DC.relation" content="US:6440417" scheme="references"><meta name="DC.relation" content="US:6500918" scheme="references"><meta name="DC.relation" content="US:6506724" scheme="references"><meta name="DC.relation" content="US:6514500" scheme="references"><meta name="DC.relation" content="US:6528486" scheme="references"><meta name="DC.relation" content="US:6583111" scheme="references"><meta name="DC.relation" content="US:6593295" scheme="references"><meta name="DC.relation" content="US:6602981" scheme="references"><meta name="DC.relation" content="US:6610825" scheme="references"><meta name="DC.relation" content="US:6660716" scheme="references"><meta name="DC.relation" content="US:6703359" scheme="references"><meta name="DC.relation" content="US:6706689" scheme="references"><meta name="DC.relation" content="US:6706892" scheme="references"><meta name="DC.relation" content="US:6723530" scheme="references"><meta name="DC.relation" content="US:6767887" scheme="references"><meta name="DC.relation" content="US:6821949" scheme="references"><meta name="DC.relation" content="US:6849714" scheme="references"><meta name="DC.relation" content="US:6858576" scheme="references"><meta name="DC.relation" content="US:6861236" scheme="references"><meta name="DC.relation" content="US:6872700" scheme="references"><meta name="DC.relation" content="US:6887470" scheme="references"><meta name="DC.relation" content="US:6887849" scheme="references"><meta name="DC.relation" content="US:6894024" scheme="references"><meta name="DC.relation" content="US:6902744" scheme="references"><meta name="DC.relation" content="US:6924264" scheme="references"><meta name="DC.relation" content="US:6956026" scheme="references"><meta name="DC.relation" content="US:6989366" scheme="references"><meta name="DC.relation" content="US:6998387" scheme="references"><meta name="DC.relation" content="US:7090851" scheme="references"><meta name="DC.relation" content="US:7105508" scheme="references"><meta name="DC.relation" content="US:7112567" scheme="references"><meta name="DC.relation" content="US:7144854" scheme="references"><meta name="DC.relation" content="US:7166695" scheme="references"><meta name="citation_reference" content="Akil et al., &quot;Endogenous Opioids: Biology and Function,&quot; Ann. Rev. Neurosci., 7:223-255 (1984)."><meta name="citation_reference" content="Barragan et al., &quot;Interactions of exendin-(9-39) with the Effects of Glucagon-like Peptide-1-(7-36) Amide and of Exendin-4 on Arterial Blood Pressure and Heart Rate in Rats,&quot; Regulatory Peptides, 67:63-68 (1996)."><meta name="citation_reference" content="Bell et al., &quot;Hamster Preproglucagon Contains the Sequence of Glucagon and Two Related Peptides,&quot; Nature, 302:716-718 (1983)."><meta name="citation_reference" content="Benhar et al., &quot;Pseudomonas Exotoxin A Mutants,&quot; J. Biol. Chem., 269(18):13398-13404 (1994)."><meta name="citation_reference" content="Bergmann et al., &quot;Cationized Serum Albumin Enhances Response of Cultured Fetal Rat Long Bones to Parathyroid Hormone,&quot; Endocrinology, 116(5):1729-1733 (1985)."><meta name="citation_reference" content="Bhargava et al., &quot;Immobilization of Active Urokinase on Albumin Microspheres: Use of a Chemical Dehydrant and Process Monitoring,&quot; Pharmaceutical Research, 9(6):776-781 (1992)."><meta name="citation_reference" content="Breton et al., &quot;Prolonged Half-Life in the Circulation of a Chemical Conjugate Between a Pro-Urokinase Derivative and Human Serum Albumin,&quot; Eur. J. Biochem., 231(3):563-569 (1995)."><meta name="citation_reference" content="Calara et al., &quot;A Randomized, Open-Label, Crossover Study Examining the Effect of Injection Site on Bioavailability of Exentide (Synthetic Exendin-4),&quot; Clin. Ther., 27(2):210-214 (2005)."><meta name="citation_reference" content="Davis et al., &quot;Reduction of immunogenicity and Extension of Circulating Half-Life of Peptides Proteins,&quot; Peptide and Protein Drug Delivery, Lee, V. H. L., ed., Marcel Dekker, Inc., NY, NY; 831-864 (1991)."><meta name="citation_reference" content="Delgado et al., &quot;The Uses and Properties of PEG-Linked Proteins,&quot; Critical Reviews in Therapeutic Drug Carrier Systems, 9(3,4):249-304 (1992)."><meta name="citation_reference" content="Dias-Cabral, A.C. et al. (2003) &quot;Effect of salts and temperature on the adsorption of bovine serum albumin on polypropylene glycol-Sepharose under linear and overloaded chromatographic conditions,&quot; Journal of Chromatography, 1018: 137-153."><meta name="citation_reference" content="Drucker, &quot;Perspectives in Diabetes,&quot; Diabetes, 47(2):159-169 (Feb. 1998)."><meta name="citation_reference" content="Edwards et al., &quot;Exendin-4 Reduces Fasting and Postprandial Glucose and Decreases Energy Intake in Healthy Voluneers,&quot; Am. J. Physiol. Endocrinol. Metab., 281:E155-E161 (2001)."><meta name="citation_reference" content="Edwards et al., &quot;Glucagon-like Peptide 1 Has a Physiological Role in the Control of Postprandial Glucose in Humans,&quot; Diabetes, 48:86-93 (1999)."><meta name="citation_reference" content="Eng et al., &quot;Prolonged Effect of Exendin-4 on Hyperglycemia of db/db Mice,&quot; J. Biol. Chem., 267(11):7402-7405 (1992)."><meta name="citation_reference" content="Eng, &quot;Isolation and Characterization of Exendin-4, an Exendin-3 Analogue, from Heloderma suspecum Venom,&quot; Diabetes, 45:152A (abstract 554) (1996)."><meta name="citation_reference" content="Foa et al., &quot;Glucagon and Other Products of the Proglucagon Gene: Physiology and Possible Role in the Pathogenesis of Disease,&quot; Giomale Italiano Di Diabetologia, 11:(Supplemental)1-42 (1991)."><meta name="citation_reference" content="Francis et al., &quot;PEGylation of Cytokines and other Therapeutic Proteins and Peptides: The Importance of Biological Optimisation of Coupling Techniques,&quot; International Journal of Hematology, 68:1-18 (1998)."><meta name="citation_reference" content="Gombotz et al., &quot;Biodegradable Polymers for Protein and Peptide Drug Delivery,&quot; Bioconjug. Chem., 6:332-351 (1995)."><meta name="citation_reference" content="Goodson et al., &quot;Site-Directed Pegylation of Recombinant Interleukin-2 at Its Glycosylation Site,&quot; Bio/Technology, 8:343-346 (1990)."><meta name="citation_reference" content="Goosen, &quot;Optimization of Microencapsulation Parameters: Semipermeable Microcapsules as a Bioartificial Pancreas,&quot; Biotechnology and Bioengineering, XXVII:146-150 (1985)."><meta name="citation_reference" content="Heinrich et al., &quot;Pre-proglucagon Messenger Ribonucleic Acid: Nucleotide and Encoded Amino Acid Sequences of the Rat Pancreatic Complementary Deoxyribonucleic Acid,&quot; Endocrinology, 115:2176-2181 (1984)."><meta name="citation_reference" content="Hirai et al., &quot;A New Mast Cell Degranulating Peptide &quot;mastoparan&quot; in the Venom of Vespula lewisii,&quot; Chem. Pharm. Bull., 27(8):1942-1944 (1979)."><meta name="citation_reference" content="Holmes, Darren L. et al. (2000) &quot;Site Specific 1:1 Opoid:Albumin conjugate with in Vitro Activity and Long in Vivo Duration,&quot; Bioconjugate Chemistry, 11(4): 439-444."><meta name="citation_reference" content="Hupe-Sodmann et al., &quot;Endoproteolysis of Glucagon-like Peptide (GLP)-1(7-36) amide by Ectopeptidases in RINm5F Cells,&quot; Peptides, 18(5):625-632 (1997)."><meta name="citation_reference" content="Ishikawa et al., &quot;Enzyme-Labeling with Maleimides and Its Application to the Immunoassay of Peptide Hormones,&quot; Enzyme-Labeled Immunoassay of Hormones and Drugs, Walter deGruyter &amp; Co., Berlin, New York, pp. 43-57 (Oct. 7, 1978)."><meta name="citation_reference" content="Isoai et al., &quot;A Potent Anti-Metastatic Activity of Tumor Invasion-Inhibiting Factor-2 and Albumin Conjugate,&quot; Biochem. Biophys. Res. Commun., 192(1):7-14 (1993)."><meta name="citation_reference" content="Jette, Lucie et al. (2005) &quot;Human Growth Hormone-Release Factor (hGRF)1-29- Albumin Bioconjugates Activate the GRF Receptor on the Anterior Pituitary in Rats: Indentification of CJC-1295 as a Long-Lasting GRF Analog,&quot; Endocrinilogy, 146(7): 3052-3058."><meta name="citation_reference" content="Kapas et al., &quot;Cloning and Expression of cDNA Encoding a Rat Adrenomedullin Receptor,&quot; J. Biol. Chem., 270(43):25344-25347 (1995)."><meta name="citation_reference" content="Knusli et al., &quot;Polyethylene Glycol (PEG) Modification of Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Enhances Neutrophil Priming Activity but not Colony Stimulating Activity,&quot; British Journal of Haematology, 82:654-663 (1992)."><meta name="citation_reference" content="Kolodny et al., &quot;A Conjugation of Synthetic Peptides to Proteins: Quantitation from S-Carboxymethylcysteine Released Upn Acid Hydrolysis,&quot; Analytical Biochemistry, 187:136-140 (1990)."><meta name="citation_reference" content="Leger, Roger et al. (2003) &quot;Synthesis and in Vitro Analysis of Atrial Natriuretic Peptide-Albumin Conjugates,&quot; Bioorganic &amp; Medicinal Chemistry Letters 13: 3571-3575."><meta name="citation_reference" content="Leger, Roger et al. (2004) &quot;Identification of CJC-1131-albumin bioconjugate as a stable and bioactive GLP-1(7-36) analog,&quot; Bioorganic &amp; Medicinal Chemistry Letters, 14: 4395-4398."><meta name="citation_reference" content="Lopez et al., &quot;Mammalian Pancreatic Preproglucagon Contains Three Glucagon-related Peptides,&quot; Proc. Natl. Acad. Sci. USA, 80:5485-5489 (1983)."><meta name="citation_reference" content="Mao et al., &quot;Superoxide Dismutase: Improving Its Pharmacological Properties by Conjugation with Human Serum Albumin,&quot; Biomat. Art. Cells, Art. Org., 17(3):229-244 (1989)."><meta name="citation_reference" content="Marburg et al., &quot;Introduction of the Maleimide Function onto Resin-Bound Peptides: A Simple, High Yield Process Useful for Discriminating among Several Lysines,&quot; Bioconjug. Chem., 7:612-616 (1996)."><meta name="citation_reference" content="Mariani, Massimo et al. (Sep. 1998) &quot;A Competitive Enzyme-Linked Immunosorbent Assay for Measuring the Levels of Serum Antibody to Haemophilus influenzae Type b,&quot; Clinical and Diagnostic Laboratory Immunology, 5(5): 667-674."><meta name="citation_reference" content="Meurer et al., &quot;Properties of Native and In Vitro Glycosylated Forms of the Glucagon-like Peptide-1 Receptor Antagonist Exendin (9-39),&quot;Metabolism, 48(6):716-724 (1999)."><meta name="citation_reference" content="Mumby et al., &quot;Antisera of Designed Specificity for Subunits of Guanine Nucleotide-binding Regulatory Proteins,&quot; Proc. Natl. Acad. Sci., 83:265-269 (1986)."><meta name="citation_reference" content="Oren et al., &quot;Mode of Action of Linear Amphipathic alpha-Helical Antimicrobial Peptides,&quot; Biopolymers (Peptide Science), 47:451-463 (1998)."><meta name="citation_reference" content="Paige et al., &quot;Prolonged Circulation of Recombinant Human Granulocyte-Colony Stimulating Factor by Covalent Linkage to Albumin Through a Heterobifunctional Polyethylene Glycol,&quot; Pharm. Res., 12(12): 1883-1888 (1995)."><meta name="citation_reference" content="Patrias et al., &quot;Trimethylaminuria (Fish-Malodor Syndrome) and the Flavin Monooxygenases,&quot; Biotech Report, 106-107 (1994/1995)."><meta name="citation_reference" content="Poznansky et al., &quot;Growth Hormone-Albumin Conjugates Reduced Renal Toxicity and Altered Plasma Clearance,&quot; FEBS Letters, 239(1):18-22 (1988)."><meta name="citation_reference" content="Poznansky, &quot;Enzyme-Protein Conjugates: New Possibilities for Enzyme Therapy,&quot; Pharmac. Ther., 21:53-76 (1983)."><meta name="citation_reference" content="Qu et al., &quot;A Role for Melanin-Concentrating Hormone in the Central Regulation of Feeding Behaviour,&quot; Nature, 380:243-247 (1996)."><meta name="citation_reference" content="Raufman, &quot;Bioactive Peptides from Lizard Venoms,&quot; Regulatory Peptides, 61:1-18 (1996)."><meta name="citation_reference" content="Reubi et al., &quot;Specific High Affinity Binding Sites for Somatostatin-28 on Pancreatic beta-Cells: Differences with Brain Somatostatin Receptors,&quot; Endocrinology, 110(3):1049-1051 (1982)."><meta name="citation_reference" content="Ringsdorf, &quot;Structure and Properties of Pharmacologically Active Polymers,&quot; J. Polymer Sci. Symposium No. 51, pp. 135-153 (1975)."><meta name="citation_reference" content="Ritzel et al., &quot;A Synthetic Glucagon-like Peptide-1 Analog with Improved Plasma Stability,&quot; Journal of Endocrinology, 159:93-102 (1998)."><meta name="citation_reference" content="Robberecht et al., &quot;Immunoreactive Helodermin-like Peptides in Rat: A New Class of Mammalian Neuropeptides Related to Secretin and VIP,&quot; Biochem. Biophys. Res. Commun., 130(1):333-342 (1985)."><meta name="citation_reference" content="Ruiz-Grande et al., &quot;Lipolytic Action of Glucagon-like Peptides in Isolated Rat Adipocytes,&quot; Peptides, 13(1)13-16 (1992)."><meta name="citation_reference" content="Santiago, &quot;Incidence of IDDM and Frequency of the DQbeta1 and DQalpha1,&quot; Diabetes, Abstract book, 56&lt;SUP&gt;th &lt;/SUP&gt;Annual Meeting and Scientific Sessions, 847 (Jun. 8-11, 1996)."><meta name="citation_reference" content="Schirra et al., &quot;Exendin(9-39)amide is an Antagonist of Glucagon-like Peptide-1(7-36)amide in Humans,&quot; J. Clin. Invest., 101(7):1421-1430 (1998)."><meta name="citation_reference" content="Selkoe, &quot;Physiological Production of the beta-Amyloid Protein and the Mechanism of Alzheimer&#39;s Disease,&quot; TINS, 16(10):403-409 (1993)."><meta name="citation_reference" content="Siegel et al., &quot;Biological Activity of GLP-1 Analogues with N-Terminal Modifications,&quot; Regulatory Peptides, 79(23):93-102 (1999)."><meta name="citation_reference" content="Smith et al., &quot;Atrial Natriuretic Factor During Fetal and Postnatal Life: A Review,&quot; J. Dev. Physiol., 12:55-62 (1989)."><meta name="citation_reference" content="Stehle et al., &quot;The Loading Rate Determines Tumor Targeting Properties of Methotrexate-Albumin Conjugates in Rats,&quot; Anti-Cancer Drugs, 8:677-685 (1997)."><meta name="citation_reference" content="Syed et al., &quot;Potent Antithrombin Activity and Delayed Clearance from the Circulation Characterize Recombinant Hirudin Genetically Fused to Albumin,&quot; Blood, 89(9):3243-3252 (1997)."><meta name="citation_reference" content="Thibaudeau, Karen et al. (2005) &quot;Synthesis and Evaluation of Insulin-Human Serum Albumin Conjugates,&quot; Bioconjugate Chem., 16: 1000-1008."><meta name="citation_reference" content="Thim et al., &quot;Molecules in Focus: CART, a New Anorectic Peptide,&quot; Int. J. Biochem. Cell. Biol., 30:1281-1284 (1998)."><meta name="citation_reference" content="Turton et al., &quot;A Role for Glucagon-like-Peptide-1 in the Central Regulation of Feeding,&quot; Nature, 379:69-72 (1996)."><meta name="citation_reference" content="U.S. Appl. No. 09/623,533, filed Sep. 5, 2000, Boudjellab et al."><meta name="citation_reference" content="U.S. Appl. No. 09/623,533, filed Sep. 5, 2000, Bridon et al."><meta name="citation_reference" content="U.S. Appl. No. 09/623,543, filed Sep. 5, 2000, Beliveau et al."><meta name="citation_reference" content="U.S. Appl. No. 09/623,543, filed Sep. 5, 2000, Bridon et al."><meta name="citation_reference" content="U.S. Appl. No. 09/657,336, filed Sep. 7, 2000, Boudjellab et al."><meta name="citation_reference" content="U.S. Appl. No. 09/657,431, filed Sep. 7, 2000, Beliveau et al."><meta name="citation_reference" content="U.S. Appl. No. 11/040,810, filed Jan. 21, 2005, Bakis et al."><meta name="citation_reference" content="U.S. Appl. No. 11/066,697, filed Feb. 25, 2005, Bridon et al."><meta name="citation_reference" content="U.S. Appl. No. 11/067,556, filed Feb. 25, 2005, Bidon et al."><meta name="citation_reference" content="Vilaseca et al., &quot;Proteins Conjugates of Defined Structure: Synthesis and Use of a New Carrier Molecule,&quot; Bioconjug. Chem., 4:515-520 (1993)."><meta name="citation_reference" content="Yeh et al., &quot;Design of Yeast-Secreted Albumin Derivatives for Human Therapy: Biological and Antiviral Properties of a Serum Albumin-CD4 Genetic Conjugate,&quot; Proc. Natl. Acad. Sci. USA, 89:1904-1908 (1992)."><meta name="citation_reference" content="Young et al., &quot;Glucose-Lowering and Insulin-Sensitizing Actions of Exendin-4,&quot; Diabetes, 48:1026-1034 (1999)."><meta name="citation_reference" content="Zalipsky, &quot;Functionalized Poly(ethylene glycol) for Preparation of Biologically Relevent Conjugates,&quot; Bioconjug. Chem., 6:150-165 (1995)."><meta name="citation_reference" content="Zegers et al., &quot;An Improved Conjugation Method for Controlled Covalent Coupling of Synthetic Peptides to Proteins Using Glutaraldehyde in a Dialysis Method,&quot; Journal of Immunological Methods, 130:195-200 (1990)."><meta name="citation_patent_number" content="US:7307148"><meta name="citation_patent_application_number" content="US:11/112,277"><link rel="canonical" href="http://www.google.com/patents/US7307148"/><meta property="og:url" content="http://www.google.com/patents/US7307148"/><meta name="title" content="Patent US7307148 - Method for purification of albumin conjugates"/><meta name="description" content="The present invention relates to a method for separating albumin conjugate from unconjugated albumin in a solution comprising albumin conjugate and unconjugated albumin by loading the solution onto a hydrophobic support equilibrated in aqueous buffer having a high salt content; applying to the support a gradient of decreasing salt concentration; and collecting the eluted albumin conjugate."/><meta property="og:title" content="Patent US7307148 - Method for purification of albumin conjugates"/><meta property="og:type" content="book"/><meta property="og:site_name" content="Google Books"/><meta property="og:image" content="http://www.google.com/patents?id=&amp;printsec=frontcover&amp;img=1&amp;zoom=1"/><link rel="image_src" href="http://www.google.com/patents?id=&amp;printsec=frontcover&amp;img=1&amp;zoom=1"/><script>(function(){try{var aa=function(a,b,c,d){d=d||{};d._sn=["cfg",b,c].join(".");window.gbar.logger.ml(a,d)};var g=window.gbar=window.gbar||{},l=window.gbar.i=window.gbar.i||{},m={},n;function _tvn(a,b){var c=parseInt(a,10);return isNaN(c)?b:c}function _tvf(a,b){var c=parseFloat(a);return isNaN(c)?b:c}function _tvv(a){return!!a}function p(a,b,c){(c||g)[a]=b}g.bv={n:_tvn("2",0),r:"",f:".67.",e:"0",m:_tvn("0",1)};
function q(a,b,c){var d="on"+b;if(a.addEventListener)a.addEventListener(b,c,!1);else if(a.attachEvent)a.attachEvent(d,c);else{var f=a[d];a[d]=function(){var a=f.apply(this,arguments),b=c.apply(this,arguments);return void 0==a?b:void 0==b?a:b&&a}}}var s=function(a){return function(){return g.bv.m==a}},ba=s(1),ca=s(2);p("sb",ba);p("kn",ca);l.a=_tvv;l.b=_tvf;l.c=_tvn;l.i=aa;var da=window.gbar.i.i;var t,u,v,w;function ea(a){v=a}function fa(a){var b;if(b=v&&window.encodeURIComponent)b=a.href,b=!b.match(/^http[s]?:\/\/accounts\.google\.[^/]*\/ClearSID/i)&&!b.match(/^http[s]?:\/\/[^/]*\/accounts\/ClearSID/i);if(b=b&&encodeURIComponent(v()))a.href=a.href.replace(/([?&]continue=)[^&]*/,"$1"+b)}function ga(a){window.gApplication&&(a.href=window.gApplication.getTabUrl(a.href))}
function ha(a){var b=document.forms[0].q,c=window.encodeURIComponent&&b&&b.value,b=b&&b.placeholder;c&&c!=b&&(a.href=a.href.replace(/([?&])q=[^&]*|$/,function(a,b){return(b||"&")+"q="+encodeURIComponent(c)}))}n=l.a("")?ga:ha;
function x(a,b,c,d,f,e){var h=document.getElementById(a);if(h){var k=h.style;k.left=d?"auto":b+"px";k.right=d?b+"px":"auto";k.top=c+"px";k.visibility=u?"hidden":"visible";f&&e?(k.width=f+"px",k.height=e+"px"):(x(t,b,c,d,h.offsetWidth,h.offsetHeight),u=u?"":a)}}
var y=[],ia=function(a,b){y.push(b)},ja=function(a){a=a||window.event;var b=a.target||a.srcElement;a.cancelBubble=!0;null==t&&(a=document.createElement(Array.every||window.createPopup?"iframe":"div"),a.frameBorder="0",t=a.id="gbs",a.src="javascript:''",b.parentNode.appendChild(a),q(document,"click",z));var c=b,b=0;"gb3"!=c.className&&(c=c.parentNode);a=c.getAttribute("aria-owns")||"gbi";var d=c.offsetWidth,f=20<c.offsetTop?46:24;document.getElementById("tphdr")&&(f-=3);var e=!1;do b+=c.offsetLeft||
0;while(c=c.offsetParent);var c=(document.documentElement.clientWidth||document.body.clientWidth)-b-d,h,d=document.body,k=document.defaultView;k&&k.getComputedStyle?(d=k.getComputedStyle(d,""))&&(h=d.direction):h=d.currentStyle?d.currentStyle.direction:d.style.direction;h="rtl"==h;if("gbi"==a){for(d=0;k=y[d++];)k();A(null,window.navExtra);h&&(b=c,e=!0)}else h||(b=c,e=!0);u!=a&&z();x(a,b,f,e)},z=function(){u&&x(u,0,0)},A=function(a,b){var c,d=document.getElementById("gbi"),f=a;f||(f=d.firstChild);
for(;b&&(c=b.pop());){var e=d,h=c,k=f;w||(w="gb2");e.insertBefore(h,k).className=w}},ka=function(a,b,c){if((b=document.getElementById(b))&&a){a.className="gb4";var d=document.createElement("span");d.appendChild(a);d.appendChild(document.createTextNode(" | "));d.id=c;b.appendChild(d)}},la=function(){return document.getElementById("gb_70")},ma=function(){return!!u};p("qs",n);p("setContinueCb",ea);p("pc",fa);p("tg",ja);p("close",z);p("addLink",ka);p("almm",A);p("si",la);p("adh",ia);p("op",ma);var B=function(){},C=function(){},F=function(a){var b=new Image,c=D;b.onerror=b.onload=b.onabort=function(){try{delete E[c]}catch(a){}};E[c]=b;b.src=a;D=c+1},E=[],D=0;p("logger",{il:C,ml:B,log:F});var G=window.gbar.logger;var H={},na={},I=[],oa=l.b("0.1",.1),pa=l.a("1",!0),qa=function(a,b){I.push([a,b])},ra=function(a,b){H[a]=b},sa=function(a){return a in H},J={},K=function(a,b){J[a]||(J[a]=[]);J[a].push(b)},ta=function(a){K("m",a)},L=function(a,b){var c=document.createElement("script");c.src=a;c.async=pa;Math.random()<oa&&(c.onerror=function(){c.onerror=null;B(Error("Bundle load failed: name="+(b||"UNK")+" url="+a))});(document.getElementById("xjsc")||document.getElementsByTagName("body")[0]||
document.getElementsByTagName("head")[0]).appendChild(c)},N=function(a){for(var b=0,c;(c=I[b])&&c[0]!=a;++b);!c||c[1].l||c[1].s||(c[1].s=!0,M(2,a),c[1].url&&L(c[1].url,a),c[1].libs&&m.d&&m.d(c[1].libs))},O=function(a){K("gc",a)},P=null,ua=function(a){P=a},M=function(a,b,c){if(P){a={t:a,b:b};if(c)for(var d in c)a[d]=c[d];try{P(a)}catch(f){}}};p("mdc",H);p("mdi",na);p("bnc",I);p("qGC",O);p("qm",ta);p("qd",J);p("lb",N);p("mcf",ra);p("bcf",qa);p("aq",K);p("mdd","");p("has",sa);
p("trh",ua);p("tev",M);var Q=l.b("0.1",.001),R=0;
function _mlToken(a,b){try{if(1>R){R++;var c,d=a,f=b||{},e=encodeURIComponent,h=["//www.google.com/gen_204?atyp=i&zx=",(new Date).getTime(),"&jexpid=",e("17483"),"&srcpg=",e("prop=22"),"&jsr=",Math.round(1/Q),"&ogev=",e("9VPsU7zaEuvJsQSS3IG4CA"),"&ogf=",g.bv.f,"&ogrp=",e("1"),"&ogv=",e("1407723702.0"),"&oggv="+e("es_plusone_gc_20140723.0_p0"),"&ogd=",e("com"),"&ogc=",e("CZE"),"&ogl=",e("en")];f._sn&&(f._sn="og."+
f._sn);for(var k in f)h.push("&"),h.push(e(k)),h.push("="),h.push(e(f[k]));h.push("&emsg=");h.push(e(d.name+":"+d.message));var r=h.join("");S(r)&&(r=r.substr(0,2E3));c=r;var Aa=window.gbar.logger._aem(a,c);F(Aa)}}catch(Na){}}var S=function(a){return 2E3<=a.length},va=function(a,b){return b};function T(a){B=a;p("_itl",S,G);p("_aem",va,G);p("ml",B,G);a={};H.er=a}l.a("")?T(function(a){throw a;}):l.a("1")&&Math.random()<Q&&T(_mlToken);I.push(["m",{url:"//ssl.gstatic.com/gb/js/scm_7385cc5883250b43a39405734c1bea59.js"}]);g.mcf("c",{});g.sg={c:""};if(l.a("1")){var wa=l.a("");I.push(["gc",{auto:wa,url:"//ssl.gstatic.com/gb/js/abc/gci_91f30755d6a6b787dcc2a4062e6e9824.js",libs:"googleapis.client:plusone:gapi.iframes"}]);var xa={version:"gci_91f30755d6a6b787dcc2a4062e6e9824.js",index:"",lang:"en"};H.gc=xa;var U=function(a){window.googleapis&&window.iframes?a&&a():(a&&O(a),N("gc"))};p("lGC",U);l.a("1")&&p("lPWF",U)};window.__PVT="";if(l.a("1")&&l.a("1")){var V=function(a){U(function(){K("pw",a);N("pw")})};p("lPW",V);I.push(["pw",{url:"//ssl.gstatic.com/gb/js/abc/pwm_45f73e4df07a0e388b0fa1f3d30e7280.js"}]);var W=[],ya=function(a){W[0]=a},za=function(a,b){var c=b||{};c._sn="pw";B(a,c)},Ba={signed:W,elog:za,base:"https://plusone.google.com/u/0",loadTime:(new Date).getTime()};H.pw=Ba;var X=function(a,b){for(var c=b.split("."),d=function(){var b=arguments;a(function(){for(var a=g,d=0,e=c.length-1;d<e;++d)a=a[c[d]];a[c[d]].apply(a,b)})},f=g,e=0,h=c.length-1;e<h;++e)f=
f[c[e]]=f[c[e]]||{};return f[c[e]]=d};X(V,"pw.clk");X(V,"pw.hvr");p("su",ya,g.pw)};function Ca(){function a(){for(var b;(b=e[h++])&&"m"!=b[0]&&!b[1].auto;);b&&(M(2,b[0]),b[1].url&&L(b[1].url,b[0]),b[1].libs&&m.d&&m.d(b[1].libs));h<e.length&&setTimeout(a,0)}function b(){0<f--?setTimeout(b,0):a()}var c=l.a("1"),d=l.a(""),f=3,e=I,h=0,k=window.gbarOnReady;if(k)try{k()}catch(r){da(r,"ml","or")}d?p("ldb",a):c?q(window,"load",b):b()}p("rdl",Ca);var Da={D:1,H:2,da:3,p:4,W:5,M:6,F:7,g:8,ha:9,U:10,L:11,T:12,S:13,N:14,Q:15,P:16,fa:17,w:18,O:19,ga:20,ea:21,u:22,G:23,ja:24,ka:25,ia:26,A:27,j:28,o:29,k:30,ca:31,Z:32,$:33,J:34,K:35,ba:36,aa:37,Y:38,B:39,R:40,v:41,X:42,V:43,h:48,C:49,I:500},Y=[1,2,3,4,5,6,9,10,11,13,14,28,29,30,34,35,37,38,39,40,41,42,43,48,49,500];var Z=l.b("0.001",1E-4),Ea=l.b("1",1),Fa=!1,Ga=!1;if(l.a("1")){var Ha=Math.random();Ha<=Z&&(Fa=!0);Ha<=Ea&&(Ga=!0)}var Ia=Da,$=null;function Ja(){var a=0,b=function(b,d){l.a(d)&&(a|=b)};b(1,"");b(2,"");b(4,"");b(8,"");return a}
function Ka(a,b){var c=Z,d=Fa,f;f=a;if(!$){$={};for(var e=0;e<Y.length;e++){var h=Y[e];$[h]=!0}}if(f=!!$[f])c=Ea,d=Ga;if(d){d=encodeURIComponent;g.rp?(f=g.rp(),f="-1"!=f?f:"1"):f="1";c=["//www.google.com/gen_204?atyp=i&zx=",(new Date).getTime(),"&oge=",a,"&ogex=",d("17483"),"&ogev=",d("9VPsU7zaEuvJsQSS3IG4CA"),"&ogf=",g.bv.f,"&ogp=",d("22"),"&ogrp=",d(f),"&ogsr=",Math.round(1/c),"&ogv=",d("1407723702.0"),"&oggv="+
d("es_plusone_gc_20140723.0_p0"),"&ogd=",d("com"),"&ogl=",d("en"),"&ogc=",d("CZE"),"&ogus=",Ja()];if(b){"ogw"in b&&(c.push("&ogw="+b.ogw),delete b.ogw);var k;f=b;e=[];for(k in f)0!=e.length&&e.push(","),e.push(La(k)),e.push("."),e.push(La(f[k]));k=e.join("");""!=k&&(c.push("&ogad="),c.push(d(k)))}F(c.join(""))}}function La(a){"number"==typeof a&&(a+="");return"string"==typeof a?a.replace(".","%2E").replace(",","%2C"):a}C=Ka;p("il",C,G);var Ma={};H.il=Ma;setTimeout(function(){C(Ia.g)},0);}catch(e){window.gbar&&gbar.logger&&gbar.logger.ml(e,{"_sn":"cfg.init"});}})();
(function(){try{var b=window.gbar.i.i;var c=window.gbar;var f=function(d){try{var a=document.getElementById("gbom");a&&d.appendChild(a.cloneNode(!0))}catch(e){b(e,"omas","aomc")}};c.aomc=f;}catch(e){window.gbar&&gbar.logger&&gbar.logger.ml(e,{"_sn":"cfg.init"});}})();
(function(){try{var a=window.gbar;a.mcf("pm",{p:""});}catch(e){window.gbar&&gbar.logger&&gbar.logger.ml(e,{"_sn":"cfg.init"});}})();
(function(){try{window.gbar.rdl();}catch(e){window.gbar&&gbar.logger&&gbar.logger.ml(e,{"_sn":"cfg.init"});}})();
if (window['_OC_timingAction']) {window['_OC_timingAction']('patents_refpage');}</script><style>#gbar,#guser{font-size:13px;padding-top:1px !important;}#gbar{float:left;height:22px}#guser{padding-bottom:7px !important;text-align:right}.gbh,.gbd{border-top:1px solid #c9d7f1;font-size:1px}.gbh{height:0;position:absolute;top:24px;width:100%}#gbs,.gbm{background:#fff;left:0;position:absolute;text-align:left;visibility:hidden;z-index:1000}.gbm{border:1px solid;border-color:#c9d7f1 #36c #36c #a2bae7;z-index:1001}.gb1{margin-right:.5em}.gb1,.gb3{zoom:1}.gb2{display:block;padding:.2em .5em}.gb2,.gb3{text-decoration:none !important;border-bottom:none}a.gb1,a.gb4{text-decoration:underline !important}a.gb1,a.gb2,a.gb3,a.gb4{color:#00c !important}.gbi .gb3,.gbi .gb2,.gbi .gb4{color:#dd8e27 !important}.gbf .gb3,.gbf .gb2,.gbf .gb4{color:#900 !important}a.gb2:hover{background:#36c;color:#fff !important}#gbar .gbz0l{color:#000 !important;cursor:default;font-weight:bold;text-decoration:none !important}
#gbar { padding:.3em .6em !important;}</style></head><body  topmargin="3" marginheight="3"><div id=gbar><nobr><a onclick=gbar.qs(this);gbar.logger.il(1,{t:1}); class=gb1 id=gb_1 href="https://www.google.com/search?sa=N&tab=tw">Search</a> <a onclick=gbar.qs(this);gbar.logger.il(1,{t:2}); class=gb1 id=gb_2 href="http://www.google.com/search?hl=en&tbm=isch&source=og&sa=N&tab=ti">Images</a> <a onclick=gbar.qs(this);gbar.logger.il(1,{t:8}); class=gb1 id=gb_8 href="http://maps.google.com/maps?hl=en&sa=N&tab=tl">Maps</a> <a onclick=gbar.qs(this);gbar.logger.il(1,{t:78}); class=gb1 id=gb_78 href="https://play.google.com/?hl=en&sa=N&tab=t8">Play</a> <a onclick=gbar.qs(this);gbar.logger.il(1,{t:36}); class=gb1 id=gb_36 href="http://www.youtube.com/results?sa=N&tab=t1">YouTube</a> <a onclick=gbar.logger.il(1,{t:5}); class=gb1 id=gb_5 href="http://news.google.com/nwshp?hl=en&tab=tn">News</a> <a onclick=gbar.logger.il(1,{t:23}); class=gb1 id=gb_23 href="https://mail.google.com/mail/?tab=tm">Gmail</a> <a onclick=gbar.logger.il(1,{t:25}); class=gb1 id=gb_25 href="https://drive.google.com/?tab=to">Drive</a> <a class=gb3 href="http://www.google.com/intl/en/options/" onclick="this.blur();gbar.tg(event);return !1" aria-haspopup=true><u>More</u> <small>&#9660;</small></a><div class=gbm id=gbi><a onclick=gbar.logger.il(1,{t:24}); class=gb2 id=gb_24 href="https://www.google.com/calendar?tab=tc">Calendar</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:51}); class=gb2 id=gb_51 href="http://translate.google.com/?hl=en&sa=N&tab=tT">Translate</a><a onclick=gbar.logger.il(1,{t:17}); class=gb2 id=gb_17 href="http://www.google.com/mobile/?hl=en&tab=tD">Mobile</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:10}); class=gb2 id=gb_10 href="http://www.google.com/search?hl=en&tbo=u&tbm=bks&source=og&sa=N&tab=tp">Books</a><a onclick=gbar.logger.il(1,{t:212}); class=gb2 id=gb_212 href="https://wallet.google.com/manage/?tab=ta">Wallet</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:6}); class=gb2 id=gb_6 href="http://www.google.com/search?hl=en&tbo=u&tbm=shop&source=og&sa=N&tab=tf">Shopping</a><a onclick=gbar.logger.il(1,{t:30}); class=gb2 id=gb_30 href="http://www.blogger.com/?tab=tj">Blogger</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:27}); class=gb2 id=gb_27 href="http://www.google.com/finance?sa=N&tab=te">Finance</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:31}); class=gb2 id=gb_31 href="https://plus.google.com/photos?sa=N&tab=tq">Photos</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:12}); class=gb2 id=gb_12 href="http://www.google.com/search?hl=en&tbo=u&tbm=vid&source=og&sa=N&tab=tv">Videos</a><div class=gb2><div class=gbd></div></div><a onclick=gbar.logger.il(1,{t:66}); href="http://www.google.com/intl/en/options/" class=gb2>Even more &raquo;</a></div></nobr></div><div id=guser width=100%><nobr><span id=gbn class=gbi></span><span id=gbf class=gbf></span><span id=gbe></span><a target=_top id=gb_70 href="https://www.google.com/accounts/Login?service=&continue=http://www.google.com/patents%3Fhl%3Den&hl=en" class=gb4>Sign in</a><div style="display: none"><div class=gbm id=gbd5 aria-owner=gbg5><div class=gbmc><ol id=gbom class=gbmcc></ol></div></div></div></nobr></div><div class=gbh style=left:0></div><div class=gbh style=right:0></div><div role="alert" style="position: absolute; left: 0; right: 0;"><a href="http://www.google.com/patents/us7307148?hl=en&amp;output=html_text" title="Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader."><img border="0" src="http://www.google.com/images/cleardot.gif"alt="Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader."></a></div><div id="guser"><nobr></nobr></div><div style="clear:both;"></div><div id="gb-top-search-box" class="gb-top-search-box-small gb-reset"><table><tr><td class="logo"><a href="http://www.google.com/patents" class="logo-link"><img class="logo-img" src="/intl/en/images/logos/google_logo_41.png" alt="Go to Google Books Home" height="41"/></a></td><td><form action="http://www.google.com/search" name="f" id="vheadf" method="get"><span id="hf"></span><input type="hidden" name="tbm" value="pts"/><input type="hidden" name="tbo" value="1"/><input type="hidden" name="hl" value="en"/><table><tr><td><div class="inputs"><table><tr><td><div class="text-input"><input type="text" name="q" id="vheadq" class="text" maxlength="2048" size="31" value="" title="Search Patents" accesskey="s" autocomplete="off"/><script>window._OC_autoDir &&window._OC_autoDir('vheadq', 'tia-vheadq');</script></div></td><td><div class="submit-input"><input name="btnG" class="submit" type="submit" value=""/></div></td></tr></table></div></td><td class="col-ext-links"><div class="ext-links"><a href="http://www.google.com/advanced_patent_search">&lt;nobr&gt;Advanced Patent Search&lt;/nobr&gt;</a></div></td></tr></table></form></td></tr></table></div><div class="kd-appbar"><h2 class="kd-appname"><a href="/patents">Patents</a></h2><div class="kd-buttonbar left" id="left-toolbar-buttons"><a id="appbar-write-review-link" href=""></a><a id="appbar-view-print-sample-link" href=""></a><a id="appbar-view-ebook-sample-link" href=""></a><a id="appbar-patents-prior-art-finder-link" href="https://www.google.com/patents/related/US7307148"></a><a id="appbar-patents-discuss-this-link" href="http://www.google.com/url?id=F_Z_BAABERAJ&amp;q=http://patents.stackexchange.com/redirect/google-patents%3Fpatent%3DUS7307148&amp;usg=AFQjCNHPi4PZRXK0cniMKMhZDZMrBNosVQ" data-is-grant="true"></a><a id="appbar-read-patent-link" href="//docs.google.com/viewer?url=patentimages.storage.googleapis.com/pdfs/US7307148.pdf"></a><a id="appbar-download-pdf-link" href="//patentimages.storage.googleapis.com/pdfs/US7307148.pdf"></a><a class="appbar-application-grant-link" data-label="Application" href="/patents/US20050267293"></a><a class="appbar-application-grant-link" data-selected="true" data-label="Grant" href="/patents/US7307148"></a></div><div class="kd-buttonbar right" id="right-toolbar-buttons"></div></div><div id="books-microdata" itemscope=""itemtype="http://schema.org/Book"itemid="http://www.google.com/patents/US7307148" style="display:none"><span itemprop="description">The present invention relates to a method for separating albumin conjugate from unconjugated albumin in a solution comprising albumin conjugate and unconjugated albumin by loading the solution onto a hydrophobic support equilibrated in aqueous buffer having a high salt content; applying to the support...</span><span itemprop="url">http://www.google.com/patents/US7307148?utm_source=gb-gplus-share</span><span class="main-title" itemprop="name">Patent US7307148 - Method for purification of albumin conjugates</span><img itemprop="image" src="http://www.google.com/patents?id=&amp;printsec=frontcover&amp;img=1&amp;zoom=1"alt="Patent US7307148 - Method for purification of albumin conjugates" title="Patent US7307148 - Method for purification of albumin conjugates"></div><div style="display: none"><ol id="ofe-gear-menu-contents" class="gbmcc"><li class="gbe gbmtc"><a class="gbmt goog-menuitem-content" id="" href="http://www.google.com/advanced_patent_search">Advanced Patent Search</a></li></ol></div><table id="viewport_table" cellpadding="0" style="clear:both" cellspacing="0"><tr><td id="viewport_td"><div class=vertical_module_list_row><div id=intl_patents class=about_content><div id=intl_patents_v><table class="patent-bibdata"><tr><td class="patent-bibdata-heading">Publication number</td><td class="single-patent-bibdata">US7307148 B2</td></tr><tr><td class="patent-bibdata-heading">Publication type</td><td class="single-patent-bibdata">Grant</td></tr><tr><td class="patent-bibdata-heading">Application number</td><td class="single-patent-bibdata">US 11/112,277</td></tr><tr><td class="patent-bibdata-heading">Publication date</td><td class="single-patent-bibdata">Dec 11, 2007</td></tr><tr><td class="patent-bibdata-heading">Filing date</td><td class="single-patent-bibdata">Apr 22, 2005</td></tr><tr><td class="patent-bibdata-heading">Priority date<span class="patent-tooltip-anchor patent-question-icon"data-tooltip-text="The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed."></span></td><td class="single-patent-bibdata">Apr 23, 2004</td></tr><tr><td class="patent-bibdata-heading">Fee status<span class="patent-tooltip-anchor patent-question-icon"data-tooltip-text="The fee status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status or dates listed."></span></td><td class="single-patent-bibdata">Paid</td></tr><tr class="patent-bibdata-list-row "><td class="patent-bibdata-heading">Also published as</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value"><a href="/patents/CA2564031A1">CA2564031A1</a>, </span><span class="patent-bibdata-value"><a href="/patents/CN1956998A">CN1956998A</a>, </span><span class="patent-bibdata-value"><a href="/patents/CN1956998B">CN1956998B</a>, </span><span class="patent-bibdata-value"><a href="/patents/DE602005014969D1">DE602005014969D1</a>, </span><span class="patent-bibdata-value"><a href="/patents/DE602005022239D1">DE602005022239D1</a>, </span><span class="patent-bibdata-value"><a href="/patents/EP1745078A1">EP1745078A1</a>, </span><span class="patent-bibdata-value"><a href="/patents/EP1745078A4">EP1745078A4</a>, </span><span class="patent-bibdata-value"><a href="/patents/EP1745078B1">EP1745078B1</a>, </span><span class="patent-bibdata-value"><a href="/patents/EP2100904A1">EP2100904A1</a>, </span><span class="patent-bibdata-value"><a href="/patents/EP2100904B1">EP2100904B1</a>, </span><span class="patent-bibdata-value"><a href="/patents/EP2230257A1">EP2230257A1</a>, </span><span class="patent-bibdata-value"><a href="/patents/US20050267293">US20050267293</a>, </span><span class="patent-bibdata-value"><a href="/patents/US20080146783">US20080146783</a>, </span><span class="patent-bibdata-value"><a href="/patents/US20120022234">US20120022234</a>, </span><span class="patent-bibdata-value"><a href="/patents/WO2005103087A1">WO2005103087A1</a></span></span></td></tr><tr class="patent-bibdata-list-row alternate-patent-number"><td class="patent-bibdata-heading">Publication number</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value">11112277, </span><span class="patent-bibdata-value">112277, </span><span class="patent-bibdata-value">US 7307148 B2, </span><span class="patent-bibdata-value">US 7307148B2, </span><span class="patent-bibdata-value">US-B2-7307148, </span><span class="patent-bibdata-value">US7307148 B2, </span><span class="patent-bibdata-value">US7307148B2</span></span></td></tr><tr class="patent-bibdata-list-row "><td class="patent-bibdata-heading">Inventors</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value"><a href="http://www.google.com/search?tbo=p&tbm=pts&hl=en&q=ininventor:%22Nathalie+Bousquet-Gagnon%22">Nathalie Bousquet-Gagnon</a>, </span><span class="patent-bibdata-value"><a href="http://www.google.com/search?tbo=p&tbm=pts&hl=en&q=ininventor:%22Omar+Quraishi%22">Omar Quraishi</a>, </span><span class="patent-bibdata-value"><a href="http://www.google.com/search?tbo=p&tbm=pts&hl=en&q=ininventor:%22Dominique+P.+Bridon%22">Dominique P. Bridon</a></span></span></td></tr><tr class="patent-bibdata-list-row "><td class="patent-bibdata-heading">Original Assignee</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value"><a href="http://www.google.com/search?tbo=p&tbm=pts&hl=en&q=inassignee:%22Conjuchem+Biotechnologies+Inc.%22">Conjuchem Biotechnologies Inc.</a></span></span></td></tr><tr class="patent-bibdata-list-row "><td class="patent-bibdata-heading">Export Citation</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value"><a href="/patents/US7307148.bibtex">BiBTeX</a>, </span><span class="patent-bibdata-value"><a href="/patents/US7307148.enw">EndNote</a>, </span><span class="patent-bibdata-value"><a href="/patents/US7307148.ris">RefMan</a></span></span></td></tr><tr class="patent-internal-links"><td colspan=2><span class="patent-bibdata-value"><a href="#backward-citations">Patent Citations</a> (102),</span> <span class="patent-bibdata-value"><a href="#npl-citations">Non-Patent Citations</a> (75),</span> <span class="patent-bibdata-value"><a href="#forward-citations">Referenced by</a> (10),</span> <span class="patent-bibdata-value"><a href="#classifications">Classifications</a> (25),</span> <span class="patent-bibdata-value"><a href="#legal-events">Legal Events</a> (9)</span> </td></tr><tr><td colspan=2 class="patent-bibdata-external-link-spacer-top"></td></tr><tr class="patent-bibdata-external-link-spacer-bottom"></tr><tr><td colspan=2><span class="patent-bibdata-heading">External Links:&nbsp;</span><span><span class="patent-bibdata-value"><a href="http://www.google.com/url?id=F_Z_BAABERAJ&q=http://patft.uspto.gov/netacgi/nph-Parser%3FSect2%3DPTO1%26Sect2%3DHITOFF%26p%3D1%26u%3D/netahtml/PTO/search-bool.html%26r%3D1%26f%3DG%26l%3D50%26d%3DPALL%26RefSrch%3Dyes%26Query%3DPN/7307148&usg=AFQjCNEww3cFWo5811KagPVcYXmiSQw4SQ">USPTO</a>, </span><span class="patent-bibdata-value"><a href="http://www.google.com/url?id=F_Z_BAABERAJ&q=http://assignments.uspto.gov/assignments/q%3Fdb%3Dpat%26pat%3D7307148&usg=AFQjCNEdsX6j2_E8b3nTS9T0F_APJKSTgA">USPTO Assignment</a>, </span><span class="patent-bibdata-value"><a href="http://www.google.com/url?id=F_Z_BAABERAJ&q=http://worldwide.espacenet.com/publicationDetails/biblio%3FCC%3DUS%26NR%3D7307148B2%26KC%3DB2%26FT%3DD&usg=AFQjCNH2ULn--Ec8H1_1pYbcF_PwZDAjPw">Espacenet</a></span></span></td></tr><tr class="patent-bibdata-group-spacer"></tr></table><div class="number-and-title"><span class="patent-title"><invention-title mxw-id="PT55824443" lang="EN" load-source="patent-office">Method for purification of albumin conjugates</invention-title></span><br><span class="patent-number">US 7307148 B2</span></div><div class="patent-section patent-abstract-section"><div class="patent-section-header"><span class="patent-section-title">Abstract</span></div><div class="patent-text"><abstract mxw-id="PA51240212" lang="EN" load-source="patent-office"> <div num="p-0001" class="abstract">The present invention relates to a method for separating albumin conjugate from unconjugated albumin in a solution comprising albumin conjugate and unconjugated albumin by loading the solution onto a hydrophobic support equilibrated in aqueous buffer having a high salt content; applying to the support a gradient of decreasing salt concentration; and collecting the eluted albumin conjugate.</div>
  </abstract></div></div><div class="patent-section patent-drawings-section"><div class="patent-section-header"><span class="patent-section-title">Images<span class="patent-section-count">(76)</span></span></div><div class="patent-drawings-body"><div class="patent-drawings-carousel"><div class="drawings"><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/US7307148B2/US07307148-20071211-D00001.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/US7307148B2/US07307148-20071211-D00001.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/US7307148B2/US07307148-20071211-D00002.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/US7307148B2/US07307148-20071211-D00002.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/US7307148B2/US07307148-20071211-D00003.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/US7307148B2/US07307148-20071211-D00003.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/US7307148B2/US07307148-20071211-D00004.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/US7307148B2/US07307148-20071211-D00004.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/US7307148B2/US07307148-20071211-D00005.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/US7307148B2/US07307148-20071211-D00005.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/US7307148B2/US07307148-20071211-D00006.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/US7307148B2/US07307148-20071211-D00006.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/US7307148B2/US07307148-20071211-D00007.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/US7307148B2/US07307148-20071211-D00007.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/US7307148B2/US07307148-20071211-D00008.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/US7307148B2/US07307148-20071211-D00008.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/US7307148B2/US07307148-20071211-D00009.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/US7307148B2/US07307148-20071211-D00009.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/US7307148B2/US07307148-20071211-D00010.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/US7307148B2/US07307148-20071211-D00010.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/US7307148B2/US07307148-20071211-D00011.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/US7307148B2/US07307148-20071211-D00011.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/US7307148B2/US07307148-20071211-D00012.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/US7307148B2/US07307148-20071211-D00012.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/US7307148B2/US07307148-20071211-D00013.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/US7307148B2/US07307148-20071211-D00013.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/US7307148B2/US07307148-20071211-D00014.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/US7307148B2/US07307148-20071211-D00014.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/US7307148B2/US07307148-20071211-D00015.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/US7307148B2/US07307148-20071211-D00015.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/US7307148B2/US07307148-20071211-D00016.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/US7307148B2/US07307148-20071211-D00016.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/US7307148B2/US07307148-20071211-D00017.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/US7307148B2/US07307148-20071211-D00017.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/US7307148B2/US07307148-20071211-D00018.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/US7307148B2/US07307148-20071211-D00018.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/US7307148B2/US07307148-20071211-D00019.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/US7307148B2/US07307148-20071211-D00019.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/US7307148B2/US07307148-20071211-D00020.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/US7307148B2/US07307148-20071211-D00020.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/US7307148B2/US07307148-20071211-D00021.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/US7307148B2/US07307148-20071211-D00021.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/US7307148B2/US07307148-20071211-D00022.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/US7307148B2/US07307148-20071211-D00022.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/US7307148B2/US07307148-20071211-D00023.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/US7307148B2/US07307148-20071211-D00023.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/US7307148B2/US07307148-20071211-D00024.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/US7307148B2/US07307148-20071211-D00024.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/US7307148B2/US07307148-20071211-D00025.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/US7307148B2/US07307148-20071211-D00025.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/US7307148B2/US07307148-20071211-D00026.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/US7307148B2/US07307148-20071211-D00026.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/US7307148B2/US07307148-20071211-D00027.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/US7307148B2/US07307148-20071211-D00027.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/US7307148B2/US07307148-20071211-D00028.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/US7307148B2/US07307148-20071211-D00028.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/US7307148B2/US07307148-20071211-D00029.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/US7307148B2/US07307148-20071211-D00029.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/US7307148B2/US07307148-20071211-D00030.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/US7307148B2/US07307148-20071211-D00030.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/US7307148B2/US07307148-20071211-D00031.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/US7307148B2/US07307148-20071211-D00031.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/US7307148B2/US07307148-20071211-D00032.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/US7307148B2/US07307148-20071211-D00032.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/US7307148B2/US07307148-20071211-D00033.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/US7307148B2/US07307148-20071211-D00033.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/US7307148B2/US07307148-20071211-D00034.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/US7307148B2/US07307148-20071211-D00034.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/US7307148B2/US07307148-20071211-D00035.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/US7307148B2/US07307148-20071211-D00035.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/US7307148B2/US07307148-20071211-D00036.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/US7307148B2/US07307148-20071211-D00036.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/US7307148B2/US07307148-20071211-D00037.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/US7307148B2/US07307148-20071211-D00037.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/US7307148B2/US07307148-20071211-D00038.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/US7307148B2/US07307148-20071211-D00038.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/US7307148B2/US07307148-20071211-D00039.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/US7307148B2/US07307148-20071211-D00039.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/US7307148B2/US07307148-20071211-D00040.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/US7307148B2/US07307148-20071211-D00040.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/US7307148B2/US07307148-20071211-D00041.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/US7307148B2/US07307148-20071211-D00041.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/US7307148B2/US07307148-20071211-D00042.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/US7307148B2/US07307148-20071211-D00042.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/US7307148B2/US07307148-20071211-D00043.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/US7307148B2/US07307148-20071211-D00043.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/US7307148B2/US07307148-20071211-D00044.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/US7307148B2/US07307148-20071211-D00044.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/US7307148B2/US07307148-20071211-D00045.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/US7307148B2/US07307148-20071211-D00045.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/US7307148B2/US07307148-20071211-D00046.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/US7307148B2/US07307148-20071211-D00046.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/US7307148B2/US07307148-20071211-D00047.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/US7307148B2/US07307148-20071211-D00047.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/US7307148B2/US07307148-20071211-D00048.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/US7307148B2/US07307148-20071211-D00048.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/US7307148B2/US07307148-20071211-D00049.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/US7307148B2/US07307148-20071211-D00049.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/US7307148B2/US07307148-20071211-D00050.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/US7307148B2/US07307148-20071211-D00050.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/US7307148B2/US07307148-20071211-D00051.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/US7307148B2/US07307148-20071211-D00051.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/US7307148B2/US07307148-20071211-D00052.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/US7307148B2/US07307148-20071211-D00052.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/US7307148B2/US07307148-20071211-D00053.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/US7307148B2/US07307148-20071211-D00053.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/US7307148B2/US07307148-20071211-D00054.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/US7307148B2/US07307148-20071211-D00054.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/US7307148B2/US07307148-20071211-D00055.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/US7307148B2/US07307148-20071211-D00055.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/US7307148B2/US07307148-20071211-D00056.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/US7307148B2/US07307148-20071211-D00056.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/US7307148B2/US07307148-20071211-D00057.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/US7307148B2/US07307148-20071211-D00057.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/US7307148B2/US07307148-20071211-D00058.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/US7307148B2/US07307148-20071211-D00058.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/US7307148B2/US07307148-20071211-D00059.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/US7307148B2/US07307148-20071211-D00059.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/US7307148B2/US07307148-20071211-D00060.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/US7307148B2/US07307148-20071211-D00060.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/US7307148B2/US07307148-20071211-D00061.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/US7307148B2/US07307148-20071211-D00061.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/US7307148B2/US07307148-20071211-D00062.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/US7307148B2/US07307148-20071211-D00062.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/US7307148B2/US07307148-20071211-D00063.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/US7307148B2/US07307148-20071211-D00063.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/US7307148B2/US07307148-20071211-D00064.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/US7307148B2/US07307148-20071211-D00064.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/US7307148B2/US07307148-20071211-D00065.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/US7307148B2/US07307148-20071211-D00065.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/US7307148B2/US07307148-20071211-D00066.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/US7307148B2/US07307148-20071211-D00066.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/US7307148B2/US07307148-20071211-D00067.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/US7307148B2/US07307148-20071211-D00067.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/US7307148B2/US07307148-20071211-D00068.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/US7307148B2/US07307148-20071211-D00068.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/US7307148B2/US07307148-20071211-D00069.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/US7307148B2/US07307148-20071211-D00069.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/US7307148B2/US07307148-20071211-D00070.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/US7307148B2/US07307148-20071211-D00070.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/US7307148B2/US07307148-20071211-D00071.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/US7307148B2/US07307148-20071211-D00071.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/US7307148B2/US07307148-20071211-D00072.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/US7307148B2/US07307148-20071211-D00072.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/US7307148B2/US07307148-20071211-D00073.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/US7307148B2/US07307148-20071211-D00073.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/US7307148B2/US07307148-20071211-D00074.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/US7307148B2/US07307148-20071211-D00074.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/US7307148B2/US07307148-20071211-D00075.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/US7307148B2/US07307148-20071211-D00075.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/US7307148B2/US07307148-20071211-D00076.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/US7307148B2/US07307148-20071211-D00076.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div></div></div><div class="patent-drawings-control patent-drawings-prev"><img class="patent-drawings-button-img" alt="Previous page"src="/googlebooks/images/kennedy/page_left.png"width="21" height="21" /></div><div class="patent-drawings-control patent-drawings-next"><img class="patent-drawings-button-img" alt="Next page"src="/googlebooks/images/kennedy/page_right.png"width="21" height="21" /></div></div></div><div class="patent-post-drawings"></div><div class="patent-section patent-claims-section"><div class="patent-section-header"><span class="patent-section-title">Claims<span class="patent-section-count">(28)</span></span></div><div class="patent-text"><div mxw-id="PCLM9313351" lang="EN" load-source="patent-office" class="claims">
    <div class="claim"> <div id="CLM-00001" num="00001" class="claim">
      <div class="claim-text">1. A method for separating albumin conjugate from unconjugated albumin in a solution comprising albumin conjugate and unconjugated albumin, the method comprising:
<div class="claim-text">a) loading said solution onto a hydrophobic interaction chromatography matrix equilibrated in aqueous buffer at a salt concentration high enough to promote matrix-protein interactions;</div>
<div class="claim-text">b) applying to said matrix a gradient of decreasing salt concentration; and</div>
<div class="claim-text">c) collecting said albumin conjugate.</div>
</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00002" num="00002" class="claim">
      <div class="claim-text">2. The method of <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein said albumin conjugate consists of a molecule comprising a Michael acceptor covalently bonded to albumin.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00003" num="00003" class="claim">
      <div class="claim-text">3. The method of <claim-ref idref="CLM-00002">claim 2</claim-ref>, wherein said Michael acceptor is a maleimide group.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00004" num="00004" class="claim">
      <div class="claim-text">4. The method of <claim-ref idref="CLM-00003">claim 3</claim-ref>, wherein said maleimide group is maleimid-propionic acid.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00005" num="00005" class="claim">
      <div class="claim-text">5. The method of <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein said albumin is selected from the group consisting of serum albumin and recombinant albumin.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00006" num="00006" class="claim">
      <div class="claim-text">6. The method of <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein said albumin is selected from the group consisting of human albumin, rat albumin, mouse albumin, swine albumin, bovine albumin, dog albumin, and rabbit albumin.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00007" num="00007" class="claim">
      <div class="claim-text">7. The method of <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein said albumin is human serum albumin.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00008" num="00008" class="claim">
      <div class="claim-text">8. The method of <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein said albumin is modified with a fatty acid, a metal ion, a sugar, or a combination thereof.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00009" num="00009" class="claim">
      <div class="claim-text">9. The method of <claim-ref idref="CLM-00008">claim 8</claim-ref>, wherein said sugar is selected from the group consisting of glucose, lactose, and mannose.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00010" num="00010" class="claim">
      <div class="claim-text">10. The method of <claim-ref idref="CLM-00002">claim 2</claim-ref>, wherein said molecule is selected from the group consisting of a peptide, a DNA, an RNA, and a combination thereof, to which said Michael acceptor is covalently bonded, optionally through a linker.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00011" num="00011" class="claim">
      <div class="claim-text">11. The method of <claim-ref idref="CLM-00010">claim 10</claim-ref>, wherein said molecule is a peptide having a molecular weight of at least 57 daltons.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00012" num="00012" class="claim">
      <div class="claim-text">12. The method of <claim-ref idref="CLM-00010">claim 10</claim-ref>, wherein said peptide is selected from the group consisting of glucagon like peptide 1 (GLP-1), atrial natriuretic peptide (ANP), kringle 5 (KS), dynorphin, exendin-4, growth hormone releasing factor (GRF), insulin, natriuretic peptides, enfuvirtide (T-20), T-1249, C-34, soluble C-35 peptide BK (SC-35), peptide YY (PYY), and analogs thereof.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00013" num="00013" class="claim">
      <div class="claim-text">13. The method of <claim-ref idref="CLM-00010">claim 10</claim-ref>, wherein said molecule is selected from the group consisting of:
<div class="claim-text">3′,4′-didehydro-4′-deoxy-C′-norvincaleukoblastine;</div>
<div class="claim-text">2′-deoxy-2′,2′-difluorocytidine; and</div>
<div class="claim-text">5β,20-epoxy-1 ,2α,4,7β,10β,13α-hexahydroxy-tax-11-en-9-one, 4,10-diacetate 2-benzoate, 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine.</div>
</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00014" num="00014" class="claim">
      <div class="claim-text">14. The method of <claim-ref idref="CLM-00010">claim 10</claim-ref>, wherein said molecule is covalently attached to said albumin through an acid sensitive covalent bond or a peptide sequence susceptible to proteolytic cleavage, thereby allowing the separation of said molecule and albumin and the entry of the molecule into a cell.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00015" num="00015" class="claim">
      <div class="claim-text">15. The method of <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein said hydrophobic interaction chromatography matrix is a column containing a hydrophobic resin.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00016" num="00016" class="claim">
      <div class="claim-text">16. The method of <claim-ref idref="CLM-00015">claim 15</claim-ref>, wherein said hydrophobic resin is a bead-formed agarose-based gel filtration matrix covalently coupled to a ligand selected from the group consisting of an octyl group, a phenyl group, and a butyl group.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00017" num="00017" class="claim">
      <div class="claim-text">17. The method of <claim-ref idref="CLM-00015">claim 15</claim-ref>, wherein said hydrophobic resin is a bead-formed agarose-based gel filtration matrix covalently coupled to a butyl group.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00018" num="00018" class="claim">
      <div class="claim-text">18. The method of <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein said gradient of decreasing salt concentration has a starting salt concentration of between 500 and 3000 mM.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00019" num="00019" class="claim">
      <div class="claim-text">19. The method of <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein said salt is selected from the group consisting of ammonium phosphate, ammonium sulfate, and magnesium phosphate.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00020" num="00020" class="claim">
      <div class="claim-text">20. The method of <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein said salt is ammonium phosphate or ammonium sulfate.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00021" num="00021" class="claim">
      <div class="claim-text">21. The method of <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein said salt is ammonium sulfate.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00022" num="00022" class="claim">
      <div class="claim-text">22. The method of <claim-ref idref="CLM-00002">claim 2</claim-ref>, wherein said bond is between said Michael acceptor and cysteine 34 of said albumin.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00023" num="00023" class="claim">
      <div class="claim-text">23. The method of <claim-ref idref="CLM-00002">claim 2</claim-ref>, <claim-ref idref="CLM-00003">3</claim-ref>, or <b>4</b>, wherein said molecule is a peptide to which said Michael acceptor is covalently bonded, optionally through a linker.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00024" num="00024" class="claim">
      <div class="claim-text">24. The method of <claim-ref idref="CLM-00023">claim 23</claim-ref>, wherein said peptide is an analog of glucagon like peptide 1 (GLP-1), glucagon like peptide 2 (GLP-2), atrial natriuretic peptide (ANP), kringle 5 (KS), dynorphin, exendin-4, growth hormone releasing factor (GRF), insulin, natriuretic peptides, enfuvirtide (T-20), T-1249, C-34, soluble C-35 peptide EK (SC-35), or peptide YY (PYY).</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00025" num="00025" class="claim">
      <div class="claim-text">25. The method of <claim-ref idref="CLM-00002">claim 2</claim-ref>, <claim-ref idref="CLM-00003">3</claim-ref>, or <b>4</b>, wherein said molecule is selected from the group consisting of GLP-1 (7-36) dAla<sup>8 </sup>Lys<sup>37 </sup>(ε-AEEA-MPA)-CONH<sub>2 </sub>(SEQ ID NO:1),GRF (1-29) dAla<sup>2 </sup>Gin<sup>8 </sup>Ala<sup>15 </sup>Leu<sup>27 </sup>Lys<sup>30 </sup>(ε-MPA) CONH<sub>2 </sub>(SEQ ID NO:2), Ac-K5 Lys<sup>8 </sup>(ε-MPA)-NH<sub>2 </sub>(SEQ ID NO:3), Insulin B1-MPA (SEQ ID NO:4), Insulin A1-MPA (SEQ ID NO:5), MPA-AEEA-C34-CONH<sub>2 </sub>(SEQ ID NO:6), C34 (1-34) Lys<sup>35 </sup>(ε-AEEA-MPA)-CONH<sub>2 </sub>(SEQ ID NO:7), C34 (1-34) Lys<sup>13 </sup>(ε-AEEA-MPA)-CONH<sub>2 </sub>(SEQ ID NO:8), GLP-1 (7-36) Lys<sup>37 </sup>(ε-MPA)-NH<sub>2 </sub>(SEQ ID NO:9), GLP-1 (7-36) dAla<sup>8 </sup>Lys<sup>37 </sup>(ε-MPA)-NH<sub>2 </sub>(SEQ ID NO:10), GLP-1 (7-36) Lys<sup>26 </sup>(ε-AEEA-AEEA-MPA) (SEQ ID NO:11), GLP-1 (7-36) Lys<sup>34 </sup>(ε-AEEA-AEEA-MPA) (SEQ ID NO:12), Exendin-4-(1-39) Lys<sup>40 </sup>(ε-MPA)-NH<sub>2 </sub>(SEQ ID NO:13), Exendin-4 (9-39) Lys<sup>40 </sup>(ε-AEEA-MPA)-CONH<sub>2 </sub>(SEQ ID NO:14), Dyn A (1-13) (MPA)-NH<sub>2 </sub>(SEQ ID NO:15), MPA-AEEA-ANP (99-126)-CONH<sub>2 </sub>(SEQ ID NO:16), Dyn A (7-13) Lys<sup>13 </sup>(ε-MPA)-CONH<sub>2 </sub>(SEQ ID NO:17), acetyl-Phe-His-cyclohexylstatyl-lle-Lys (ε-AEEA-MPA)-CONH<sub>2 </sub>(SEQ ID NO:18), GLP-1 (7-36) Lys<sup>23 </sup>(ε-AEEA-MPA)-CONH<sub>2 </sub>(SEQ ID NO:19), GLP-1 (7-36) Lys<sup>18 </sup>(ε-AEEA-MPA)-CONH<sub>2 </sub>(SEQ ID NO:20), GLP-1 (7-36) Lys<sup>26 </sup>(ε-AEEA-MPA)-CONH<sub>2 </sub>(SEQ ID NO:21), GLP-1 (7-37) Lys<sup>27 </sup>(ε-AEEA-MPA)-CONH<sub>2 </sub>(SEQ ID NO:22), GLP-1 (7-36) Lys<sup>37 </sup>(ε-AEEA-AEEA-MPA)-CONH<sub>2 </sub>(SEQ ID NO:23), GLP-1 (7-36) Lys<sup>37 </sup>(ε-AEEA-MPA)-CONH<sub>2 </sub>(SEQ ID NO:24), Exendin-4-(1-39) Lys<sup>40 </sup>(ε-AEEA-MPA)-CONH<sub>2 </sub>(SEQ ID NO:25), GLP-1 (7-36) Lys<sup>34 </sup>(ε-AEEA-MPA)-CONH<sub>2 </sub>(SEQ ID NO:26), Insulin B1-OA-MPA (SEQ ID NO:27), Insulin B29-MPA (SEQ ID NO:28), GRF (1-29) Lys<sup>30 </sup>(ε-MPA)-CONH<sub>2 </sub>(SEQ ID NO:29), GRF (1-29) dAla<sup>2 </sup>Gln<sup>8 </sup>dArg<sup>11 </sup>Ala<sup>15 </sup>Leu<sup>27 </sup>Lys<sup>30 </sup>(ε-MPA)-CONH<sub>2 </sub>(SEQ ID NO:30), GRF (1-29) dAla<sup>2 </sup>Lys<sup>30 </sup>(ε-MPA)-CONH<sub>2 </sub>(SEQ ID NO:31), GLP-1 (9-36) Lys<sup>37 </sup>(ε-AEEA-MPA)-CONH<sub>2 </sub>(SEQ ID NO:32), Ac-T20 (1-36) Lys<sup>37 </sup>(ε-AEEA-MPA)-CONH<sub>2 </sub>(SEQ ID NO:33), Ac-T1249 (1-39) Lys<sup>40 </sup>(ε-AEEA-MPA)-CONH<sub>2 </sub>(SEQ ID NO:34), 3′,4′-didehydro-4′-deoxy-C′-norvincaleukoblastine -AEEA-MPA, C34 (1-34) Lys<sup>13 </sup>(ε-MPA)-CONH<sub>2 </sub>(SEQ ID NO:36), C34 (1-34) Lys<sup>35 </sup>(ε-MPA)-CONH<sub>2 </sub>(SEQ ID NO:37), MPA-C34 (1-34)-CONH<sub>2 </sub>(SEQ ID NO:38), Ac-C34 (1-34) Glu<sup>2 </sup>Lys<sup>6 </sup>Lys<sup>7 </sup>Glu<sup>9 </sup>Glu<sup>10 </sup>Lys<sup>13 </sup>Lys<sup>14 </sup>Glu<sup>16 </sup>Glu<sup>17 </sup>Lys<sup>20 </sup>Lys<sup>21 </sup>Glu<sup>23 </sup>Glu<sup>24 </sup>Lys<sup>27 </sup>Glu<sup>31 </sup>Lys<sup>34 </sup>Lys<sup>35 </sup>Lys<sup>36</sup>(ε-AEEA-MPA)-CONH<sub>2 </sub>(SEQ ID NO:39), MPA-AEEA-C34 (1-34) Glu<sup>2 </sup>Lys<sup>6 </sup>Lys<sup>7 </sup>Glu<sup>9 </sup>Glu<sup>10 </sup>Lys<sup>13 </sup>Lys<sup>14 </sup>Glu<sup>16 </sup>Glu<sup>17 </sup>Lys<sup>21 </sup>Glu<sup>23 </sup>Glu<sup>24 </sup>Lys<sup>27 </sup>Glu<sup>31 </sup>Lys<sup>34 </sup>Lys<sup>35 </sup>CONH<sub>2 </sub>(SEQ ID NO:40), PYY (3-36) Lys<sup>4 </sup>(ε-OA-MPA)-CONH<sub>2 </sub>(SEQ ID NO:41), MPA-OA-PYY (3-36)-CONH<sub>2 </sub>(SEQ ID NO:42), Insulin B29-AEES2-MPA (SEQ ID NO:43), Insulin B1-AEES2-MPA (SEQ ID NO:44), Insulin B29-OA-MPA (SEQ ID NO:45), MPA-PYY (3-36)-CONH<sub>2 </sub>(SEQ ID NO:46), PYY (3-36) Lys<sup>37 </sup>(ε-MPA)-CONH<sub>2 </sub>(SEQ ID NO:47), MPA-PYY (22-36)-CONH<sub>2 </sub>(SEQ ID NO:48), Acetyl-PYY (22-36) Lys<sup>37 </sup>(ε-MPA)-CONH<sub>2 </sub>(SEQ ID NO:49), MPA-ANP (99-126)-CONH<sub>2 </sub>(SEQ ID NO:50), MPA-EEEEP-ANP (99-126) (SEQ ID NO:51), and GLP-2 (1-33) Gly<sup>2 </sup>Lys<sup>34 </sup>(ε-MPA)-CONH<sub>2 </sub>(SEQ ID NO:52).</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00026" num="00026" class="claim">
      <div class="claim-text">26. The method of <claim-ref idref="CLM-00024">claim 24</claim-ref>, wherein said peptide is GLP-1 (7-36) dAla<sup>8 </sup>Lys<sup>37</sup>.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00027" num="00027" class="claim">
      <div class="claim-text">27. The method of <claim-ref idref="CLM-00024">claim 24</claim-ref>, wherein said peptide is Exendin-4 (1-39) Lys<sup>40</sup>.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00028" num="00028" class="claim">
      <div class="claim-text">28. The method of <claim-ref idref="CLM-00002">claim 2</claim-ref>, <claim-ref idref="CLM-00003">3</claim-ref>, or <b>4</b>, wherein said molecule is GLP-1 (7-36) dAla<sup>8 </sup>Lys<sup>37 </sup>(ε-AEEA-MPA)-CONH<sub>2</sub>.</div>
    </div>
  </div> </div></div></div><div class="patent-section patent-description-section"><div class="patent-section-header"><span class="patent-section-title">Description</span></div><div class="patent-text"><div mxw-id="PDES16335895" lang="EN" load-source="patent-office" class="description">
    <heading>RELATED APPLICATION</heading> <p num="p-0002">This application claims priority to U.S. provisional patent application Ser. No. 60/565,228 filed Apr. 23, 2004, which is expressly incorporated by reference in its entirety.</p>
    <heading>BACKGROUND OF THE INVENTION</heading> <p num="p-0003">(a) Field of the Invention</p>
    <p num="p-0004">This invention relates to a method of purification for isolating albumin conjugates from a solution comprising both albumin conjugates and unconjugated albumin.</p>
    <p num="p-0005">(b) Description of Prior Art</p>
    <p num="p-0006">WO 95/10302 and WO 99/24074 describe the formation of conjugates of albumin wherein the molecule of interest has a reactive functionality coupled thereto that is adapted to covalently bond to albumin, thus forming a conjugate. These conjugates can be formed in vivo, but they can be formed in vitro as well. The formation of the conjugate in vitro involves the addition of a molecule coupled to a reactive functionality to a solution of albumin. The primary end products from this reaction are unconjugated albumin, the albumin conjugate and the unreacted molecule coupled to the reactive functionality.</p>
    <p num="p-0007">It would be highly desirable to be provided with a method for purifying albumin conjugate from a solution comprising albumin conjugate and unconjugated albumin.</p>
    <heading>SUMMARY OF THE INVENTION</heading> <p num="p-0008">In accordance with the present invention there is provided a method for separating albumin conjugate from unconjugated albumin in a solution comprising albumin conjugate and unconjugated albumin, the method comprising:
</p> <ul> <li id="ul0001-0001" num="0008">a) loading the solution onto a hydrophobic solid support equilibrated in aqueous buffer having a high salt content;</li> <li id="ul0001-0002" num="0009">b) applying to the support a gradient of decreasing salt content; and</li> <li id="ul0001-0003" num="0010">c) collecting eluted albumin conjugate.</li> </ul> <p num="p-0009">In a preferred embodiment of the present invention, the albumin conjugate consists of a molecule having a Michael acceptor covalently coupled thereto which bonds to albumin, and more preferably the bond is between the Michael acceptor and cysteine 34 of albumin.</p>
    <p num="p-0010">In a more preferred embodiment of the present invention, the Michael acceptor is a maleimide group, and more preferably, the maleimide group is maleimid-propionic acid (MPA). The Michael acceptor is optionally coupled to the molecule via a linker. The linker is preferably selected in the group consisting of hydroxyethyl motifs such as (2-amino)ethoxy acetic acid (AEA), ethylenediamine (EDA), 2-[2-(2-amino)ethoxy)]ethoxy acetic acid (AEEA), amino ethoxy ethyl amino succinic acid (AEEAS); one or more alkyl chains (C1-C10) motifs such as glycine, 3-aminopropionic acid (APA), 8-aminooctanoic acid (AOA), octanoic acid (OA), 4-aminobenzoic acid (APhA). Preferred linkers are OA, ADE, AEA, AEEA and AEEAS. A combination of two linkers can also be used such as, for examples, AEEA-EDA, AEEA-AEEA, AEEAS-AEEAS, and AEA-AEEA.</p>
    <p num="p-0011">In a preferred embodiment of the present invention, the albumin is selected from the group consisting of serum albumin, recombinant albumin and albumin from a genomic source.</p>
    <p num="p-0012">In a preferred embodiment of the present invention, the albumin is selected from the group consisting of human albumin, rat albumin, mouse albumin, swine albumin, bovine albumin, dog albumin and rabbit albumin, more preferable human serum albumin.</p>
    <p num="p-0013">In a preferred embodiment, albumin is modified with at least one selected from the group consisting of fatty acids, metal ions, small molecules having high affinity to albumin, and sugars, such as, but not limited to, glucose, lactose and mannose.</p>
    <p num="p-0014">In a preferred embodiment of the present invention, the molecule is selected from the group consisting of a peptide, DNA, RNA, small organic molecule and a combination thereof. The peptide has preferentially a molecular weight of at least 57 daltons. The peptide is intended to include, but not being limited to, GLP-1, GLP-2, ANP, K5, dynorphin, GRF, insulin, natriuretic peptides, T-20, T-1249, C-34 and PYY. The small molecule is intended to include, but not being limited to, vinorelbine, gemcitabine and paclitaxel. In a more preferred embodiment of the present invention, when the molecule is a DNA, RNA or a small organic molecule, it is covalently attached to the albumin through an acid sensitive covalent bond or a peptide sequence susceptible to proteolytic cleavage, thereby allowing the separation of the molecule from albumin and the entry of the molecule into a cell.</p>
    <p num="p-0015">In a preferred embodiment of the present invention, the hydrophobic solid support is a column containing a hydrophobic resin such as, but not limited to, octyl sepharose, phenyl sepharose and butyl sepharose and more preferably butyl sepharose.</p>
    <p num="p-0016">In another embodiment of the present invention, the hydrophobic solid support comprising a hydrophobic ligand such as Cibacron Blue F3G-A, ether or isopropyl groups in association with a support such as polystyrene/divinyl benzene matrix.</p>
    <p num="p-0017">Substances are separated on the basis of their varying strengths of hydrophobic interactions with hydrophobic ligands immobilized to an uncharged matrix. This technique is usually performed with moderately high concentrations of salts (≈1M) in the start buffer (salt promoted adsorption). Elution is achieved by a linear or stepwise decrease in salt concentration.</p>
    <p num="p-0018">The type of ligand, the degree of substitution, the pH and the type and concentration of salt used during the adsorption stage have a profound effect on the overall performance (e.g. selectivity and capacity) of a HIC matrix (Hydrophobic Interaction Chromatography matrix).</p>
    <p num="p-0019">The solvent is one of the most important parameters which influence capacity and selectivity in HIC (Hydrophobic Interaction Chromatography). In general, the adsorption process is more selective than the desorption process. It is therefore important to optimize the start buffer with respect to pH, type of solvent, type of salt and concentration of salt. The addition of various “salting-out” salts to the sample promotes ligand-protein interactions in HIC. As the concentration of salt is increased, the amount of bound protein increases up to the precipitation point for the protein. Each type of salt differs in its ability to promote hydrophobic interactions. The influence of different salts on hydrophobic interaction follows the well-known Hofmeisters series found below:</p>
    <heading>Hofmeisters Series</heading> <heading>Salting-Out Effect</heading> <p num="h-0006">Anions:
<br>PO<sub>4</sub> <sup>3−</sup>&gt;SO<sub>4</sub> <sup>2−</sup>&gt;CH<sub>3</sub>COO<sup>−</sup>&gt;Cl<sup>−</sup>&gt;Br<sup>−</sup>&gt;NO<sub>3</sub> <sup>−</sup>&gt;ClO<sub>4</sub> <sup>−</sup>&gt;I<sup>−</sup>&gt;SCN<sup>−</sup> </p>
    <heading>Chaotropic Effect</heading> <p num="h-0008">Cations:
<br>NH<sub>4</sub> <sup>+</sup>&lt;Rb<sup>+</sup>&lt;K<sup>+</sup>&lt;Na<sup>+</sup>&lt;Cs<sup>+</sup>&lt;Li<sup>+</sup>&lt;Mg<sup>2+</sup>&lt;Ba<sup>2+</sup> </p>
    <p num="p-0020">Increasing the salting-out effect strengthens the hydrophobic interactions, whereas increasing the chaotropic effect weakens them. Therefore, ammonium sulfate exhibits a stronger salting-out effect than sodium chloride. The most commonly used salts for HIC are ammonium sulfate ((NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub>), sodium sulfate ((Na)<sub>2</sub>SO<sub>4</sub>)), magnesium sulfate (MgSO<sub>4</sub>), sodium chloride (NaCl), potassium chloride (KCl), and ammonium acetate (CH<sub>3</sub>COONH<sub>4</sub>).</p>
    <p num="p-0021">Protein binding to HIC adsorbents is promoted by moderate to high concentrations of “salting-out” salts, most of which also have a stabilizing influence on protein structure due to their preferential exclusion from native globular proteins, i.e. the interaction between the salt and the protein surface is thermodynamically unfavorable. The salt concentration should be high enough (e.g. 500-1000 mM) to promote ligand-protein interactions yet below that which causes precipitation of the protein in the sample. In the case of albumin, the salt concentration should be kept below 3M (moles per liter). The principle mechanism of salting-out consists of the salt-induced increase of the surface tension of water (Melander and Horvath, 1977). Thus, a compact structure becomes energetically more favorable because it corresponds to smaller protein-solution interfacial area.</p>
    <p num="p-0022">Interestingly, we found that under the same conditions (i.e. buffer composed of SO<sub>4</sub> <sup>2−</sup>, PO<sub>4</sub> <sup>2−</sup> or CH<sub>3</sub>COO<sup>−</sup> with any counter ion), these salts exhibit their salting-out effect upon essentially all conjugated albumin described herein in a manner different to non-conjugated albumin (i.e. mercaptalbumin and albumin capped with cysteine), thus enabling a consistent chromatographic separation between conjugated albumin versus non-conjugated albumin. That is, we observe that lower concentrations of salt are required to promote interactions between ligand and conjugated albumin than between ligand and non-conjugated albumin. This chromatographic separation is essentially independent of (a) the sequence of albumin (e.g. human, mouse, rat, etc.) (b) the source of albumin (i.e. plasma derived or recombinant) (c) the molecular weight of the conjugated molecule, (d) the position of the Michael acceptor (or maleimide group) within the structure of the molecule, (e) the peptide sequence or chemical structure of the molecule, and (f) the three-dimensional structure of the conjugated molecule, e.g. linear versus loop structure.</p>
    <p num="p-0023">In a preferred embodiment of the present invention, the salt of the aqueous buffer has a sufficient salting out effect. For providing a sufficient salting out effect, the salt is preferably, but not limited to, phosphate, sulfate and acetate. More preferably, the salt is phosphate or sulfate. The selection of the cation of the buffer is less critical and therefore, such cation can be selected, without limitation, from the group consisting of NH<sub>4</sub> <sup>+</sup>, Rb<sup>+</sup>, K<sup>+</sup>, Na<sup>+</sup>, Cs<sup>+</sup>, Li<sup>+</sup>, Mg<sup>2+</sup> and Ba<sup>2+</sup>.</p>
    <p num="p-0024">The aqueous buffer is preferably ammonium phosphate, ammonium sulfate and magnesium phosphate, and more preferably ammonium sulfate.</p>
    <p num="p-0025">In a preferred embodiment of the present invention, the buffer pH is between 3.0 and 9.0; more preferably between 6.0 and 8.0, and even more preferably, the pH is 7.0.</p>
    <p num="p-0026">In a preferred embodiment of the present invention, the buffer and the hydrophobic solid support are at room temperature (about 25° C.) or at 4° C. or in between.</p>
    <p num="p-0027">Table 1 shows an example of the effect of varying salts for purification of preformed HSA: first GLP-1 analogue conjugate from a solution of HSA using butyl-sepharose resin (structure of the first GLP-1 analogue is described in Example 1 below).</p>
    <p num="p-0028">
      <tables id="TABLE-US-00001" num="00001"> <table frame="none" colsep="0" rowsep="0" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="3"> <colspec colname="1" colwidth="91pt" align="left"> </colspec> <colspec colname="2" colwidth="56pt" align="center"> </colspec> <colspec colname="3" colwidth="70pt" align="center"> </colspec> <thead> <tr class="description-tr"> <td namest="1" nameend="3" rowsep="1" class="description-td" colspan="3">TABLE 1</td>
              </tr> <tr class="description-tr"> <td namest="1" nameend="3" align="center" rowsep="1" class="description-td" colspan="3"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
                <td class="description-td">Starting salt</td>
                <td class="description-td">Starting salt</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
                <td class="description-td">concentration of</td>
                <td class="description-td">concentration of</td>
              </tr> <tr class="description-tr"> <td class="description-td">Salt type</td>
                <td class="description-td">750 mM</td>
                <td class="description-td">1,750 mM</td>
              </tr> <tr class="description-tr"> <td namest="1" nameend="3" align="center" rowsep="1" class="description-td" colspan="3"> </td>
              </tr> </thead> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">Ammonium phosphate</td>
                <td class="description-td">Yes</td>
                <td class="description-td">yes</td>
              </tr> <tr class="description-tr"> <td class="description-td">Ammonium sulfate</td>
                <td class="description-td">Yes</td>
                <td class="description-td">yes</td>
              </tr> <tr class="description-tr"> <td class="description-td">Ammonium chloride</td>
                <td class="description-td">No</td>
                <td class="description-td">no</td>
              </tr> <tr class="description-tr"> <td class="description-td">Ammonium iodide</td>
                <td class="description-td">No</td>
                <td class="description-td">no</td>
              </tr> <tr class="description-tr"> <td class="description-td">Ammonium thiocyanate</td>
                <td class="description-td">No</td>
                <td class="description-td">no</td>
              </tr> <tr class="description-tr"> <td class="description-td">Magnesium sulfate</td>
                <td class="description-td">No</td>
                <td class="description-td">yes</td>
              </tr> <tr class="description-tr"> <td class="description-td">Magnesium</td>
                <td class="description-td">—</td>
                <td class="description-td">—</td>
              </tr> <tr class="description-tr"> <td class="description-td">phosphate*</td>
              </tr> <tr class="description-tr"> <td class="description-td">Barium sulfate*</td>
                <td class="description-td">—</td>
                <td class="description-td">—</td>
              </tr> <tr class="description-tr"> <td namest="1" nameend="3" align="center" rowsep="1" class="description-td" colspan="3"> </td>
              </tr> <tr class="description-tr"> <td namest="1" nameend="3" align="left" id="FOO-00001" class="description-td" colspan="3">*means that the salt is not soluble at concentrations of 1750 mM or 750 mM in 20 mM sodium phosphate (pH 7), 5 mM caprylate</td>
              </tr> <tr class="description-tr"> <td namest="1" nameend="3" align="left" id="FOO-00002" class="description-td" colspan="3">Yes means that successful resolution is achieved between the HSA: first GLP-1 analogue conjugate and the non-conjugated HSA</td>
              </tr> <tr class="description-tr"> <td namest="1" nameend="3" align="left" id="FOO-00003" class="description-td" colspan="3">No means that no separation is achieved between the HSA: first GLP-1 analogue conjugate and the non-conjugated HSA</td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p num="p-0029">The term “peptide” is intended to mean an amino acid sequence having a molecular weight of at least 57 daltons. The peptidic sequence can be circular (loop structure) such as ANP, may contain more than one amino acid chain such as insulin or may be linear such as K5, dynorphin A, C-34 and GLP-1.</p>
    <p num="p-0030">All references herein are hereby incorporated by reference.</p>
    <description-of-drawings> <heading>BRIEF DESCRIPTION OF THE DRAWINGS</heading> <p num="p-0031"> <figref idrefs="DRAWINGS">FIG. 1</figref> illustrates the purification of the conjugate HSA: first GLP-1 analogue (SEQ ID NO:1) by a preferred embodiment of the method of the present invention;</p>
      <p num="p-0032"> <figref idrefs="DRAWINGS">FIG. 2</figref> illustrates the purification of the conjugate HSA: first GRF analogue (SEQ ID NO:2) by a preferred embodiment of the method of the present invention;</p>
      <p num="p-0033"> <figref idrefs="DRAWINGS">FIG. 3</figref> illustrates the purification of non-conjugated HSA by a preferred embodiment of the method of the present invention;</p>
      <p num="p-0034"> <figref idrefs="DRAWINGS">FIG. 4</figref> illustrates the purification of the conjugate rHSA: first GLP-1 analogue (SEQ ID NO:1) by a preferred embodiment of the method of the present invention;</p>
      <p num="p-0035"> <figref idrefs="DRAWINGS">FIG. 5</figref> illustrates the purification of HSA cortex by a preferred embodiment of the method of the present invention;</p>
      <p num="p-0036"> <figref idrefs="DRAWINGS">FIG. 6</figref> illustrates the purification of the conjugate HSA: K5 analogue (SEQ ID NO:3) by a preferred embodiment of the method of the present invention;</p>
      <p num="p-0037">“<figref idrefs="DRAWINGS">FIG. 7</figref> illustrates the purification of the conjugate HSA: first insulin derivative having modification on chain B (SEQ ID NO:4) by a preferred embodiment of the method of the present invention;”</p>
      <p num="p-0038">“<figref idrefs="DRAWINGS">FIG. 8</figref> illustrates the purification of the conjugate HSA: second insulin derivative having modification on chain A (SEQ ID NO:5) by a preferred embodiment of the method of the present invention;”</p>
      <p num="p-0039"> <figref idrefs="DRAWINGS">FIG. 9</figref> illustrates the purification of the conjugate HSA: first C34 analogue (SEQ ID NO:6) by a preferred embodiment of the method of the present invention;</p>
      <p num="p-0040"> <figref idrefs="DRAWINGS">FIG. 10</figref> illustrates the purification of the conjugate HSA: second C34 analogue (SEQ ID NO:7) by a preferred embodiment of the method of the present invention;</p>
      <p num="p-0041"> <figref idrefs="DRAWINGS">FIG. 11</figref> illustrates the purification of the conjugate HSA: third C34 analogue (SEQ ID NO:8) by a preferred embodiment of the method of the present invention;</p>
      <p num="p-0042"> <figref idrefs="DRAWINGS">FIG. 12</figref> illustrates the purification of L-cysteine by a preferred embodiment of the method of the present invention;</p>
      <p num="p-0043"> <figref idrefs="DRAWINGS">FIG. 13</figref> illustrates the purification of L-cysteine: first GLP-1 analogue (SEQ ID NO:1) by a preferred embodiment of the method of the present invention;</p>
      <p num="p-0044"> <figref idrefs="DRAWINGS">FIG. 14</figref> illustrates the purification of the conjugate HSA: second GLP-1 analogue (SEQ ID NO:9) by a preferred embodiment of the method of the present invention;</p>
      <p num="p-0045"> <figref idrefs="DRAWINGS">FIG. 15</figref> illustrates the purification of the conjugate HSA: third GLP-1 analogue (SEQ ID NO:10) by a preferred embodiment of the method of the present invention;</p>
      <p num="p-0046"> <figref idrefs="DRAWINGS">FIG. 16</figref> illustrates the purification of the conjugate HSA: fourth GLP-1 analogue (SEQ ID NO:11) by a preferred embodiment of the method of the present invention;</p>
      <p num="p-0047"> <figref idrefs="DRAWINGS">FIG. 17</figref> illustrates the purification of the conjugate HSA: fifth GLP-1 analogue (SEQ ID NO:12) by a preferred embodiment of the method of the present invention;</p>
      <p num="p-0048"> <figref idrefs="DRAWINGS">FIG. 18</figref> illustrates the purification of the conjugate HSA: first Exendin-4 analogue (SEQ ID NO:13) by a preferred embodiment of the method of the present invention;</p>
      <p num="p-0049"> <figref idrefs="DRAWINGS">FIG. 19</figref> illustrates the purification of the conjugate HSA: second Exendin-4 analogue (SEQ ID NO:14) by a preferred embodiment of the method of the present invention;</p>
      <p num="p-0050"> <figref idrefs="DRAWINGS">FIG. 20</figref> illustrates the purification of HSA: MPA by a preferred embodiment of the method of the present invention;</p>
      <p num="p-0051"> <figref idrefs="DRAWINGS">FIG. 21</figref> illustrates the purification of HSA by a preferred embodiment of the method of the present invention;</p>
      <p num="p-0052"> <figref idrefs="DRAWINGS">FIG. 22</figref> illustrates the purification of the conjugate HSA: second C34 analogue (SEQ ID NO:3) by a preferred embodiment of the method of the present invention;</p>
      <p num="p-0053"> <figref idrefs="DRAWINGS">FIG. 23</figref> illustrates the purification of the conjugate HSA: first Dynorphin A analogue (SEQ ID NO:15) by a preferred embodiment of the method of the present invention;</p>
      <p num="p-0054"> <figref idrefs="DRAWINGS">FIG. 24</figref> illustrates the purification of the conjugate HSA: first ANP analogue (SEQ ID NO:16) by a preferred embodiment of the method of the present invention;</p>
      <p num="p-0055"> <figref idrefs="DRAWINGS">FIG. 25</figref> illustrates the purification of the conjugate HSA: second Dynorphin A analogue (SEQ ID NO:17) by a preferred embodiment of the method of the present invention;</p>
      <p num="p-0056"> <figref idrefs="DRAWINGS">FIG. 26</figref> illustrates the purification of the conjugate HSA: ACE inhibitor (SEQ ID NO:18) by a preferred embodiment of the method of the present invention;</p>
      <p num="p-0057"> <figref idrefs="DRAWINGS">FIG. 27</figref> illustrates the purification of the conjugate HSA: sixth GLP-1 analogue (SEQ ID NO:19) by a preferred embodiment of the method of the present invention;</p>
      <p num="p-0058"> <figref idrefs="DRAWINGS">FIG. 28</figref> illustrates the purification of the conjugate HSA: seventh GLP-1 analogue (SEQ ID NO:20) by a preferred embodiment of the method of the present invention;</p>
      <p num="p-0059"> <figref idrefs="DRAWINGS">FIG. 29</figref> illustrates the purification of the conjugate HSA: eighth GLP-1 analogue (SEQ ID NO:21) by a preferred embodiment of the method of the present invention;</p>
      <p num="p-0060"> <figref idrefs="DRAWINGS">FIG. 30</figref> illustrates the purification of the conjugate HSA: ninth GLP-1 analogue (SEQ ID NO:22) by a preferred embodiment of the method of the present invention;</p>
      <p num="p-0061"> <figref idrefs="DRAWINGS">FIG. 31</figref> illustrates the purification of the conjugate HSA: tenth GLP-1 analogue (SEQ ID NO:23) by a preferred embodiment of the method of the present invention;</p>
      <p num="p-0062"> <figref idrefs="DRAWINGS">FIG. 32</figref> illustrates the purification of the conjugate HSA: eleventh GLP-1 analogue (SEQ ID NO:24) by a preferred embodiment of the method of the present invention;</p>
      <p num="p-0063"> <figref idrefs="DRAWINGS">FIG. 33</figref> illustrates the purification of the conjugate HSA: third Exendin-4 analogue (SEQ ID NO:25) by a preferred embodiment of the method of the present invention;</p>
      <p num="p-0064"> <figref idrefs="DRAWINGS">FIG. 34</figref> illustrates the purification of the conjugate HSA: twelfth GLP-1 analogue (SEQ ID NO:26) by a preferred embodiment of the method of the present invention;</p>
      <p num="p-0065">“<figref idrefs="DRAWINGS">FIG. 35</figref> illustrates the purification of the conjugate HSA: first insulin derivative having modification on chain B (SEQ ID NO:4) by a preferred embodiment of the method of the present invention;”</p>
      <p num="p-0066">“<figref idrefs="DRAWINGS">FIG. 36</figref> illustrates the purification of the conjugate HSA: third insulin derivative having modification on chain B (SEQ ID NO:27) by a preferred embodiment of the method of the present invention;”</p>
      <p num="p-0067">“<figref idrefs="DRAWINGS">FIG. 37</figref> illustrates the purification of the conjugate HSA: second insulin derivative having modification on chain B (SEQ ID NO:5) by a preferred embodiment of the method of the present invention;”</p>
      <p num="p-0068">“<figref idrefs="DRAWINGS">FIG. 38</figref> illustrates the purification of the conjugate HSA: fourth insulin derivative having modification on chain B (SEQ ID NO:28) by a preferred embodiment of the method of the present invention;”</p>
      <p num="p-0069"> <figref idrefs="DRAWINGS">FIG. 39</figref> illustrates the purification of the conjugate HSA: first GRF analogue (SEQ ID NO:2) by a preferred embodiment of the method of the present invention;</p>
      <p num="p-0070"> <figref idrefs="DRAWINGS">FIG. 40</figref> illustrates the purification of the conjugate HSA: second GRF analogue (SEQ ID NO:29) by a preferred embodiment of the method of the present invention;</p>
      <p num="p-0071"> <figref idrefs="DRAWINGS">FIG. 41</figref> illustrates the purification of the conjugate HSA: third GRF analogue (SEQ ID NO:30) by a preferred embodiment of the method of the present invention;</p>
      <p num="p-0072"> <figref idrefs="DRAWINGS">FIG. 42</figref> illustrates the purification of the conjugate HSA: fourth GRF analogue (SEQ ID NO:31) by a preferred embodiment of the method of the present invention;</p>
      <p num="p-0073"> <figref idrefs="DRAWINGS">FIG. 43</figref> illustrates the purification of the conjugate HSA: thirteenth GLP-1 analogue CJC 1365 (SEQ ID NO:32) by a preferred embodiment of the method of the present invention;</p>
      <p num="p-0074"> <figref idrefs="DRAWINGS">FIG. 44</figref> illustrates the purification of the conjugate HSA lactose: first GLP-1 analogue (SEQ ID NO:1) by a preferred embodiment of the method of the present invention;</p>
      <p num="p-0075"> <figref idrefs="DRAWINGS">FIG. 45</figref> illustrates the purification of the conjugate HSA: first T20 analogue (SEQ ID NO:33) by a preferred embodiment of the method of the present invention;</p>
      <p num="p-0076"> <figref idrefs="DRAWINGS">FIG. 46</figref> illustrates the purification of the conjugate HSA: first T1249 analogue (SEQ ID NO:34) by a preferred embodiment of the method of the present invention;</p>
      <p num="p-0077"> <figref idrefs="DRAWINGS">FIG. 47</figref> illustrates the purification of the compound HSA: first GLP-1 analogue (SEQ ID NO:1) by a preferred embodiment of the method of the present invention;</p>
      <p num="p-0078"> <figref idrefs="DRAWINGS">FIG. 48</figref> illustrates the purification of the compound HSA: first C34 analogue (SEQ ID NO:6) by a preferred embodiment of the method of the present invention;</p>
      <p num="p-0079"> <figref idrefs="DRAWINGS">FIG. 49</figref> illustrates the purification of the compound HSA: second GRF analogue (SEQ ID NO:29) by a preferred embodiment of the method of the present invention;</p>
      <p num="p-0080">“<figref idrefs="DRAWINGS">FIG. 50</figref> illustrates the purification of the conjugate HSA: vinorelbine analogue conjugate by a preferred embodiment of the method of the present invention;”</p>
      <p num="p-0081"> <figref idrefs="DRAWINGS">FIG. 51</figref> illustrates the purification of L-cysteine by a preferred embodiment of the method of the present invention;</p>
      <p num="p-0082">“<figref idrefs="DRAWINGS">FIG. 52</figref> illustrates the purification of the conjugate L-Cysteine: vinorelbine analogue by a preferred embodiment of the method of the present invention;”</p>
      <p num="p-0083"> <figref idrefs="DRAWINGS">FIG. 53</figref> illustrates the purification of the conjugate RSA: third Exendin-4 analogue (SEQ ID NO:25) by a preferred embodiment of the method of the present invention;</p>
      <p num="p-0084"> <figref idrefs="DRAWINGS">FIG. 54</figref> illustrates the purification of the conjugate HSA: fourth C34 analogue (SEQ ID NO:36) by a preferred embodiment of the method of the present invention;</p>
      <p num="p-0085"> <figref idrefs="DRAWINGS">FIG. 55</figref> illustrates the purification of the conjugate HSA: fifth C34 analogue (SEQ ID NO:37) by a preferred embodiment of the method of the present invention;</p>
      <p num="p-0086"> <figref idrefs="DRAWINGS">FIG. 56</figref> illustrates the purification of the conjugate HSA: sixth C34 analogue (SEQ ID NO:38) by a preferred embodiment of the method of the present invention;</p>
      <p num="p-0087"> <figref idrefs="DRAWINGS">FIG. 57</figref> illustrates the purification of the conjugate HSA: seventh C34 analogue (SEQ ID NO:39) by a preferred embodiment of the method of the present invention;</p>
      <p num="p-0088"> <figref idrefs="DRAWINGS">FIG. 58</figref> illustrates the purification of the conjugate HSA: eighth C34 analogue (SEQ ID NO:40) by a preferred embodiment of the method of the present invention;</p>
      <p num="p-0089"> <figref idrefs="DRAWINGS">FIG. 59</figref> illustrates the purification of the conjugate HSA: first PYY analogue (SEQ ID NO:41) by a preferred embodiment of the method of the present invention;</p>
      <p num="p-0090"> <figref idrefs="DRAWINGS">FIG. 60</figref> illustrates the purification of the conjugate HSA: second PYY analogue (SEQ ID NO:42) by a preferred embodiment of the method of the present invention;</p>
      <p num="p-0091">“<figref idrefs="DRAWINGS">FIG. 61</figref> illustrates the purification of the conjugate HSA: fifth insulin derivative having modification on chain B (SEQ ID NO:43) by a preferred embodiment of the method of the present invention;”</p>
      <p num="p-0092">“<figref idrefs="DRAWINGS">FIG. 62</figref> illustrates the purification of the conjugate HSA: sixth insulin derivative having modification on chain B (SEQ ID NO:44) by a preferred embodiment of the method of the present invention;”</p>
      <p num="p-0093">“<figref idrefs="DRAWINGS">FIG. 63</figref> illustrates the purification of the conjugate HSA: seventh insulin derivative having modification on chain B (SEQ ID NO:45) by a preferred embodiment of the method of the present invention;”</p>
      <p num="p-0094"> <figref idrefs="DRAWINGS">FIG. 64</figref> illustrates the purification of the conjugate HSA: third PYY analogue (SEQ ID NO:46) by a preferred embodiment of the method of the present invention;</p>
      <p num="p-0095"> <figref idrefs="DRAWINGS">FIG. 65</figref> illustrates the purification of the conjugate HSA: fourth PYY analogue (SEQ ID NO:47) by a preferred embodiment of the method of the present invention;</p>
      <p num="p-0096"> <figref idrefs="DRAWINGS">FIG. 66</figref> illustrates the purification of the conjugate HSA: fifth PYY analogue (SEQ ID NO:48) by a preferred embodiment of the method of the present invention;</p>
      <p num="p-0097"> <figref idrefs="DRAWINGS">FIG. 67</figref> illustrates the purification of the conjugate HSA: sixth PYY analogue (SEQ ID NO:49) by a preferred embodiment of the method of the present invention;</p>
      <p num="p-0098"> <figref idrefs="DRAWINGS">FIG. 68</figref> illustrates the purification of the conjugate HSA: second ANP analogue (SEQ ID NO:50) by a preferred embodiment of the method of the present invention;</p>
      <p num="p-0099"> <figref idrefs="DRAWINGS">FIGS. 69A-B</figref> illustrates the purification of the conjugate HSA: third ANP analogue CJC 1681 (SEQ ID NO:51) by a preferred embodiment of the method of the present invention;</p>
      <p num="p-0100"> <figref idrefs="DRAWINGS">FIG. 70</figref> illustrates the purification of the conjugate HSA: first GLP-1 analogue (SEQ ID NO:1) by a preferred embodiment of the method of the present invention;</p>
      <p num="p-0101"> <figref idrefs="DRAWINGS">FIG. 71</figref> illustrates the purification of the conjugate HSA: first GLP-1 analogue (SEQ ID NO:1) by a preferred embodiment of the method of the present invention;</p>
      <p num="p-0102"> <figref idrefs="DRAWINGS">FIG. 72</figref> illustrates the purification of the conjugate HSA: first GLP-1 analogue (SEQ ID NO:1) by a preferred embodiment of the method of the present invention;</p>
      <p num="p-0103"> <figref idrefs="DRAWINGS">FIG. 73</figref> illustrates the purification of the conjugate HSA: first GLP-1 analogue (SEQ ID NO:1) by a preferred embodiment of the method of the present invention;</p>
      <p num="p-0104"> <figref idrefs="DRAWINGS">FIG. 74</figref> illustrates the purification of the conjugate HSA: first GLP-1 analogue (SEQ ID NO:1) by a preferred embodiment of the method of the present invention;</p>
      <p num="p-0105"> <figref idrefs="DRAWINGS">FIG. 75</figref> illustrates the purification of the conjugate HSA: first GLP-2 analogue (SEQ ID NO:52) by a preferred embodiment of the method of the present invention; and</p>
      <p num="p-0106"> <figref idrefs="DRAWINGS">FIG. 76</figref> illustrates the purification of the conjugate RSA:first GLP-2 analogue (SEQ ID NO:52) by a preferred embodiment of the method of the present invention.</p>
    </description-of-drawings> <heading>DETAILED DESCRIPTION OF A PREFERRED EMBODIMENT OF THE INVENTION</heading> <p num="p-0107">In accordance with the present invention, there is provided a method for purifying albumin conjugates from a solution comprising albumin conjugates and unconjugated albumin.</p>
    <p num="h-0011">Methods</p>
    <p num="h-0012">Preparation of Control (Non-Conjugated) Human Serum Albumin (HSA) and Preformed Albumin Conjugates</p>
    <p num="p-0108">Each compound with the Michael acceptor was solubilized in nanopure water (or in DMSO if the compound was difficult to solubilize) at a concentration of 10 mM, then diluted to 1 mM into a solution of HSA (25%, 250 mg/ml, Cortex-Biochem, San Leandro, Calif.). The samples were then incubated at 37° C. for 30 min. Prior to their purification, each conjugate solution was diluted to 5% 50 mg/ml HSA in 20 mM sodium phosphate buffer (pH 7) composed of 5 mM sodium octanoate. The initial concentration of salt used in the elution gradient can be added to the buffer for diluting the mixed solution. Preferably, the initial concentration of salt is from about 750 to about 1700 mM (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub>.</p>
    <p num="h-0013">Procedure for Purification According to a Preferred Embodiment</p>
    <p num="p-0109">Using an ÄKTA purifier (Amersham Biosciences, Uppsala, Sweden), each conjugate was loaded at a flow rate of 2.5 ml/min onto a 50 ml column of butyl sepharose 4 fast flow resin (Amershan Biosciences, Uppsala, Sweden) equilibrated in 20 mM sodium phosphate buffer (pH 7) composed of 5 mM sodium octanoate and 750 mM to 1.7 M (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub>. Under these conditions, HSA conjugates having a molecular weight addition of more than 2 kDa relative to non-conjugated HSA adsorbed onto the hydrophobic resin whereas essentially all non-conjugated HSA eluted within the void volume of the column. For molecular weight additions of less than 2 kDa, a higher initial salt content may be used followed by a stepwise gradient of decreasing salt. Each conjugate was further purified from any free unconjugated compound by applying a continuous or non-continuous decreasing gradient of salt (750 to 0 mM (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub>) over 4 column volumes. In a preferred embodiment, each purified conjugate was then desalted and concentrated by diafiltration, for instance by using Amicon® ultra centrifugal (30 kDa) filter devices (Millipore Corporation, Bedford, Mass.). Finally, for prolonged storage, each conjugate solution is preferably immersed into liquid nitrogen, and lyophilized using a Labconco freeze dry system (FreeZone®4.5), and stored at −20° C.</p>
    <p num="h-0014">Examples of LC/EMS Analysis</p>
    <p num="p-0110">Following purification, 1 μl of each conjugate sample is preferably injected onto LC/EMS system. The HSA: first GLP-1 analogue (SEQ ID NO:1) conjugate was confirmed by detection of a species of highest abundance with a total mass of 70 160 Da which corresponds to the mass of mercaptalbumin (66 448 Da) where cysteine 34 is in the free thiol form, plus the mass of only one molecule of the first GLP-1 analogue (3 719.9 Da). The structure of the first GLP-1 analogue (SEQ ID NO:1) is described in Example 1 below. This is illustrated in Table 2.</p>
    <p num="p-0111">
      <tables id="TABLE-US-00002" num="00002"> <table frame="none" colsep="0" rowsep="0" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="5"> <colspec colname="offset" colwidth="14pt" align="left"> </colspec> <colspec colname="1" colwidth="42pt" align="center"> </colspec> <colspec colname="2" colwidth="56pt" align="center"> </colspec> <colspec colname="3" colwidth="49pt" align="center"> </colspec> <colspec colname="4" colwidth="56pt" align="center"> </colspec> <thead> <tr class="description-tr"> <td class="description-td"> </td>
                <td namest="offset" nameend="4" rowsep="1" class="description-td" colspan="5">TABLE 2</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
                <td namest="offset" nameend="4" align="center" rowsep="1" class="description-td" colspan="5"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
                <td class="description-td"> </td>
                <td class="description-td">Molecular</td>
                <td class="description-td">Absolute</td>
                <td class="description-td">Relative</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
                <td class="description-td">Component</td>
                <td class="description-td">Weight</td>
                <td class="description-td">Abundance</td>
                <td class="description-td">Abundance</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
                <td namest="offset" nameend="4" align="center" rowsep="1" class="description-td" colspan="5"> </td>
              </tr> </thead> <tbody valign="top"> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> </tbody> </tgroup> <tgroup align="left" colsep="0" rowsep="0" cols="5"> <colspec colname="offset" colwidth="14pt" align="left"> </colspec> <colspec colname="1" colwidth="42pt" align="center"> </colspec> <colspec colname="2" colwidth="56pt" align="center"> </colspec> <colspec colname="3" colwidth="49pt" align="char" char="."> </colspec> <colspec colname="4" colwidth="56pt" align="char" char="."> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td"> </td>
                <td class="description-td">A</td>
                <td class="description-td">70160.58</td>
                <td class="description-td">321970</td>
                <td class="description-td">100.00</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
                <td class="description-td">B</td>
                <td class="description-td">65862.95</td>
                <td class="description-td">70008</td>
                <td class="description-td">21.74</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
                <td class="description-td">C</td>
                <td class="description-td">64545.45</td>
                <td class="description-td">62888</td>
                <td class="description-td">19.53</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
                <td class="description-td">D</td>
                <td class="description-td">70320.04</td>
                <td class="description-td">41167</td>
                <td class="description-td">12.79</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
                <td class="description-td">E</td>
                <td class="description-td">61287.67</td>
                <td class="description-td">16842</td>
                <td class="description-td">5.23</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
                <td class="description-td">F</td>
                <td class="description-td">60623.81</td>
                <td class="description-td">16522</td>
                <td class="description-td">5.13</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
                <td class="description-td">G</td>
                <td class="description-td">58090.04</td>
                <td class="description-td">12473</td>
                <td class="description-td">3.87</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
                <td namest="offset" nameend="4" align="center" rowsep="1" class="description-td" colspan="5"> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p num="p-0112">The HSA: first GRF analogue (SEQ ID NO:2) conjugate was confirmed by detection of a species of highest abundance with a total mass of 70 086 Da which corresponds to the mass of mercaptalbumin (66 448 Da) where cysteine 34 is in the free thiol form, plus the mass of only one molecule of the first GRF analogue (3648.2 Da). The structure of the first GRF analogue (SEQ ID NO:2) is described in Example 2 below. This is illustrated in Table 3.</p>
    <p num="p-0113">
      <tables id="TABLE-US-00003" num="00003"> <table frame="none" colsep="0" rowsep="0" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="5"> <colspec colname="offset" colwidth="14pt" align="left"> </colspec> <colspec colname="1" colwidth="42pt" align="center"> </colspec> <colspec colname="2" colwidth="56pt" align="center"> </colspec> <colspec colname="3" colwidth="49pt" align="center"> </colspec> <colspec colname="4" colwidth="56pt" align="center"> </colspec> <thead> <tr class="description-tr"> <td class="description-td"> </td>
                <td namest="offset" nameend="4" rowsep="1" class="description-td" colspan="5">TABLE 3</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
                <td namest="offset" nameend="4" align="center" rowsep="1" class="description-td" colspan="5"> </td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
                <td class="description-td"> </td>
                <td class="description-td">Molecular</td>
                <td class="description-td">Absolute</td>
                <td class="description-td">Relative</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
                <td class="description-td">Component</td>
                <td class="description-td">Weight</td>
                <td class="description-td">Abundance</td>
                <td class="description-td">Abundance</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
                <td namest="offset" nameend="4" align="center" rowsep="1" class="description-td" colspan="5"> </td>
              </tr> </thead> <tbody valign="top"> <tr class="description-tr"> <td class="description-td"> </td>
              </tr> </tbody> </tgroup> <tgroup align="left" colsep="0" rowsep="0" cols="5"> <colspec colname="offset" colwidth="14pt" align="left"> </colspec> <colspec colname="1" colwidth="42pt" align="center"> </colspec> <colspec colname="2" colwidth="56pt" align="center"> </colspec> <colspec colname="3" colwidth="49pt" align="char" char="."> </colspec> <colspec colname="4" colwidth="56pt" align="char" char="."> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td"> </td>
                <td class="description-td">A</td>
                <td class="description-td">70086.06</td>
                <td class="description-td">279413</td>
                <td class="description-td">100.00</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
                <td class="description-td">B</td>
                <td class="description-td">63214.84</td>
                <td class="description-td">53333</td>
                <td class="description-td">19.09</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
                <td class="description-td">C</td>
                <td class="description-td">62148.17</td>
                <td class="description-td">38582</td>
                <td class="description-td">13.81</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
                <td class="description-td">D</td>
                <td class="description-td">70247.98</td>
                <td class="description-td">34870</td>
                <td class="description-td">12.48</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
                <td class="description-td">E</td>
                <td class="description-td">56795.96</td>
                <td class="description-td">10523</td>
                <td class="description-td">3.77</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
                <td class="description-td">F</td>
                <td class="description-td">62695.49</td>
                <td class="description-td">9813</td>
                <td class="description-td">3.51</td>
              </tr> <tr class="description-tr"> <td class="description-td"> </td>
                <td namest="offset" nameend="4" align="center" rowsep="1" class="description-td" colspan="5"> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p num="p-0114">The following examples illustrate several compounds having a maleimide group as Michael acceptor that have been conjugated to albumin and purified in accordance with the method of the present invention.</p>
    <p num="p-0115">The following examples are for the purpose of illustrating the present invention and not of limiting its scope.</p>
    <p num="p-0116">In the following examples, the gradient numbers refer to the following gradient details, where CV means a column volume of 50 ml.</p>
    <p num="p-0117">Gradient #1: Linear 750-0 mM (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub>, over 4 CV, flow rate of 2.5 ml/min.</p>
    <p num="p-0118">Gradient #2: Step gradient 1.75M-1.2M (NH<sub>4</sub>)<sub>2</sub>SO<sub>4 </sub>over 0.5 CV, followed by 1.2M-875 mM (NH<sub>4</sub>)<sub>2</sub>SO<sub>4 </sub>over 5 CV, and finally 875 mM-0 mM (NH<sub>4</sub>)<sub>2</sub>SO<sub>4 </sub>over 0.5 CV flow rate of 2.5 ml/min.</p>
    <p num="p-0119">Gradient #3: Linear 900-0 mM (NH<sub>4</sub>)<sub>2</sub>SO<sub>4 </sub>over 4 CV, flow rate of 2.5 ml/min.</p>
    <p num="p-0120">Gradient #4: Step gradient 1.5M-1.1M (NH<sub>4</sub>)<sub>2</sub>SO<sub>4 </sub>over 0.5 CV, followed by 1.1M-375 mM (NH<sub>4</sub>)<sub>2</sub>SO<sub>4 </sub>over 6 CV, and finally 375 mM-0 mM (NH<sub>4</sub>)<sub>2</sub>SO<sub>4 </sub>over 0.5 CV, flow rate of 2.5 ml/min.</p>
    <p num="p-0121">Gradient #5: Linear 750-0 mM (NH<sub>4</sub>)<sub>2</sub>SO<sub>4 </sub>over 2 CV, flow rate of 2.5 ml/min.</p>
    <p num="p-0122">Gradient #6: Step gradient 1.75M-0M (NH<sub>4</sub>)<sub>2</sub>SO<sub>4 </sub>over 6 CV, flow rate of 2.5 ml/min.</p>
    <p num="p-0123">Gradient #7: Linear 750-0 mM (NH<sub>4</sub>)<sub>2</sub>SO<sub>4 </sub>over 6 CV, flow rate of 2.5 ml/min.</p>
    <heading>EXAMPLE 1</heading> <heading>Purification of HSA:First GLP-1 Analogue (SEQ ID NO:1) Conjugate</heading> <p num="p-0124">The first GLP-1 analogue is GLP-1 (7-36) dAla<sup>8 </sup>Lys<sup>37 </sup>(ε-AEEA-MPA)-CONH<sub>2 </sub>and has the following sequence:
</p> <ul> <li id="ul0002-0001" num="0000"> <ul> <li id="ul0003-0001" num="0127">H(dA)EGTFTSDVSSYLEGQAAKEFIAWLVKGRK(AEEA-MPA)-CONH<sub>2 </sub> </li> </ul> </li> </ul> <p num="p-0125">The purification of a conjugate made from reacting 1 ml 25% 250 mg/ml HSA (Cortex-Biochem, San Leandro, Calif.) with 1 mM first GLP-1 analogue diluted into 9 ml of buffer made of 20 mM sodium phosphate buffer pH 7.0, 5 mM sodium caprylate and 750 mM (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub>, was performed on a column of Butyl sepharose using the gradient #1 described above. In <figref idrefs="DRAWINGS">FIG. 1</figref> the purified conjugate fraction elutes during the gradient of decreasing (NH<sub>4</sub>)<sub>2</sub>SO<sub>4 </sub>concentration as fraction B (F8-F9), whereas non-conjugated albumin elutes within the void volume of the column (fraction A). The conjugate fraction was concentrated with Ultrafree™ filter 30 kDa and analyzed using LC-EMS.</p>
    <heading>EXAMPLE 2</heading> <heading>Purification of HSA:First GRF Analogue (SEQ ID NO:2) Conjugate</heading> <p num="p-0126">The first GRF analogue is GRF (1-29) dAla<sup>2 </sup>Gln<sup>8 </sup>Ala<sup>15 </sup>Leu<sup>27 </sup>Lys<sup>30 </sup>(ε-MPA) CONH<sub>2 </sub>and has the following sequence:
</p> <ul> <li id="ul0004-0001" num="0000"> <ul> <li id="ul0005-0001" num="0130">YaDAIFTQSYRKVLAQLSARKLLQDILSRK(MPA)-CONH<sub>2 </sub> </li> </ul> </li> </ul> <p num="p-0127">The purification of a conjugate made from reacting 1 ml 25% 250 mg/ml HSA (Cortex-Biochem, San Leandro, Calif.) with 1 mM first GRF analogue diluted into 9 ml of 20 mM sodium phosphate buffer (pH 7.0), 5 mM sodium caprylate and 750 mM (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub>, was performed on a column of Butyl sepharose using the gradient #1 described above. In <figref idrefs="DRAWINGS">FIG. 2</figref> the purified conjugate fraction appears in fraction B (F6-F7) whereas non-conjugated albumin elutes within the void volume of the column (fraction A). The conjugate fraction was concentrated with Ultrafree™ filter 30 kDa and analyzed using LC-EMS.</p>
    <heading>EXAMPLE 3</heading> <heading>Purification of Non-Conjugated HSA 1 ml</heading> <p num="p-0128">The purification of 1 ml 25% 250 mg/ml non-conjugated HSA (Cortex-Biochem, San Leandro, Calif.) diluted into 9 ml of buffer (pH 7.0) made of 20 mM sodium phosphate buffer, 5 mM sodium caprylate and 750 mM (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub>, was performed on a column of Butyl sepharose using the gradient #1 described above. Essentially all albumin molecules elute within the void volume and no protein species is observed at 280 nm during (NH<sub>4</sub>)<sub>2</sub>SO<sub>4 </sub>gradient. <figref idrefs="DRAWINGS">FIG. 3</figref> illustrates the separation curve obtained.</p>
    <heading>EXAMPLE 4</heading> <heading>Purification of rHSA:First GLP-1 Analogue (SEQ ID NO:1) Conjugate</heading> <p num="p-0129">The first GLP-1 analogue is GLP-1 (7-36) dAla<sup>8 </sup>Lys<sup>37 </sup>(ε-AEEA-MPA)-CONH<sub>2 </sub>and his sequence is shown in Example 1.</p>
    <p num="p-0130">The purification of a conjugate made from reacting 5 ml 5% rHSA (recombinant HSA new century culture grade) with 200 μM first GLP-1 analogue diluted into 5 ml of a buffer made of 20 mM sodium phosphate buffer, 5 mM sodium caprylate and 750 mM (NH<sub>4</sub>)<sub>2</sub>SO<sub>4 </sub>was performed on a column of Butyl sepharose using the gradient #1 described above. In <figref idrefs="DRAWINGS">FIG. 4</figref> the purified conjugate fraction appears in fraction B (F7-F8-F9).</p>
    <heading>EXAMPLE 5</heading> <heading>Purification of HSA 10 ml</heading> <p num="p-0131">The purification of 10 ml 25% 250 mg/ml HSA (Cortex-Biochem, San Leandro, Calif.) diluted into 40 ml of a buffer made of 20 mM sodium phosphate buffer (pH 7.0), 5 mM sodium caprylate and 750 mM (NH<sub>4</sub>)<sub>2</sub>SO<sub>4 </sub>was performed on a column of Butyl sepharose using the gradient #1 described above. Essentially all albumin molecules elute within a void volume and no protein species is observed at 280 nm during (NH<sub>4</sub>)<sub>2</sub>SO<sub>4 </sub>gradient. <figref idrefs="DRAWINGS">FIG. 5</figref> illustrates the separation curve obtained.</p>
    <heading>EXAMPLE 6</heading> <heading>Purification of HSA:K5 Analogue (SEQ ID NO:3) Conjugate</heading> <p num="p-0132">The K5 analogue is Ac-K5 Lys<sup>8 </sup>(ε-MPA)-NH<sub>2 </sub>and has the following sequence:</p>
    <p num="p-0133">
      <chemistry id="CHEM-US-00001" num="00001"> <div class="patent-image"> <a href="//patentimages.storage.googleapis.com/US7307148B2/US07307148-20071211-C00001.png"> <img id="EMI-C00001" he="36.41mm" wi="68.92mm" file="US07307148-20071211-C00001.TIF" alt="Figure US07307148-20071211-C00001" img-content="chem" img-format="tif" src="//patentimages.storage.googleapis.com/US7307148B2/US07307148-20071211-C00001.png" class="patent-full-image" width="275" height="145"> </a> </div>
        <attachments> <attachment idref="CHEM-US-00001" attachment-type="cdx" file="US07307148-20071211-C00001.CDX"> </attachment> <attachment idref="CHEM-US-00001" attachment-type="mol" file="US07307148-20071211-C00001.MOL"> </attachment> </attachments> </chemistry> </p>
    <p num="p-0134">The purification of a conjugate made from reacting 4 ml 25% 250 mg/ml HSA (Cortex-Biochem, San Leandro, Calif.) with 1 mM K5 analogue diluted into 16 ml of 20 mM sodium phosphate buffer (pH 7.0), 5 mM sodium caprylate and 750 mM (NH<sub>4</sub>)<sub>2</sub>SO<sub>4 </sub>was performed on a column of Butyl sepharose using the gradient #1 described above. In <figref idrefs="DRAWINGS">FIG. 6</figref> the purified conjugate fraction appears in fraction A with albumin and in fraction B (F6-F7-F8).</p>
    <heading>EXAMPLE 7</heading> <heading>Purification of HSA:First Insulin Derivative (SEQ ID NO:4) Conjugate</heading> <p num="p-0135">The first insulin derivative is human insulin with MPA on position B1 and is represented in <figref idrefs="DRAWINGS">FIG. 1</figref> below.</p>
    <heading>“Purification of HSA:First Insulin Derivative Conjugate</heading> <p num="p-0136">The first insulin derivative is human insulin with MPA on position B1 of B chain (SEQ ID NO: 4) and native A chain (SEQ ID NO: 35). <figref idrefs="DRAWINGS">FIG. 1</figref> below represents the first insulin derivative.”</p>
    <p num="p-0137">“<figref idrefs="DRAWINGS">FIG. 1</figref> also represents the other insulin derivatives that are disclosed in further examples. <figref idrefs="DRAWINGS">FIG. 1</figref> provides the information concerning the intra disulfide bridge in A chain and the two inter disulfide bridges between A chain and B chain for all insulin derivatives exemplified.”</p>
    <p num="p-0138">
      <chemistry id="CHEM-US-00002" num="00002"> <div class="patent-image"> <a href="//patentimages.storage.googleapis.com/US7307148B2/US07307148-20071211-C00002.png"> <img id="EMI-C00002" he="243.67mm" wi="155.96mm" file="US07307148-20071211-C00002.TIF" alt="Figure US07307148-20071211-C00002" img-content="chem" img-format="tif" src="//patentimages.storage.googleapis.com/US7307148B2/US07307148-20071211-C00002.png" class="patent-full-image" width="623" height="974"> </a> </div>
        <attachments> <attachment idref="CHEM-US-00002" attachment-type="cdx" file="US07307148-20071211-C00002.CDX"> </attachment> <attachment idref="CHEM-US-00002" attachment-type="mol" file="US07307148-20071211-C00002.MOL"> </attachment> </attachments> </chemistry> </p>
    <p num="p-0139">The purification of a conjugate made from reacting 1 ml 25% 250 mg/ml HSA (Cortex-Biochem, San Leandro, Calif.) with 1 mM first insulin derivative diluted into 9 ml of 20 mM sodium phosphate buffer (pH 7.0), 5 mM sodium caprylate and 750 mM (NH<sub>4</sub>)<sub>2</sub>SO<sub>4 </sub>was performed on a column of Butyl sepharose using the gradient #1 described above. In <figref idrefs="DRAWINGS">FIG. 7</figref> the purified conjugate fraction appears in fraction B (F6-F7-F8).</p>
    <heading>EXAMPLE 8</heading> <heading>“Purification of HSA: Second Insulin Derivative Conjugate</heading> <p num="p-0140">The second insulin derivative is human insulin with MPA on position A1 of A chain (SEQ ID NO: 5) and native B chain (SEQ ID NO: 53); and is represented in <figref idrefs="DRAWINGS">FIG. 1</figref> shown above in Example 7.”</p>
    <p num="p-0141">The purification of a conjugate made from reacting 1 ml 25% 250 mg/ml HSA (Cortex-Biochem, San Leandro, Calif.) with 1 mM second insulin derivative diluted into 9 ml of 20 mM sodium phosphate buffer (pH 7.0), 5 mM sodium caprylate and 750 mM (NH<sub>4</sub>)<sub>2</sub>SO<sub>4 </sub>was performed on a column of Butyl sepharose using gradient #1 described above. In <figref idrefs="DRAWINGS">FIG. 8</figref> the purified conjugate fraction appears in fraction B (F6-F7-F8).</p>
    <heading>EXAMPLE 9</heading> <heading>Purification of HSA: First C34 Analogue (SEQ ID NO:6) Conjugate</heading> <p num="p-0142">The first C34 analogue is MPA-AEEA-C34-CONH<sub>2 </sub>and has the following sequence:</p>
    <p num="p-0143">
      <chemistry id="CHEM-US-00003" num="00003"> <div class="patent-image"> <a href="//patentimages.storage.googleapis.com/US7307148B2/US07307148-20071211-C00003.png"> <img id="EMI-C00003" he="13.38mm" wi="154.52mm" file="US07307148-20071211-C00003.TIF" alt="Figure US07307148-20071211-C00003" img-content="chem" img-format="tif" src="//patentimages.storage.googleapis.com/US7307148B2/US07307148-20071211-C00003.png" class="patent-full-image" width="618" height="53"> </a> </div>
        <attachments> <attachment idref="CHEM-US-00003" attachment-type="cdx" file="US07307148-20071211-C00003.CDX"> </attachment> <attachment idref="CHEM-US-00003" attachment-type="mol" file="US07307148-20071211-C00003.MOL"> </attachment> </attachments> </chemistry> </p>
    <p num="p-0144">The purification of a conjugate made from reacting 5 ml 25% 250 mg/ml HSA (Cortex-Biochem, San Leandro, Calif.) with 1 mM first C34 analogue diluted into 20 ml of 20 mM sodium phosphate buffer (pH 7.0), 5 mM sodium caprylate and 750 mM (NH<sub>4</sub>)<sub>2</sub>SO<sub>4 </sub>was performed on a column of Butyl sepharose using gradient #1 described above. In <figref idrefs="DRAWINGS">FIG. 9</figref> the purified conjugate fraction appears in fraction F2.</p>
    <heading>EXAMPLE 10</heading> <heading>Purification of HSA:Second C34 Analogue (SEQ ID NO:7) Conjugate</heading> <p num="p-0145">The second C34 analogue is C34 (1-34) Lys<sup>35 </sup>(ε-AEEA-MPA)-CONH<sub>2 </sub>and has the following structure:</p>
    <p num="p-0146">
      <chemistry id="CHEM-US-00004" num="00004"> <div class="patent-image"> <a href="//patentimages.storage.googleapis.com/US7307148B2/US07307148-20071211-C00004.png"> <img id="EMI-C00004" he="13.38mm" wi="157.56mm" file="US07307148-20071211-C00004.TIF" alt="Figure US07307148-20071211-C00004" img-content="chem" img-format="tif" src="//patentimages.storage.googleapis.com/US7307148B2/US07307148-20071211-C00004.png" class="patent-full-image" width="630" height="53"> </a> </div>
        <attachments> <attachment idref="CHEM-US-00004" attachment-type="cdx" file="US07307148-20071211-C00004.CDX"> </attachment> <attachment idref="CHEM-US-00004" attachment-type="mol" file="US07307148-20071211-C00004.MOL"> </attachment> </attachments> </chemistry> </p>
    <p num="p-0147">The purification of a conjugate made from reacting 5 ml 25% 250 mg/ml HSA (Cortex-Biochem, San Leandro, Calif.) with 1 mM second C34 analogue diluted into 20 ml of 20 mM sodium phosphate buffer, 5 mM sodium caprylate and 750 mM (NH<sub>4</sub>)<sub>2</sub>SO<sub>4 </sub>was performed on a column of Butyl sepharose using gradient #1 described above. In <figref idrefs="DRAWINGS">FIG. 10</figref> the purified conjugate fraction appears in fraction F2.</p>
    <heading>EXAMPLE 11</heading> <heading>Purification of HSA:Third C34 Analogue (SEQ ID NO:8) Conjugate</heading> <p num="p-0148">The third C34 analogue is C34 (1-34) Lys<sup>13 </sup>(ε-AEEA-MPA)-CONH<sub>2 </sub>and has the following structure:</p>
    <p num="p-0149">
      <chemistry id="CHEM-US-00005" num="00005"> <div class="patent-image"> <a href="//patentimages.storage.googleapis.com/US7307148B2/US07307148-20071211-C00005.png"> <img id="EMI-C00005" he="13.38mm" wi="154.52mm" file="US07307148-20071211-C00005.TIF" alt="Figure US07307148-20071211-C00005" img-content="chem" img-format="tif" src="//patentimages.storage.googleapis.com/US7307148B2/US07307148-20071211-C00005.png" class="patent-full-image" width="618" height="53"> </a> </div>
        <attachments> <attachment idref="CHEM-US-00005" attachment-type="cdx" file="US07307148-20071211-C00005.CDX"> </attachment> <attachment idref="CHEM-US-00005" attachment-type="mol" file="US07307148-20071211-C00005.MOL"> </attachment> </attachments> </chemistry> </p>
    <p num="p-0150">The purification of a conjugate made from reacting 5 ml 25% 250 mg/ml HSA (Cortex-Biochem, San Leandro, Calif.) with 1 mM third C34 analogue diluted into 20 ml of 20 mM sodium phosphate buffer (pH 7.0), 5 mM sodium caprylate and 750 mM (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub>, was performed on a column of Butyl sepharose using gradient #1 described above. In <figref idrefs="DRAWINGS">FIG. 11</figref> the purified conjugate fraction appears in fraction F2.</p>
    <heading>EXAMPLE 12</heading> <heading>Purification of I-Cysteine</heading> <p num="p-0151">The purification of 121 mg of I-cysteine in 2 ml of a buffer made of 20 mM sodium phosphate, 5 mM sodium caprylate and 750 mM (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub>, was performed on a column of Butyl sepharose using the gradient #5 described above. <figref idrefs="DRAWINGS">FIG. 12</figref> illustrates the separation curve obtained, where L-cysteine elutes within the void volume of the column (F3).</p>
    <heading>EXAMPLE 13</heading> <heading>Purification of L-Cysteine: First GLP-1 Analogue (SEQ ID NO:1) Conjugate</heading> <p num="p-0152">The first GLP-1 analogue is GLP-1 (7-36) dAla<sup>8 </sup>Lys<sup>37 </sup>(ε-AEEA-MPA)-CONH<sub>2 </sub>and his sequence is shown above in Example 1.</p>
    <p num="p-0153">The purification of a conjugate made from reacting 121 mg L-cysteine with 36.36 mg first GLP-1 analogue diluted into 2 ml of 20 mM sodium phosphate buffer (pH 7.0), 5 mM sodium caprylate and 750 mM (NH<sub>4</sub>)<sub>2</sub>SO<sub>4 </sub>was performed on a column of Butyl sepharose using gradient #5 described above. <figref idrefs="DRAWINGS">FIG. 13</figref> illustrates the separation curve obtained where the excess L-cysteine elutes in F3 (column void volume) and the L-Cysteine:first GLP-1 analogue conjugate elutes in 0 mM (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub>.</p>
    <heading>EXAMPLE 14</heading> <heading>Purification of HSA:Second GLP-1 Analogue (SEQ ID NO:9) Conjugate</heading> <p num="p-0154">The second GLP-1 analogue is GLP-1 (7-36) Lys<sup>37 </sup>(ε-MPA)-NH<sub>2 </sub>and has the following sequence:
</p> <ul> <li id="ul0006-0001" num="0000"> <ul> <li id="ul0007-0001" num="0159">HAEGTFTSDVSSYLEGQAAKEFIAWLVKGRK(ε-MPA)</li> </ul> </li> </ul> <p num="p-0155">The purification of a conjugate made from reacting 2.5 ml 25% 250 mg/ml HSA (Cortex-Biochem, San Leandro, Calif.) with 1 mM second GLP-1 analogue diluted into 10 ml of 20 mM sodium phosphate buffer (pH 7.0), 5 mM sodium caprylate and 750 mM (NH<sub>4</sub>)<sub>2</sub>SO<sub>4 </sub>was performed on a column of Butyl sepharose using gradient #5 described above. In <figref idrefs="DRAWINGS">FIG. 14</figref> the purified conjugate fraction appears in fraction F2.</p>
    <heading>EXAMPLE 15</heading> <heading>Purification of HSA:Third GLP-1 Analogue (SEQ ID NO:10) Conjugate</heading> <p num="p-0156">The third GLP-1 analogue is GLP-1 (7-36) dAla<sup>8 </sup>Lys<sup>37</sup>(ε-MPA)-NH<sub>2 </sub>and has the following sequence:
</p> <ul> <li id="ul0008-0001" num="0000"> <ul> <li id="ul0009-0001" num="0162">H(dA)EGTFTSDVSSYLEGQAAKEFIAWLVKGRK(MPA)-CONH<sub>2 </sub> </li> </ul> </li> </ul> <p num="p-0157">The purification of a conjugate made from reacting 2.5 ml 25% 250 mg/ml HSA (Cortex-Biochem, San Leandro, Calif.) with 1 mM third GLP-1 analogue diluted into 10 ml of 20 mM sodium phosphate buffer (pH 7.0), 5 mM sodium caprylate and 750 mM (NH<sub>4</sub>)<sub>2</sub>SO<sub>4 </sub>was performed on a column of Butyl sepharose using gradient #5 described above. In <figref idrefs="DRAWINGS">FIG. 15</figref> the purified conjugate fraction appears in fraction F2.</p>
    <heading>EXAMPLE 16</heading> <heading>Purification of HSA:Fourth GLP-1 Analogue (SEQ ID NO:11) Conjugate</heading> <p num="p-0158">The fourth GLP-1 analogue is GLP-1 (7-36) Lys<sup>26 </sup>(ε-AEEA-AEEA-MPA) and has the following sequence:
</p> <ul> <li id="ul0010-0001" num="0000"> <ul> <li id="ul0011-0001" num="0165">HAEGTFTSDVSSYLEGQAAK(ε-AEEA-AEEA-MPA) EFIAWLVKGR</li> </ul> </li> </ul> <p num="p-0159">The purification of a conjugate made from reacting 2.5 ml 25% 250 mg/ml HSA (Cortex-Biochem, San Leandro, Calif.) with 1 mM fourth GLP-1 analogue diluted into 10 ml of 20 mM sodium phosphate buffer (pH 7.0), 5 mM sodium caprylate and 750 mM (NH<sub>4</sub>)<sub>2</sub>SO<sub>4 </sub>was performed on a column of Butyl sepharose using gradient #1 described above. In <figref idrefs="DRAWINGS">FIG. 16</figref> the purified conjugate fraction appears in fraction F2.</p>
    <heading>EXAMPLE 17</heading> <heading>Purification of HSA:Fifth GLP-1 Analogue (SEQ ID NO:12) Conjugate</heading> <p num="p-0160">The fifth GLP-1 analogue is GLP-1 (7-36) Lys<sup>34 </sup>(ε-AEEA-AEEA-MPA) and has the following sequence:
</p> <ul> <li id="ul0012-0001" num="0000"> <ul> <li id="ul0013-0001" num="0168">HAEGTFTSDVSSYLEGQAAKEFIAWLVK(ε-AEEA-AEEA-MPA)GR</li> </ul> </li> </ul> <p num="p-0161">The purification of a conjugate made from reacting 2.5 ml 25% 250 mg/ml HSA (Cortex-Biochem, San Leandro, Calif.) with 1 mM fifth GLP-1 analogue diluted into 10 ml of 20 mM sodium phosphate buffer (pH 7.0), 5 mM sodium caprylate and 750 mM (NH<sub>4</sub>)<sub>2</sub>SO<sub>4 </sub>was performed on a column of Butyl sepharose using gradient #1 described above. In <figref idrefs="DRAWINGS">FIG. 17</figref> the purified conjugate fraction appears in fraction F2.</p>
    <heading>EXAMPLE 18</heading> <heading>Purification of HSA: First Exendin-4 Analogue (SEQ ID NO:13) Conjugate</heading> <p num="p-0162">The first exendin-4 analogue is Exendin-4-(1-39) Lys<sup>40 </sup>(ε-MPA)-NH<sub>2 </sub>and has the following sequence:
</p> <ul> <li id="ul0014-0001" num="0000"> <ul> <li id="ul0015-0001" num="0171">HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPSK(ε-MPA)-CONH<sub>2 </sub> </li> </ul> </li> </ul> <p num="p-0163">The purification of a conjugate made from reacting 1 ml 25% 250 mg/ml HSA (Cortex-Biochem, San Leandro, Calif.) with 1 mM first Exendin-4 analogue diluted into 9 ml of 20 mM sodium phosphate buffer (pH 7.0), 5 mM sodium caprylate and 750 mM (NH<sub>4</sub>)<sub>2</sub>SO<sub>4 </sub>was performed on a column of Butyl sepharose using gradient #1 described above. In <figref idrefs="DRAWINGS">FIG. 18</figref> the purified conjugate fraction appears in fraction F2.</p>
    <heading>EXAMPLE 19</heading> <heading>Purification of HSA:Second Exendin-4 Analogue (SEQ ID NO:14) Conjugate</heading> <p num="p-0164">The second Exendin-4 analogue is Exendin-4 (9-39) Lys<sup>40 </sup>(ε-AEEA-MPA)-CONH<sub>2 </sub>and has the following sequence:
</p> <ul> <li id="ul0016-0001" num="0000"> <ul> <li id="ul0017-0001" num="0174">DLSKQMEEEAVRLFIEWLKNGGPSSGAPPPSK(AEEA-MPA)-CONH<sub>2 </sub> </li> </ul> </li> </ul> <p num="p-0165">The purification of a conjugate made from reacting 3.5 ml 25% HSA cortex with 1 mM second Exendin-4 analogue diluted into 21.5 ml of 20 mM sodium phosphate buffer (pH 7.0), 5 mM sodium caprylate and 750 mM (NH<sub>4</sub>)<sub>2</sub>SO<sub>4 </sub>was performed on a column of Butyl sepharose using gradient #1 described above. In <figref idrefs="DRAWINGS">FIG. 19</figref> the purified conjugate fraction appears in fraction F2.</p>
    <heading>EXAMPLE 20</heading> <heading>Purification of HSA: MPA</heading> <p num="p-0166">The purification of a conjugate made from reacting 1 ml 25% 250 mg/ml HSA (Cortex-Biochem, San Leandro, Calif.) with 2 mM MPA diluted into 9 ml of 20 mM sodium phosphate buffer (pH 7.0), 5 mM sodium caprylate and 1750 mM (NH<sub>4</sub>)<sub>2</sub>SO<sub>4 </sub>was performed on a column of Butyl sepharose using gradient #2 described above. In <figref idrefs="DRAWINGS">FIG. 20</figref> the fraction of mercaptalbumin is in fraction A (F5) and capped albumin is in fraction B (F7-F8). The conjugate fraction was concentrated with Amicon™ filter 30 kDa.</p>
    <heading>EXAMPLE 21</heading> <heading>Purification of HSA</heading> <p num="p-0167">The purification of 1 ml 25% 250 mg/ml HSA (Cortex-Biochem, San Leandro, Calif.) diluted into 9 ml of 20 mM sodium phosphate buffer (pH 7.0), 5 mM sodium caprylate and 1750 mM (NH<sub>4</sub>)<sub>2</sub>SO<sub>4 </sub>was performed on a column of Butyl sepharose using the gradient #2 described above. When using gradient #2, unlike gradients #1 and #5, both conjugated albumin and non-conjugated albumin adsorbs onto the hydrophobic resin during sample loading. <figref idrefs="DRAWINGS">FIG. 21</figref> illustrates the separation curve obtained where F4 and F5 are enriched in mercaptalbumin and F6, F7 and F8 are enriched in capped albumin.</p>
    <heading>EXAMPLE 22</heading> <heading>Purification of HSA:Second C34 Analogue (SEQ ID NO:3) Conjugate</heading> <p num="p-0168">The second C34 analogue is C34 (1-34) Lys<sup>35 </sup>(ε-AEEA-MPA)-CONH<sub>2 </sub>and his structure is shown in Example 10.</p>
    <p num="p-0169">The purification of a conjugate made from reacting 1 ml 25% 250 mg/ml HSA (Cortex-Biochem, San Leandro, Calif.) with 1 mM second C34 analogue diluted into 9 ml of a buffer made of 20 mM sodium phosphate buffer (pH 7.0), 5 mM sodium caprylate and 1750 mM (NH<sub>4</sub>)<sub>2</sub>SO<sub>4 </sub>was performed on a column of Butyl sepharose using gradient #2 described above. In <figref idrefs="DRAWINGS">FIG. 22</figref> mercaptalbumin appears in fraction A (F5) and capped albumin and the purified conjugated is in fraction B (F7-F8).</p>
    <heading>EXAMPLE 23</heading> <heading>Purification of HSA:First Dynorphin A Analogue (SEQ ID NO:15) Conjugate</heading> <p num="p-0170">The first Dynorphin A analogue is Dyn A (1-13) (MPA)-NH<sub>2 </sub>and has the following sequence: YGGFLRRIRPKLK(MPA)-CONH<sub>2</sub>.</p>
    <p num="p-0171">The purification of a conjugate made from reacting 1 ml 25% 250 mg/ml HSA (Cortex-Biochem, San Leandro, Calif.) with 1 mM first Dynorphin A analogue diluted into 9 ml of 20 mM sodium phosphate buffer (pH 7.0), 5 mM sodium caprylate and 1750 mM (NH<sub>4</sub>)<sub>2</sub>SO<sub>4 </sub>was performed on a column of Butyl sepharose using gradient #2 described above. In <figref idrefs="DRAWINGS">FIG. 23</figref> the purified conjugate fraction appears in fraction A (F11-F12)</p>
    <heading>EXAMPLE 24</heading> <heading>Purification of HSA:First ANP Analogue (SEQ ID NO:16) Conjugate</heading> <p num="p-0172">The first ANP analogue is MPA-AEEA-ANP (99-126)—CONH<sub>2 </sub>and has the following structure:</p>
    <p num="p-0173">
      <tables id="TABLE-US-00004" num="00004"> <table frame="none" colsep="0" rowsep="0" pgwide="1" tabstyle="monospace" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="2"> <colspec colname="1" colwidth="280pt" align="left"> </colspec> <colspec colname="2" colwidth="161pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">    MPA-AEEA-Ser-Leu-Arg-Arg-Ser-Ser-Cys-Phe-Gly-Gly-Arg-Met-Asp-</td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">                                     |</td>
              </tr> <tr class="description-tr"> <td class="description-td">Arg-Ile-Gly-Ala-Gln-Ser-Gly-Leu-Gly-Cys-Asn-Ser-Phe-Arg-Tyr-CONH<sub>2</sub> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p num="p-0174">The purification of a conjugate made from reacting 1 ml 25% 250 mg/ml HSA (Cortex-Biochem, San Leandro, Calif.) with 1 mM first ANP analogue diluted into 9 ml of 20 mM sodium phosphate buffer (pH 7.0), 5 mM sodium caprylate and 1750 mM (NH<sub>4</sub>)<sub>2</sub>SO<sub>4 </sub>was performed on a column of Butyl sepharose using gradient #2 described above. In <figref idrefs="DRAWINGS">FIG. 24</figref> the purified conjugate fraction appears in fraction A (F14).</p>
    <heading>EXAMPLE 25</heading> <heading>Purification of HSA:Second Dynorphin A Analogue (SEQ ID NO:17) Conjugate</heading> <p num="p-0175">The second Dynorphin A analogue is Dyn A (7-13) Lys<sup>13 </sup>(ε-MPA)-CONH<sub>2 </sub>and has the following sequence:
</p> <ul> <li id="ul0018-0001" num="0000"> <ul> <li id="ul0019-0001" num="0186">RIRPKLK(MPA)-CONH<sub>2 </sub> </li> </ul> </li> </ul> <p num="p-0176">The purification of a conjugate made from reacting 1 ml 25% 250 mg/ml HSA (Cortex-Biochem, San Leandro, Calif.) with 1 mM second Dynorphin A analogue diluted into 9 ml of 20 mM sodium phosphate buffer (pH 7.0), 5 mM sodium caprylate and 1750 mM (NH<sub>4</sub>)<sub>2</sub>SO<sub>4 </sub>was performed on a column of Butyl sepharose using gradient #2 described above. In <figref idrefs="DRAWINGS">FIG. 25</figref> the purified conjugate fraction appears in fraction A (F9).</p>
    <heading>EXAMPLE 26</heading> <heading>Purification of HSA: ACE Inhibitor (SEQ ID NO:18) Conjugate</heading> <p num="p-0177">The ACE inhibitor used in this example is acetyl-Phe-His-cyclohexylstatyl-Ile-Lys (ε-AEEA-MPA)-CONH<sub>2 </sub>and has the following sequence:</p>
    <p num="p-0178">
      <chemistry id="CHEM-US-00006" num="00006"> <div class="patent-image"> <a href="//patentimages.storage.googleapis.com/US7307148B2/US07307148-20071211-C00006.png"> <img id="EMI-C00006" he="28.70mm" wi="60.20mm" file="US07307148-20071211-C00006.TIF" alt="Figure US07307148-20071211-C00006" img-content="chem" img-format="tif" src="//patentimages.storage.googleapis.com/US7307148B2/US07307148-20071211-C00006.png" class="patent-full-image" width="240" height="114"> </a> </div>
        <attachments> <attachment idref="CHEM-US-00006" attachment-type="cdx" file="US07307148-20071211-C00006.CDX"> </attachment> <attachment idref="CHEM-US-00006" attachment-type="mol" file="US07307148-20071211-C00006.MOL"> </attachment> </attachments> </chemistry> </p>
    <p num="p-0179">The purification of a conjugate made from reacting 1 ml 25% 250 mg/ml HSA (Cortex-Biochem, San Leandro, Calif.) with 1 mM ACE inhibitor diluted into 9 ml of 20 mM sodium phosphate buffer (pH 7.0), 5 mM sodium caprylate and 1750 mM (NH<sub>4</sub>)<sub>2</sub>SO<sub>4 </sub>was performed on a column of Butyl sepharose using gradient #2 described above. In <figref idrefs="DRAWINGS">FIG. 26</figref> the purified conjugate fraction appears in fraction A (F14).</p>
    <heading>EXAMPLE 27</heading> <heading>Purification of HSA: Sixth GLP-1 Analogue (SEQ ID NO:19) Conjugate</heading> <p num="p-0180">The sixth GLP-1 analogue is GLP-1 (7-36) Lys<sup>23 </sup>(ε-AEEA-MPA)-CONH<sub>2 </sub>and has the following sequence:
</p> <ul> <li id="ul0020-0001" num="0000"> <ul> <li id="ul0021-0001" num="0192">HAEGTFTSDVSSYLEGK(AEEA-MPA)AAKEFIAWLVKGR-CONH<sub>2 </sub> </li> </ul> </li> </ul> <p num="p-0181">The purification of a conjugate made from reacting 3 ml 25% 250 mg/ml HSA (Cortex-Biochem, San Leandro, Calif.) with 1 mM sixth GLP-1 analogue diluted into 22 ml of 20 mM sodium phosphate buffer (pH 7.0), 5 mM sodium caprylate and 1750 mM (NH<sub>4</sub>)<sub>2</sub>SO<sub>4 </sub>was performed on a column of Butyl sepharose using gradient #1 described above. In <figref idrefs="DRAWINGS">FIG. 27</figref> the purified conjugate fraction appears in fraction F2.</p>
    <heading>EXAMPLE 28</heading> <heading>Purification of HSA: Seventh GLP-1 Analogue (SEQ ID NO:20) Conjugate</heading> <p num="p-0182">The seventh GLP-1 analogue is GLP-1 (7-36) Lys<sup>18 </sup>(ε-AEEA-MPA)-CONH<sub>2 </sub>and has the following sequence:
</p> <ul> <li id="ul0022-0001" num="0000"> <ul> <li id="ul0023-0001" num="0195">HAEGTFTSDVSK(AEEA-MPA)YLEGQAAKEFIAWLVKGR-CONH<sub>2 </sub> </li> </ul> </li> </ul> <p num="p-0183">The purification of a conjugate made from reacting 3 ml 25% 250 mg/ml HSA (Cortex-Biochem, San Leandro, Calif.) with 1 mM seventh GLP-1 analogue diluted into 22 ml of 20 mM sodium phosphate buffer (pH 7.0), 5 mM sodium caprylate and 750 mM (NH<sub>4</sub>)<sub>2</sub>SO<sub>4 </sub>was performed on a column of Butyl sepharose using gradient #1 described above. In <figref idrefs="DRAWINGS">FIG. 28</figref> the purified conjugate fraction appears in fraction F2.</p>
    <heading>EXAMPLE 29</heading> <heading>Purification of HSA: Eighth GLP-1 Analogue (SEQ ID NO:21) Conjugate</heading> <p num="p-0184">The eighth GLP-1 analogue is GLP-1 (7-36) Lys<sup>26 </sup>(ε-AEEA-MPA)-CONH<sub>2 </sub>and has the following sequence:
</p> <ul> <li id="ul0024-0001" num="0000"> <ul> <li id="ul0025-0001" num="0198">HAEGTFTSDVSSYLEGQAAK(AEEA-MPA)EFIAWLVKGR-CONH<sub>2 </sub> </li> </ul> </li> </ul> <p num="p-0185">The purification of a conjugate made from reacting 2.5 ml 25% 250 mg/ml HSA (Cortex-Biochem, San Leandro, Calif.) with 1 mM eighth GLP-1 analogue diluted into 22.5 ml of 20 mM sodium phosphate buffer (pH 7.0), 5 mM sodium caprylate and 750 mM (NH<sub>4</sub>)<sub>2</sub>SO<sub>4 </sub>was performed on a column of Butyl sepharose using gradient #1 described above. In <figref idrefs="DRAWINGS">FIG. 29</figref> the purified conjugate fraction appears in fraction F2.</p>
    <heading>EXAMPLE 30</heading> <heading>Purification of HSA:Ninth GLP-1 Analogue (SEQ ID NO:22) Conjugate</heading> <p num="p-0186">The ninth GLP-1 analogue is GLP-1 (7-37) Lys<sup>27 </sup>(ε-AEEA-MPA)-CONH<sub>2 </sub>and has the following sequence:
</p> <ul> <li id="ul0026-0001" num="0000"> <ul> <li id="ul0027-0001" num="0201">HAEGTFTSDVSSYLEGQAAKK(AEEA-MPA)FIAWLVKGR-CONH<sub>2 </sub> </li> </ul> </li> </ul> <p num="p-0187">The purification of a conjugate made from reacting 3 ml 25% 250 mg/ml HSA (Cortex-Biochem, San Leandro, Calif.) with 1 mM ninth GLP-1 analogue diluted into 22 ml of 20 mM sodium phosphate buffer (pH 7.0), 5 mM sodium caprylate and 750 mM (NH<sub>4</sub>)<sub>2</sub>SO<sub>4 </sub>was performed on a column of Butyl sepharose using gradient #1 described above. In <figref idrefs="DRAWINGS">FIG. 30</figref> the purified conjugate fraction appears in fraction F2.</p>
    <heading>EXAMPLE 31</heading> <heading>Purification of HSA: Tenth GLP-1 Analogue (SEQ ID NO:23) Conjugate</heading> <p num="p-0188">The tenth GLP-1 analogue is GLP-1 (7-36) Lys<sup>37 </sup>(ε-AEEA-AEEA-MPA)-CONH<sub>2 </sub>and has the following sequence:
</p> <ul> <li id="ul0028-0001" num="0000"> <ul> <li id="ul0029-0001" num="0204">HAEGTFTSDVSSYLEGQAAKEFIAWLVKGRK-AEEA-AEEA-MPA-CONH<sub>2 </sub> </li> </ul> </li> </ul> <p num="p-0189">The purification of a conjugate made from reacting 2.5 ml 25% 250 mg/ml HSA (Cortex-Biochem, San Leandro, Calif.) with 1 mM tenth GLP-1 analogue diluted into 22.5 ml of 20 mM sodium phosphate buffer (pH 7.0), 5 mM sodium caprylate and 750 mM (NH<sub>4</sub>)<sub>2</sub>SO<sub>4 </sub>was performed on a column of Butyl sepharose using gradient #1 described above. In <figref idrefs="DRAWINGS">FIG. 31</figref> the purified conjugate fraction appears in fraction F2.</p>
    <heading>EXAMPLE 32</heading> <heading>Purification of HSA: Eleventh GLP-1 Analogue (SEQ ID NO:24) Conjugate</heading> <p num="p-0190">The eleventh GLP-1 analogue is GLP-1 (7-36) Lys<sup>37 </sup>(ε-AEEA-MPA)-CONH<sub>2 </sub>and has the following sequence:
</p> <ul> <li id="ul0030-0001" num="0000"> <ul> <li id="ul0031-0001" num="0207">HAEGTFTSDVSSYLEGQAAKEFIAWLVKGRK(AEEA-MPA)-CONH<sub>2 </sub> </li> </ul> </li> </ul> <p num="p-0191">The purification of a conjugate made from reacting 2.5 ml 25% 250 mg/ml HSA (Cortex-Biochem, San Leandro, Calif.) with 1 mM eleventh GLP-1 analogue diluted into 22.5 ml of 20 mM sodium phosphate buffer (pH 7.0), 5 mM sodium caprylate and 750 mM (NH<sub>4</sub>)<sub>2</sub>SO<sub>4 </sub>was performed on a column of Butyl sepharose using gradient #1 described above. In <figref idrefs="DRAWINGS">FIG. 32</figref> the purified conjugate fraction appears in fraction F2.</p>
    <heading>EXAMPLE 33</heading> <heading>Purification of HSA: Third Exendin-4 Analogue (SEQ ID NO:25) Conjugate</heading> <p num="p-0192">The third Exendin-4 analogue is Exendin-4-(1-39) Lys<sup>40 </sup>(ε-AEEA-MPA)-CONH<sub>2 </sub>and has the following sequence:
</p> <ul> <li id="ul0032-0001" num="0000"> <ul> <li id="ul0033-0001" num="0210">HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPSK(ε-AEEA-MPA)-CONH<sub>2 </sub> </li> </ul> </li> </ul> <p num="p-0193">The purification of a conjugate made from reacting 2.5 ml 25% 250 mg/ml HSA (Cortex-Biochem, San Leandro, Calif.) with 1 mM third Exendin-4 analogue diluted into 22.5 ml of 20 mM sodium phosphate buffer (pH 7.0), 5 mM sodium caprylate and 750 mM (NH<sub>4</sub>)<sub>2</sub>SO<sub>4 </sub>was performed on a column of Butyl sepharose using gradient #1 described above. In <figref idrefs="DRAWINGS">FIG. 33</figref> the purified conjugate fraction appears in fraction F2.</p>
    <heading>EXAMPLE 34</heading> <heading>Purification of HSA: Twelfth GLP-1 Analogue (SEQ ID NO:26) Conjugate</heading> <p num="p-0194">The twelfth GLP-1 analogue is GLP-1 (7-36) Lys<sup>34 </sup>(ε-AEEA-MPA)-CONH<sub>2 </sub>and has the following sequence:
</p> <ul> <li id="ul0034-0001" num="0000"> <ul> <li id="ul0035-0001" num="0213">HAEGTFTSDVSSYLEGQAAKEFIAWLVK(ε-AEEA-MPA)GR-CONH<sub>2 </sub> </li> </ul> </li> </ul> <p num="p-0195">The purification of a conjugate made from reacting 2.5 ml 25% 250 mg/ml HSA (Cortex-Biochem, San Leandro, Calif.) with 1 mM twelfth GLP-1 analogue diluted into 22.5 ml of 20 mM sodium phosphate buffer (pH 7.0), 5 mM sodium caprylate and 750 mM (NH<sub>4</sub>)<sub>2</sub>SO<sub>4 </sub>was performed on a column of Butyl sepharose using gradient #1 described above. In <figref idrefs="DRAWINGS">FIG. 34</figref> the purified conjugate fraction appears in fraction F2.</p>
    <heading>EXAMPLE 35</heading> <heading>“Purification of HSA: First Insulin Derivative Conjugate</heading> <p num="p-0196">The first insulin derivative is human insulin with MPA on position B1 of B chain (SEQ ID NO: 4) and native A chain (SEQ ID NO: 35); and his structure is detailed in Example 7.”</p>
    <p num="p-0197">The purification of a conjugate made from reacting 2.5 ml 25% 250 mg/ml HSA (Cortex-Biochem, San Leandro, Calif.) with 1 mM first insulin derivative diluted into 22.5 ml of 20 mM sodium phosphate buffer (pH 7.0), 5 mM sodium caprylate and 750 mM (NH<sub>4</sub>)<sub>2</sub>SO<sub>4 </sub>was performed on a column of Butyl sepharose using gradient #1 described above. In <figref idrefs="DRAWINGS">FIG. 35</figref> the purified conjugate fraction appears in fraction F2.</p>
    <heading>EXAMPLE 36</heading> <heading>“Purification of HSA: Third Insulin Derivative Conjugate</heading> <p num="p-0198">The third insulin derivative is human insulin with OA-MPA on position B1 of B chain (SEQ ID NO: 27) and native A chain (SEQ ID NO: 35); and is represented in <figref idrefs="DRAWINGS">FIG. 1</figref> shown above in Example 7.”</p>
    <p num="p-0199">The purification of a conjugate made from reacting 4 ml 25% 250 mg/ml HSA (Cortex-Biochem, San Leandro, Calif.) with 1 mM third insulin derivative diluted into 21 ml of 20 mM sodium phosphate buffer (pH 7.0), 5 mM sodium caprylate and 750 mM (NH<sub>4</sub>)<sub>2</sub>SO<sub>4 </sub>was performed on a column of Butyl sepharose using gradient #1 described above. In <figref idrefs="DRAWINGS">FIG. 36</figref> the purified conjugate fraction appears in fraction F2.</p>
    <heading>EXAMPLE 37</heading> <heading>“Purification of HSA: Second Insulin Derivative Conjugate</heading> <p num="p-0200">The second insulin derivative is human insulin with MPA on position A1 of A chain (SEQ ID NO: 5) and native B chain (SEQ ID NO: 53); and is represented in <figref idrefs="DRAWINGS">FIG. 1</figref> shown above in Example 7.”</p>
    <p num="p-0201">The purification of a conjugate made from reacting 3 ml 25% 250 mg/ml HSA (Cortex-Biochem, San Leandro, Calif.) with 1 mM second insulin derivative diluted into 22 ml of 20 mM sodium phosphate buffer (pH 7.0), 5 mM sodium caprylate and 750 mM (NH<sub>4</sub>)<sub>2</sub>SO<sub>4 </sub>was performed on a column of Butyl sepharose using gradient #1 described above. In <figref idrefs="DRAWINGS">FIG. 37</figref> the purified conjugate fraction appears in fraction F2.</p>
    <heading>EXAMPLE 38</heading> <heading>“Purification of HSA: Fourth Insulin Derivative Conjugate</heading> <p num="p-0202">The fourth insulin derivative is human insulin with MPA on position B29 of B chain (SEQ ID NO: 28) and native A chain (SEQ ID NO: 35); and is represented in <figref idrefs="DRAWINGS">FIG. 1</figref> shown above in Example 7.”</p>
    <p num="p-0203">The purification of a conjugate made from reacting 3 ml 25% 250 mg/ml HSA (Cortex-Biochem, San Leandro, Calif.) with 1 mM fourth insulin derivative diluted into 22 ml of 20 mM sodium phosphate buffer (pH 7.0), 5 mM sodium caprylate and 750 mM (NH<sub>4</sub>)<sub>2</sub>SO<sub>4 </sub>was performed on a column of Butyl sepharose using gradient #1 described above. In <figref idrefs="DRAWINGS">FIG. 38</figref> the purified conjugate fraction appears in fraction F2.</p>
    <heading>EXAMPLE 39</heading> <heading>Purification of HSA: First GRF Analogue (SEQ ID NO:2) Conjugate</heading> <p num="p-0204">The first GRF analogue is GRF (1-29) dAla<sup>2 </sup>Gln<sup>8 </sup>Ala<sup>15 </sup>Leu<sup>27 </sup>Lys<sup>30 </sup>(ε-MPA) CONH<sub>2 </sub>and his sequence is shown in Example 2.</p>
    <p num="p-0205">The purification of a conjugate made from reacting 3.7 ml 25% 250 mg/ml HSA (Cortex-Biochem, San Leandro, Calif.) with 1 mM first GRF analogue diluted into 22 ml of 20 mM sodium phosphate buffer (pH 7.0), 5 mM sodium caprylate and 750 mM (NH<sub>4</sub>)<sub>2</sub>SO<sub>4 </sub>was performed on a column of Butyl sepharose using gradient #1 described above. In <figref idrefs="DRAWINGS">FIG. 39</figref> the purified conjugate fraction appears in fraction F2.</p>
    <heading>EXAMPLE 40</heading> <heading>Purification of HSA: Second GRF Analogue (SEQ ID NO:29) Conjugate</heading> <p num="p-0206">The second GRF analogue is GRF(1-29) Lys<sup>30 </sup>(ε-MPA)-CONH<sub>2 </sub>and has the following sequence:
</p> <ul> <li id="ul0036-0001" num="0000"> <ul> <li id="ul0037-0001" num="0226">YADAIFTNSYRKVLGQLSARKLLQDIMSRK(MPA)-CONH<sub>21 </sub> </li> </ul> </li> </ul> <p num="p-0207">The purification of a conjugate made from reacting 2.5 ml 25% 250 mg/ml HSA (Cortex-Biochem, San Leandro, Calif.) with 1 mM second GRF analogue diluted into 22.5 ml of 20 mM sodium phosphate buffer (pH 7.0), 5 mM sodium caprylate and 900 mM (NH<sub>4</sub>)<sub>2</sub>SO<sub>4 </sub>was performed on a column of Butyl sepharose using gradient #3 described above. In <figref idrefs="DRAWINGS">FIG. 40</figref> the purified conjugate fraction appears in fraction F2.</p>
    <heading>EXAMPLE 41</heading> <heading>Purification of HSA: Third GRF Analogue (SEQ ID NO:30) Conjugate</heading> <p num="p-0208">The third GRF analogue is GRF (1-29) dAla<sup>2 </sup>Gln<sup>8 </sup>dArg<sup>11 </sup>Ala<sup>15 </sup>Leu<sup>27 </sup>Lys<sup>30 </sup>(ε-MPA)-CONH<sub>2 </sub>and has the following sequence:
</p> <ul> <li id="ul0038-0001" num="0000"> <ul> <li id="ul0039-0001" num="0229">YaDAIFTNSYRKVLAQLSARKLLQDILSRK(MPA)-CONH<sub>2 </sub> </li> </ul> </li> </ul> <p num="p-0209">The purification of a conjugate made from reacting 2.5 ml 25% 250 mg/ml HSA (Cortex-Biochem, San Leandro, Calif.) with 1 mM third GRF analogue diluted into 22.5 ml of 20 mM sodium phosphate buffer (pH 7.0), 5 mM sodium caprylate and 750 mM (NH<sub>4</sub>)<sub>2</sub>SO<sub>4 </sub>was performed on a column of Butyl sepharose using gradient #3 described above. In <figref idrefs="DRAWINGS">FIG. 41</figref> the purified conjugate fraction appears in fraction F2.</p>
    <heading>EXAMPLE 42</heading> <heading>Purification of HSA: Fourth GRF Analogue (SEQ ID NO:31) Conjugate</heading> <p num="p-0210">The fourth GRF analogue is GRF (1-29) dAla<sup>2 </sup>Lys<sup>30 </sup>(ε-MPA)-CONH<sub>2 </sub>and has the following sequence:
</p> <ul> <li id="ul0040-0001" num="0000"> <ul> <li id="ul0041-0001" num="0232">YaDAIFTNSYRKVLGQLSARKLLQDIMSRK(MPA)-CONH<sub>2 </sub> </li> </ul> </li> </ul> <p num="p-0211">The purification of a conjugate made from reacting 2.5 ml 25% HSA (Cortex-Biochem, San Leandro, Calif.) with 1 mM fourth GRF analogue diluted in 22.5 ml of 20 mM sodium phosphate buffer (pH 7.0), 5 mM sodium caprylate and 900 mM (NH<sub>4</sub>)<sub>2</sub>SO<sub>4 </sub>was performed on a column of Butyl sepharose using gradient #3 described above. In <figref idrefs="DRAWINGS">FIG. 42</figref> the purified conjugate fraction appears in fraction F2.</p>
    <heading>EXAMPLE 43</heading> <heading>Purification of HSA: Thirteenth GLP-1 Analogue CJC 1365 (SEQ ID NO:32) Conjugate</heading> <p num="p-0212">The thirteenth GLP-1 analogue is GLP-1 (9-36) Lys<sup>37 </sup>(ε-AEEA-MPA)-CONH<sub>2 </sub>and has the following sequence:
</p> <ul> <li id="ul0042-0001" num="0000"> <ul> <li id="ul0043-0001" num="0235">EGTFTSDVSSYLEGQAAKEFIAWLVKGRK(ε-AEEA-MPA)-CONH<sub>2 </sub> </li> </ul> </li> </ul> <p num="p-0213">The purification of a conjugate made from reacting 3.5 ml 25% HSA (Cortex-Biochem, San Leandro, Calif.) and 1 mM thirteenth GLP-1 analogue diluted in 21.5 ml of 20 mM sodium phosphate buffer (pH 7.0), 5 mM sodium caprylate and 750 mM (NH<sub>4</sub>)<sub>2</sub>SO<sub>4 </sub>was performed on a column of Butyl sepharose using gradient #1 described above. In <figref idrefs="DRAWINGS">FIG. 43</figref> the purified conjugate fraction appears in fraction F2.</p>
    <heading>EXAMPLE 44</heading> <heading>Purification of HSA Lactose:First GLP-1 Analogue (SEQ ID NO:1) Conjugate</heading> <p num="p-0214">The first GLP-1 analogue is GLP-1 (7-36) dAla<sup>8 </sup>Lys<sup>37 </sup>(ε-AEEA-MPA)-CONH<sub>2 </sub>and his sequence is shown above in Example 1.</p>
    <p num="p-0215">The purification of a conjugate made from reacting 4 ml 25% lactosaminated albumin (HSA pre-incubated with excess lactose at 37° C., pH 7.0) with 200 μM first GLP-1 analogue in 4 ml of a buffer made of 20 mM sodium phosphate, 5 mM sodium caprylate and 750 mM (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub>, (pH 7.0) was performed on a column of Butyl sepharose using gradient #1 described above. In <figref idrefs="DRAWINGS">FIG. 44</figref> the purified lactosaminated conjugate fraction appears in fraction F2.</p>
    <heading>EXAMPLE 45</heading> <heading>Purification of HSA: First T20 Analogue (SEQ ID NO:33) Conjugate</heading> <p num="p-0216">The first T20 analogue is Ac-T20 (1-36) Lys<sup>37 </sup>(ε-AEEA-MPA)-CONH<sub>2 </sub>and ahs the following sequence:
</p> <ul> <li id="ul0044-0001" num="0000"> <ul> <li id="ul0045-0001" num="0240">Ac-YTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWFK(AEEA-MPA)-CONH<sub>2 </sub> </li> </ul> </li> </ul> <p num="p-0217">The purification of a conjugate made from reacting 2.5 ml 25% HSA with 1 mM first T20 analogue in 10 ml of 20 mM sodium phosphate buffer (pH 7.0), 5 mM sodium caprylate and 750 mM (NH<sub>4</sub>)<sub>2</sub>SO<sub>4 </sub>was performed on a column of Butyl sepharose using gradient #1 described above. In <figref idrefs="DRAWINGS">FIG. 45</figref> the purified conjugate fraction appears in fraction F2.</p>
    <heading>EXAMPLE 46</heading> <heading>Purification of HSA: First T1249 Analogue (SEQ ID NO:34) Conjugate</heading> <p num="p-0218">The first T1249 analogue is Ac-T1249 (1-39) Lys<sup>40 </sup>(ε-AEEA-MPA)-CONH<sub>2 </sub>and has the following sequence:
</p> <ul> <li id="ul0046-0001" num="0000"> <ul> <li id="ul0047-0001" num="0243">AC-WQEWEQKITALLEQAQIQQEKNEYELQKLDKWASLWEWFK(AEEA-MPA)-CONH<sub>2 </sub> </li> </ul> </li> </ul> <p num="p-0219">The purification of a conjugate made from reacting 2 ml 25% HSA and 1 mM first T1249 analogue in 10.5 ml of 20 mM sodium phosphate buffer (pH 7.0), 5 mM sodium caprylate and 750 mM (NH<sub>4</sub>)<sub>2</sub>SO<sub>4 </sub>was performed on a column of Butyl sepharose using gradient #1 described above. In <figref idrefs="DRAWINGS">FIG. 46</figref> the purified conjugate fraction appears in fraction F4.</p>
    <heading>EXAMPLE 47</heading> <heading>Purification of a HSA: First GLP-1 Analogue (SEQ ID NO:1)</heading> <p num="p-0220">The first GLP-1 analogue is GLP-1 (7-36) dAla<sup>8 </sup>Lys<sup>37 </sup>(ε-AEEA-MPA)-CONH<sub>2 </sub>and his sequence is shown in Example 1.</p>
    <p num="p-0221">The purification of 114.45 mg of the preformed conjugate of the first GLP-1 analogue in 12.5 ml of 20 mM sodium phosphate buffer (pH 7.0), 5 mM sodium caprylate and 750 mM (NH<sub>4</sub>)<sub>2</sub>SO<sub>4 </sub>was performed on a column of Butyl sepharose using gradient #5 described above. <figref idrefs="DRAWINGS">FIG. 47</figref> illustrates the separation curve obtained with the conjugate found in fraction F2.</p>
    <heading>EXAMPLE 48</heading> <heading>Purification of a HSA: First C34 Analogue (SEQ ID NO:6)</heading> <p num="p-0222">The first C34 analogue is MPA-AEEA-C34-CONH<sub>2 </sub>and his sequence is shown above in Example 9.</p>
    <p num="p-0223">The purification of 114.45 mg of the preformed conjugate of the first C34 analogue in 12.5 ml of 20 mM sodium phosphate buffer (pH 7.0), 5 mM sodium caprylate and 750 mM (NH<sub>4</sub>)<sub>2</sub>SO<sub>4 </sub>was performed on a column of Butyl sepharose using gradient #5 described above. <figref idrefs="DRAWINGS">FIG. 48</figref> illustrates the separation curve obtained with the conjugate found in fraction F2.</p>
    <heading>EXAMPLE 49</heading> <heading>Purification of a HSA: Second GRF Analogue (SEQ ID NO:29)</heading> <p num="p-0224">The second GRF analogue is GRF(1-29) Lys<sup>30 </sup>(ε-MPA)-CONH<sub>2 </sub>and his sequence is shown above in Example 40.</p>
    <p num="p-0225">The purification of 125.53 mg of the preformed conjugate of the second GRF analogue in 12.5 ml of 20 mM sodium phosphate buffer (pH 7.0), 5 mM sodium caprylate and 750 mM (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub>, pH 7.0 was performed on a column of Butyl sepharose using gradient #5 described above. <figref idrefs="DRAWINGS">FIG. 49</figref> illustrates the separation curve obtained with the conjugate found in fraction F2.</p>
    <heading>EXAMPLE 50</heading> <heading>“Purification of HSA: Vinorelbine Analogue Conjugate</heading> <p num="p-0226">The vinorelbine analogue is a molecule of vinorelbine with AEEA-MPA coupled thereto as illustrated in the following structure:”</p>
    <p num="p-0227">
      <chemistry id="CHEM-US-00007" num="00007"> <div class="patent-image"> <a href="//patentimages.storage.googleapis.com/US7307148B2/US07307148-20071211-C00007.png"> <img id="EMI-C00007" he="55.71mm" wi="140.72mm" file="US07307148-20071211-C00007.TIF" alt="Figure US07307148-20071211-C00007" img-content="chem" img-format="tif" src="//patentimages.storage.googleapis.com/US7307148B2/US07307148-20071211-C00007.png" class="patent-full-image" width="562" height="222"> </a> </div>
        <attachments> <attachment idref="CHEM-US-00007" attachment-type="cdx" file="US07307148-20071211-C00007.CDX"> </attachment> <attachment idref="CHEM-US-00007" attachment-type="mol" file="US07307148-20071211-C00007.MOL"> </attachment> </attachments> </chemistry> </p>
    <p num="p-0228">The purification of a conjugate made from 2.5 ml 25% HSA and 1 mM vinorelbine analogue in 22.5 ml of a buffer made of 20 mM sodium phosphate buffer, 5 mM sodium caprylate and 750 mM (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub>, pH 7.0 was performed on a column of Butyl sepharose using gradient #4 described above. In <figref idrefs="DRAWINGS">FIG. 50</figref> the purified conjugate fraction appears in fraction F2. The conjugate fraction was concentrated with Amicon™ filter 30 kDa.</p>
    <heading>EXAMPLE 51</heading> <heading>Purification of L-Cysteine</heading> <p num="p-0229">The purification of 2.5 ml 40 mM L-cysteine in 22.5 ml of 20 mM sodium phosphate buffer (pH 7.0), 5 mM sodium caprylate and 1500 mM (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub>, was performed on a column of Butyl sepharose using gradient #4 described above. <figref idrefs="DRAWINGS">FIG. 51</figref> illustrates the separation curve obtained with L-cysteine eluting within the void volume of the column (fraction F3).</p>
    <heading>EXAMPLE 52</heading> <heading>“Purification of L-Cysteine:Vinorelbine Analogue Conjugate</heading> <p num="p-0230">The vinorelbine analogue is a molecule of vinorelbine with AEEA-MPA coupled thereto as illustrated in the structure shown in Example 50.”</p>
    <p num="p-0231">The purification of a conjugate made from reacting 2.5 ml 40 mM L-cysteine with 1 mM vinorelbine analogue in 22.5 ml of 20 mM sodium phosphate buffer (pH 7.0), 5 mM sodium caprylate and 750 mM (NH<sub>4</sub>)<sub>2</sub>SO<sub>4 </sub>was performed on a column of Butyl sepharose using gradient #4 described above. <figref idrefs="DRAWINGS">FIG. 52</figref> illustrates the separation curve obtained with the L-cysteine conjugate eluting within fractions F8, F9 and F10.</p>
    <heading>EXAMPLE 53</heading> <heading>Purification of RSA: Third Exendin-4 Analogue (SEQ ID NO:25) Conjugate</heading> <p num="p-0232">The third Exendin-4 analogue is Exendin-4-(1-39) Lys<sup>40 </sup>(ε-AEEA-MPA)-CONH<sub>2 </sub>and his sequence shown in Example 33.</p>
    <p num="p-0233">The purification of a conjugate made from reacting 11 ml 5% RSA (rat serum albumin) with 200 μM third Exendin-4 analogue in 11 ml of 20 mM sodium phosphate buffer (pH 7.0), 5 mM sodium caprylate and 750 mM (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub>, was performed on a column of Butyl sepharose using gradient #1 described above. In <figref idrefs="DRAWINGS">FIG. 53</figref> the purified conjugate fraction appears in fraction F2.</p>
    <heading>EXAMPLE 54</heading> <heading>Purification of HSA: Fourth C34 Analogue (SEQ ID NO:36) Conjugate</heading> <p num="p-0234">The fourth C34 analogue is C34 (1-34) Lys<sup>13 </sup>(ε-MPA)-CONH<sub>2 </sub>and has the following sequence:
</p> <ul> <li id="ul0048-0001" num="0000"> <ul> <li id="ul0049-0001" num="0260">WMEWDREINNYTK(MPA)LIHSLIEESQNQQEKNEQELL-CONH<sub>2 </sub> </li> </ul> </li> </ul> <p num="p-0235">The purification of a conjugate made from reacting 2 ml 25% HSA with 1 mM fourth C34 analogue in 13 ml of 20 mM sodium phosphate buffer (pH 7.0), 5 mM sodium caprylate and 750 mM (NH<sub>4</sub>)<sub>2</sub>SO<sub>4 </sub>was performed on a column of Butyl sepharose using gradient #1 described above. In <figref idrefs="DRAWINGS">FIG. 54</figref> the purified conjugate fraction appears in fraction F2.</p>
    <heading>EXAMPLE 55</heading> <heading>Purification of HSA: Fifth C34 Analogue (SEQ ID NO:37) Conjugate</heading> <p num="p-0236">The fifth C34 analogue is C34 (1-34) Lys<sup>35 </sup>(ε-MPA)-CONH<sub>2 </sub>and has the following sequence:
</p> <ul> <li id="ul0050-0001" num="0000"> <ul> <li id="ul0051-0001" num="0263">WMEWDREINNYTSLIHSLIEESQNQQEKNEQELLK(MPA)-CONH<sub>2 </sub> </li> </ul> </li> </ul> <p num="p-0237">The purification of a conjugate made from 2 ml 25% HSA and 1 mM fifth C34 analogue in 13 ml of a buffer made of 20 mM sodium phosphate buffer (pH 7.0), 5 mM sodium caprylate and 750 mM (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub>, was performed on a column of Butyl sepharose using gradient #1 described above. In <figref idrefs="DRAWINGS">FIG. 55</figref> the purified conjugate fraction appears in fraction F2.</p>
    <heading>EXAMPLE 56</heading> <heading>Purification of HSA: Sixth C34 Analogue (SEQ ID NO:38) Conjugate</heading> <p num="p-0238">The sixth C34 analogue MPA-C34 (1-34)—CONH<sub>2 </sub>and has the following sequence:
</p> <ul> <li id="ul0052-0001" num="0000"> <ul> <li id="ul0053-0001" num="0266">MPA-WMEWDREINNYTSLIHSLIEESQNQQEKNEQELL-CONH<sub>2 </sub> </li> </ul> </li> </ul> <p num="p-0239">The purification of a conjugate made from reacting 2 ml 25% HSA and 1 mM sixth C34 analogue in 13 ml of 20 mM sodium phosphate buffer (pH 7.0), 5 mM sodium caprylate and 750 mM (NH<sub>4</sub>)<sub>2</sub>SO<sub>4 </sub>was performed on a column of Butyl sepharose using gradient #1 described above. In <figref idrefs="DRAWINGS">FIG. 56</figref> the purified conjugate fraction appears in fraction F2.</p>
    <heading>EXAMPLE 57</heading> <heading>Purification of HSA: Seventh C34 Analogue (SEQ ID NO:39) Conjugate</heading> <p num="p-0240">The seventh C34 analogue is Ac-C34 (1-34) Glu<sup>2 </sup>Lys<sup>6 </sup>Lys<sup>7 </sup>Glu<sup>9 </sup>Glu<sup>10 </sup>Lys<sup>13 </sup>Lys<sup>14 </sup>Glu<sup>16 </sup>Glu<sup>17 </sup>Lys<sup>20 </sup>Lys<sup>21 </sup>Glu<sup>23 </sup>Glu<sup>24 </sup>Lys<sup>27 </sup>Glu<sup>31 </sup>Lys<sup>34 </sup>Lys<sup>35 </sup>Lys<sup>36 </sup>(ε-AEEA-MPA)-CONH<sub>2 </sub>and has the following sequence:
</p> <ul> <li id="ul0054-0001" num="0000"> <ul> <li id="ul0055-0001" num="0269">Ac-WEEWDKKIEEYTKKIEELIKKSEEQQKKNEEELKKK(AEEA-MPA)-CONH<sub>2 </sub> </li> </ul> </li> </ul> <p num="p-0241">The purification of a conjugate made from reacting 2 ml 25% HSA with 1 mM seventh C34 analogue in 13 ml 20 mM sodium phosphate buffer (pH 7.0), 5 mM sodium caprylate and 750 mM (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub>, was performed on a column of Butyl sepharose using gradient #1 described above. In <figref idrefs="DRAWINGS">FIG. 57</figref> the purified conjugate fraction appears in fraction F2.</p>
    <heading>EXAMPLE 58</heading> <heading>Purification of HSA: Eighth C34 Analogue (SEQ ID NO:40) Conjugate</heading> <p num="p-0242">The eighth C34 analogue is MPA-AEEA-C34 (1-34) Glu<sup>2 </sup>Lys<sup>6 </sup>Lys<sup>7 </sup>Glu<sup>9 </sup>Glu<sup>10 </sup>Lys 13 Lys<sup>14 </sup>Glu<sup>16 </sup>Lys<sup>17 </sup>Lys<sup>20 </sup>Glu<sup>23 </sup>Glu<sup>24 </sup>Lys<sup>27 </sup>Glu<sup>31 </sup>Lys<sup>34 </sup>Lys<sup>35−</sup>CONH<sub>2 </sub>and has the following sequence:
</p> <ul> <li id="ul0056-0001" num="0000"> <ul> <li id="ul0057-0001" num="0272">MPA-AEEA-WEEWDKKIEEYTKKIEELIKKSEEQQKKNEEELKK-CONH<sub>2 </sub> </li> </ul> </li> </ul> <p num="p-0243">The purification of a conjugate made from reacting 2 ml 25% HSA with 1 mM eighth C34 analogue in 13 ml of 20 mM sodium phosphate buffer (pH 7.0), 5 mM sodium caprylate and 750 mM (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub>, was performed on a column of Butyl sepharose using gradient #1 described above. In <figref idrefs="DRAWINGS">FIG. 58</figref> the purified conjugate fraction appears in fraction F2.</p>
    <heading>EXAMPLE 59</heading> <heading>Purification of HSA: First PYY Analogue (SEQ ID NO:41) Conjugate</heading> <p num="p-0244">The first PYY analogue is PYY (3-36) Lys<sup>4 </sup>(ε-OA-MPA)-CONH<sub>2 </sub>and has the following structure:</p>
    <p num="p-0245">
      <chemistry id="CHEM-US-00008" num="00008"> <div class="patent-image"> <a href="//patentimages.storage.googleapis.com/US7307148B2/US07307148-20071211-C00008.png"> <img id="EMI-C00008" he="40.72mm" wi="153.92mm" file="US07307148-20071211-C00008.TIF" alt="Figure US07307148-20071211-C00008" img-content="chem" img-format="tif" src="//patentimages.storage.googleapis.com/US7307148B2/US07307148-20071211-C00008.png" class="patent-full-image" width="615" height="162"> </a> </div>
        <attachments> <attachment idref="CHEM-US-00008" attachment-type="cdx" file="US07307148-20071211-C00008.CDX"> </attachment> <attachment idref="CHEM-US-00008" attachment-type="mol" file="US07307148-20071211-C00008.MOL"> </attachment> </attachments> </chemistry> </p>
    <p num="p-0246">The purification of a conjugate made from reacting 1.5 ml 25% HSA with 1 mM first PYY analogue in 6 ml of 20 mM sodium phosphate buffer (pH 7.0), 5 mM sodium caprylate and 750 mM (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub>, was performed on a column of Butyl sepharose using gradient #1 described above. In <figref idrefs="DRAWINGS">FIG. 59</figref> the purified conjugate fraction appears in fraction F2.</p>
    <heading>EXAMPLE 60</heading> <heading>Purification of HSA: Second PYY Analogue (SEQ ID NO:42) Conjugate</heading> <p num="p-0247">The second PYY analogue is MPA-OA-PYY (3-36)—CONH<sub>2 </sub>and has the following sequence:</p>
    <p num="p-0248">
      <chemistry id="CHEM-US-00009" num="00009"> <div class="patent-image"> <a href="//patentimages.storage.googleapis.com/US7307148B2/US07307148-20071211-C00009.png"> <img id="EMI-C00009" he="32.68mm" wi="155.87mm" file="US07307148-20071211-C00009.TIF" alt="Figure US07307148-20071211-C00009" img-content="chem" img-format="tif" src="//patentimages.storage.googleapis.com/US7307148B2/US07307148-20071211-C00009.png" class="patent-full-image" width="623" height="130"> </a> </div>
        <attachments> <attachment idref="CHEM-US-00009" attachment-type="cdx" file="US07307148-20071211-C00009.CDX"> </attachment> <attachment idref="CHEM-US-00009" attachment-type="mol" file="US07307148-20071211-C00009.MOL"> </attachment> </attachments> </chemistry> </p>
    <p num="p-0249">The purification of a conjugate made from reacting 1.5 ml 25% HSA with 1 mM second PYY analogue in 6 ml of 20 mM sodium phosphate buffer (pH 7.0), 5 mM sodium caprylate and 750 mM (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub>, was performed on a column of Butyl sepharose using gradient #1 described above. In <figref idrefs="DRAWINGS">FIG. 60</figref> the purified conjugate fraction appears in fraction F2.</p>
    <heading>EXAMPLE 61</heading> <heading>“Purification of HSA:Fifth Insulin Derivative Conjugate</heading> <p num="p-0250">The fifth insulin derivative is human insulin with AEEAS-AEEAS-MPA on position B29 of B chain (SEQ ID NO: 43) and native A chain (SEQ ID NO: 35); and is represented in <figref idrefs="DRAWINGS">FIG. 1</figref> shown above in Example 7.”</p>
    <p num="p-0251">The purification of a conjugate made from reacting 2 ml 25% HSA with 1 mM fifth insulin derivative in 15 ml of 20 mM sodium phosphate buffer (pH 7.0), 5 mM sodium caprylate and 750 mM (NH<sub>4</sub>)<sub>2</sub>SO<sub>4 </sub>was performed on a column of Butyl sepharose using gradient #1 described above. In <figref idrefs="DRAWINGS">FIG. 61</figref> the purified conjugate fraction appears in fraction F2.</p>
    <heading>EXAMPLE 62</heading> <heading>“Purification of HSA: Sixth Insulin Derivative Conjugate</heading> <p num="p-0252">The sixth insulin derivative is human insulin with AEEAS-AEEAS-MPA on position B1 of B chain (SEQ ID NO: 44) and native A chain (SEQ ID NO: 35); and is represented in <figref idrefs="DRAWINGS">FIG. 1</figref> shown above in Example 7.”</p>
    <p num="p-0253">The purification of a conjugate made from reacting 2.5 ml 25% HSA with 1 mM sixth insulin derivative in 15 ml of 20 mM sodium phosphate buffer (pH 7.0), 5 mM sodium caprylate and 750 mM (NH<sub>4</sub>)<sub>2</sub>SO<sub>4 </sub>was performed on a column of Butyl sepharose using gradient #1 described above. In <figref idrefs="DRAWINGS">FIG. 62</figref> the purified conjugate fraction appears in fraction F2.</p>
    <heading>EXAMPLE 63</heading> <heading>“Purification of HSA: Seventh Insulin Derivative Conjugate</heading> <p num="p-0254">The seventh insulin derivative is human insulin with OA-MPA on position B29 of B chain (SEQ ID NO: 45) and native A chain (SEQ ID NO: 35); and is represented in <figref idrefs="DRAWINGS">FIG. 1</figref> shown above in Example 7.”</p>
    <p num="p-0255">The purification of a conjugate made from reacting 2 ml 25% HSA with 1 mM seventh insulin derivative in 15 ml of 20 mM sodium phosphate buffer (pH 7.0), 5 mM sodium caprylate and 750 mM (NH<sub>4</sub>)<sub>2</sub>SO<sub>4 </sub>was performed on a column of Butyl sepharose using gradient #1 described above. In <figref idrefs="DRAWINGS">FIG. 63</figref> the purified conjugate fraction appears in fraction F2.</p>
    <heading>EXAMPLE 64</heading> <heading>Purification of HSA: Third PYY Analogue (SEQ ID NO:46) Conjugate</heading> <p num="p-0256">The third PYY analogue is MPA-PYY (3-36)—CONH<sub>2 </sub>and has the following sequence:
</p> <ul> <li id="ul0058-0001" num="0000"> <ul> <li id="ul0059-0001" num="0287">MPA-NH-IKPEAPGEDASPEELNRYYASLRHYLNLVTRQRY-CONH<sub>2 </sub> </li> </ul> </li> </ul> <p num="p-0257">The purification of a conjugate made from reacting 3 ml 25% HSA with 1 mM third PYY analogue in 18 ml of 20 mM sodium phosphate buffer (pH 7.0), 5 mM sodium caprylate and 750 mM (NH<sub>4</sub>)<sub>2</sub>SO<sub>4 </sub>was performed on a column of Butyl sepharose using gradient #1 described above. In <figref idrefs="DRAWINGS">FIG. 64</figref> the purified conjugate fraction appears in fraction F2.</p>
    <heading>EXAMPLE 65</heading> <heading>Purification of HSA: Fourth PYY Analogue (SEQ ID NO:47) Conjugate</heading> <p num="p-0258">The fourth PYY analogue is PYY (3-36) Lys<sup>37 </sup>(ε-MPA)-CONH<sub>2 </sub>and has the following sequence:
</p> <ul> <li id="ul0060-0001" num="0000"> <ul> <li id="ul0061-0001" num="0290">IKPEAPGEDASPEELNRYYASLRHYLNLVTRQRYK(MPA)-CONH<sub>2 </sub> </li> </ul> </li> </ul> <p num="p-0259">The purification of a conjugate made from reacting 3 ml 25% HSA with 1 mM fourth PYY analogue in 18 ml of 20 mM sodium phosphate buffer (pH 7.0), 5 mM sodium caprylate and 750 mM (NH<sub>4</sub>)<sub>2</sub>SO<sub>4 </sub>was performed on a column of Butyl sepharose using gradient #1 described above. In <figref idrefs="DRAWINGS">FIG. 65</figref> the purified conjugate fraction appears in fraction F2.</p>
    <heading>EXAMPLE 66</heading> <heading>Purification of HSA: Fifth PYY Analogue (SEQ ID NO:48) Conjugate</heading> <p num="p-0260">The fifth PYY analogue is MPA-PYY (22-36)—CONH<sub>2 </sub>and has the following sequence: (MPA)-ASLRHYLNLVTRQRY-CONH<sub>2</sub>.</p>
    <p num="p-0261">The purification of a conjugate made from reacting 6 ml 25% HSA with 1 mM fifth PYY analogue in 36 ml of 20 mM sodium phosphate buffer (pH 7.0), 5 mM sodium caprylate and 900 mM (NH<sub>4</sub>)<sub>2</sub>SO<sub>4 </sub>was performed on a column of Butyl sepharose using gradient #3 described above. In <figref idrefs="DRAWINGS">FIG. 66</figref> the purified conjugate fraction appears in fraction F2.</p>
    <heading>EXAMPLE 67</heading> <heading>Purification of HSA: Sixth PYY Analogue (SEQ ID NO:49) Conjugate</heading> <p num="p-0262">The sixth PYY analogue is Acetyl-PYY (22-36) Lys<sup>37 </sup>(ε-MPA)-CONH<sub>2 </sub>and has the following sequence: Ac-ASLRHYLNLVTRQRYK(MPA)-CONH<sub>2</sub>.</p>
    <p num="p-0263">The purification of a conjugate made from reacting 6 ml 25% HSA with 1 mM sixth PYY analogue in 36 ml of 20 mM sodium phosphate buffer (pH 7.0), 5 mM sodium caprylate and 900 mM (NH<sub>4</sub>)<sub>2</sub>SO<sub>4 </sub>was performed on a column of Butyl sepharose using gradient #3 described above. In <figref idrefs="DRAWINGS">FIG. 67</figref> the purified conjugate fraction appears in fraction F2.</p>
    <heading>EXAMPLE 68</heading> <heading>Purification of HSA: Second ANP Analogue (SEQ ID NO:50) Conjugate</heading> <p num="p-0264">The second ANP analogue is MPA-ANP (99-126)—CONH<sub>2 </sub>and has the following structure:</p>
    <p num="p-0265">
      <tables id="TABLE-US-00005" num="00005"> <table frame="none" colsep="0" rowsep="0" pgwide="1" tabstyle="monospace" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="2"> <colspec colname="1" colwidth="266pt" align="left"> </colspec> <colspec colname="2" colwidth="175pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">   MPA-Ser-Leu-Arg-Arg-Ser-Ser-Cys-Phe-Gly-Gly-Arg-Met-Asp-Arg-</td>
                <td class="description-td"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">                                 |</td>
              </tr> <tr class="description-tr"> <td class="description-td">Ile-Gly-Ala-Gln-Ser-Gly-Leu-Gly-Cys-Asn-Ser-Phe-Arg-Tyr-CONH<sub>2</sub> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <p num="p-0266">The purification of a conjugate made from reacting 1 ml 25% HSA with 1 mM second ANP analogue in 14 ml of 20 mM sodium phosphate buffer (pH 7.0), 5 mM sodium caprylate and 750 mM (NH<sub>4</sub>)<sub>2</sub>SO<sub>4 </sub>was performed on a column of Butyl sepharose using gradient #3 described above. In <figref idrefs="DRAWINGS">FIG. 68</figref> the purified conjugate fraction appears in fraction F2.</p>
    <heading>EXAMPLE 69</heading> <heading>Purification of HSA: Third ANP Analogue (SEQ ID NO:51) Conjugate</heading> <p num="p-0267">The third ANP analogue is ANP (99-126) having reacted with MAL-dPEG<sub>4</sub>™ (Quanta Biodesign, Powell, Ohio, USA) coupled to Ser<sup>99</sup>. The resulting ANP analogue is MPA-EEEEP-ANP (99-126) where EEEEP is ethoxy ethoxy ethoxy ethoxy propionic acid; and its sequence is the following:</p>
    <p num="p-0268"> <tables id="TABLE-US-00006" num="00006"> <table frame="none" colsep="0" rowsep="0" pgwide="1" tabstyle="monospace" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="2"> <colspec colname="1" colwidth="287pt" align="left"> </colspec> <colspec colname="2" colwidth="154pt" align="left"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">MPA-EEEEP-Ser-Leu-Arg-Arg-Ser-Ser-Cys-Phe-Gly-Gly-Arg-Met-Asp-Arg-</td> <td class="description-td"> </td> </tr> <tr class="description-tr"> <td class="description-td">                                  |</td> </tr> <tr class="description-tr"> <td class="description-td"> Ile-Gly-Ala-Gln-Ser-Gly-Leu-Gly-Cys-Asn-Ser-Phe-Arg-Tyr-CONH<sub>2</sub> </td> </tr> </tbody> </tgroup> </table> </tables> <br>
The purification of a conjugate made from reacting 1 ml 25% HSA with 1 mM CJC 1681 in 14 ml of 20 mM sodium phosphate buffer (pH 7.0), 5 mM sodium caprylate and 900 mM (NH<sub>4</sub>)<sub>2</sub>SO<sub>4 </sub>was performed on a column of Butyl sepharose using gradient #3 described above. In <figref idrefs="DRAWINGS">FIGS. 69A and 69B</figref> the purified conjugate fraction appears in fraction F2.
</p>
    <heading>EXAMPLE 70</heading> <heading>Purification of HSA: First GLP-1 Analogue (SEQ ID NO:1) Conjugate</heading> <p num="p-0269">The first GLP-1 analogue is GLP-1 (7-36) dAla<sup>8 </sup>Lys<sup>37 </sup>(ε-AEEA-MPA)-CONH<sub>2 </sub>and his sequence is shown above in Example 1.</p>
    <p num="p-0270">The purification of a conjugate made from reacting 1 ml 25% 250 mg/ml HSA (Cortex-Biochem, San Leandro, Calif.) with 1 mM first GLP-1 analogue diluted into 9 ml of buffer made of 20 mM sodium phosphate buffer pH 7.0, 5 mM sodium caprylate and 1.75M (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub>, was performed on a column of Butyl sepharose using the gradient #6 described above. In <figref idrefs="DRAWINGS">FIG. 70</figref> the purified conjugate fraction appears in fraction B.</p>
    <heading>EXAMPLE 71</heading> <heading>Purification of HSA: First GLP-1 Analogue (SEQ ID NO:1) Conjugate</heading> <p num="p-0271">The first GLP-1 analogue is GLP-1 (7-36) dAla<sup>8 </sup>Lys<sup>37 </sup>(ε-AEEA-MPA)-CONH<sub>2 </sub>and his sequence is shown above in Example 1.</p>
    <p num="p-0272">The purification of a conjugate made from reacting 1 ml 25% 250 mg/ml HSA (Cortex-Biochem, San Leandro, Calif.) with 1 mM first GLP-1 analogue diluted into 9 ml of buffer made of 20 mM sodium phosphate buffer pH 7.0, 5 mM sodium caprylate and 1.75M magnesium sulfate, was performed on a column of Butyl sepharose using the gradient #6 described above. In <figref idrefs="DRAWINGS">FIG. 71</figref> the purified conjugate fraction appears in fraction F2.</p>
    <heading>EXAMPLE 72</heading> <heading>Purification of HSA: First GLP-1 Analogue (SEQ ID NO:1) Conjugate</heading> <p num="p-0273">The first GLP-1 analogue is GLP-1 (7-36) dAla<sup>8 </sup>Lys<sup>37 </sup>(ε-AEEA-MPA)-CONH<sub>2 </sub>and his sequence is shown above in Example 1.</p>
    <p num="p-0274">Example with 750 mM ammonium sulfate The purification of a conjugate made from reacting 1 ml 25% 250 mg/ml HSA (Cortex-Biochem, San Leandro, Calif.) with 1 mM first GLP-1 analogue diluted into 9 ml of buffer made of 20 mM sodium phosphate buffer pH 7.0, 5 mM sodium caprylate and 750 mM (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub>, was performed on a column of Butyl sepharose using the gradient #1 described above. In <figref idrefs="DRAWINGS">FIG. 72</figref> the purified conjugate fraction appears in fraction F2.</p>
    <heading>EXAMPLE 73</heading> <heading>Purification of HSA: First GLP-1 Analogue (SEQ ID NO:1) Conjugate</heading> <p num="p-0275">The first GLP-1 analogue is GLP-1 (7-36) dAla<sup>8 </sup>Lys<sup>37 </sup>(ε-AEEA-MPA)-CONH<sub>2 </sub>and his sequence is shown above in Example 1.</p>
    <p num="p-0276">Example with 1.75M ammonium phosphate The purification of a conjugate made from reacting 1 ml 25% 250 mg/ml HSA (Cortex-Biochem, San Leandro, Calif.) with 1 mM first GLP-1 analogue diluted into 9 ml of buffer made of 20 mM sodium phosphate buffer pH 7.0, 5 mM sodium caprylate and 1.75M ammonium phosphate, was performed on a column of Butyl sepharose using the gradient #6 described above. In <figref idrefs="DRAWINGS">FIG. 73</figref> the purified conjugate fraction appears in fraction B.</p>
    <heading>EXAMPLE 74</heading> <heading>Purification of HSA: First GLP-1 Analogue (SEQ ID NO:1) Conjugate</heading> <p num="p-0277">The first GLP-1 analogue is GLP-1 (7-36) dAla<sup>8 </sup>Lys<sup>37 </sup>(ε-AEEA-MPA)-CONH<sub>2 </sub>and his sequence is shown above in Example 1.</p>
    <p num="p-0278">Example with 750 mM ammonium phosphate The purification of a conjugate made from reacting 1 ml 25% 250 mg/ml HSA (Cortex-Biochem, San Leandro, Calif.) with 1 mM first GLP-1 analogue diluted into 9 ml of buffer made of 20 mM sodium phosphate buffer pH 7.0, 5 mM sodium caprylate and 750 mM ammonium phosphate, was performed on a column of Butyl sepharose using the gradient #1 described above. In <figref idrefs="DRAWINGS">FIG. 74</figref> the purified conjugate fraction appears in fraction F2.</p>
    <heading>EXAMPLE 75</heading> <heading>Purification of HSA: First GLP-2 Analogue (SEQ ID NO:52) Conjugate</heading> <p num="p-0279">The first GLP-2 analogue is GLP-2 (1-33) Gly<sup>2 </sup>Lys<sup>34 </sup>(ε-MPA)-CONH<sub>2 </sub>and has the following sequence:
</p> <ul> <li id="ul0062-0001" num="0000"> <ul> <li id="ul0063-0001" num="0312">HGDGSFSDEMNTILDNLAARDFINWLIQTKITDK(MPA)-CONH<sub>2 </sub> </li> </ul> </li> </ul> <p num="p-0280">The purification of a conjugate made from reacting 2 ml 25% 250 mg/ml HSA (Cortex-Biochem, San Leandro, Calif.) with 1 mM first GLP-2 analogue diluted into 14 ml of buffer made of 20 mM sodium phosphate buffer pH 7.0, 5 mM sodium caprylate and 750 mM (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub>, was performed on a column of Butyl sepharose using the gradient #1 described above. In <figref idrefs="DRAWINGS">FIG. 75</figref> the purified conjugate fraction appears in fraction F2.</p>
    <heading>EXAMPLE 76</heading> <heading>Purification of RSA: First GLP-2 Analogue (SEQ ID NO:52) Conjugate</heading> <p num="p-0281">The first GLP-2 analogue is GLP-2 (1-33) Gly<sup>2 </sup>Lys<sup>34 </sup>(ε-MPA)-CONH<sub>2 </sub>and his sequence is shown in Example 75.</p>
    <p num="p-0282">The purification of a conjugate made from reacting 9 ml 25% 250 mg/ml RSA (rat serum albumin) with 1 mM first GLP-2 analogue diluted into 14 ml of buffer made of 20 mM sodium phosphate buffer pH 7.0, 5 mM sodium caprylate and 750 mM (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub>, was performed on a column of Butyl sepharose using the gradient #1 described above. In <figref idrefs="DRAWINGS">FIG. 76</figref> the purified conjugate fraction appears in fraction F2.</p>
    <p num="p-0283">While the invention has been described in connection with specific embodiments thereof, it will be understood that it is capable of further modifications and this application is intended to cover any variations, uses, or adaptations of the invention following, in general, the principles of the invention and including such departures from the present disclosure as come within known or customary practice within the art to which the invention pertains and as may be applied to the essential features hereinbefore set forth, and as follows in the scope of the appended claims.</p>
    </div></div></div><div class="patent-section patent-tabular-section"><a id="backward-citations"></a><div class="patent-section-header"><span class="patent-section-title">Patent Citations</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th class="patent-data-table-th">Cited Patent</th><th class="patent-data-table-th">Filing date</th><th class="patent-data-table-th">Publication date</th><th class="patent-data-table-th">Applicant</th><th class="patent-data-table-th">Title</th></tr></thead><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US4206199">US4206199</a></td><td class="patent-data-table-td patent-date-value">Jul 14, 1978</td><td class="patent-data-table-td patent-date-value">Jun 3, 1980</td><td class="patent-data-table-td ">Takeda Chemical Industries, Ltd.</td><td class="patent-data-table-td ">Novel glucagon fragment and its derivatives</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US4251631">US4251631</a></td><td class="patent-data-table-td patent-date-value">Feb 1, 1979</td><td class="patent-data-table-td patent-date-value">Feb 17, 1981</td><td class="patent-data-table-td ">Research Products Rehovot Ltd.</td><td class="patent-data-table-td ">Enzymes crosslink with each other after being adsorbed onto vinyl chloride polymer membrane embedded with silica</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US4423034">US4423034</a></td><td class="patent-data-table-td patent-date-value">Apr 28, 1982</td><td class="patent-data-table-td patent-date-value">Dec 27, 1983</td><td class="patent-data-table-td ">Toyo Jozo Kabushiki Kaisha</td><td class="patent-data-table-td ">Process for the preparation of antibodies</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US4462941">US4462941</a></td><td class="patent-data-table-td patent-date-value">Jun 10, 1982</td><td class="patent-data-table-td patent-date-value">Jul 31, 1984</td><td class="patent-data-table-td ">The Regents Of The University Of California</td><td class="patent-data-table-td ">Pontentiation of narcotic analgesics in tolerant hosts</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US4678671">US4678671</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Sep 9, 1986</td><td class="patent-data-table-td patent-date-value">Jul 7, 1987</td><td class="patent-data-table-td ">Cordis Europa N.V.</td><td class="patent-data-table-td ">Conjugates of anticoagulant and protein</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US4745100">US4745100</a></td><td class="patent-data-table-td patent-date-value">Feb 19, 1986</td><td class="patent-data-table-td patent-date-value">May 17, 1988</td><td class="patent-data-table-td ">Eye Research Institute Of Retina Foundation</td><td class="patent-data-table-td ">Stimulation of tear secretion</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US4766106">US4766106</a></td><td class="patent-data-table-td patent-date-value">Jan 25, 1988</td><td class="patent-data-table-td patent-date-value">Aug 23, 1988</td><td class="patent-data-table-td ">Cetus Corporation</td><td class="patent-data-table-td ">Solubilization of proteins for pharmaceutical compositions using polymer conjugation</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US4859604">US4859604</a></td><td class="patent-data-table-td patent-date-value">Aug 27, 1987</td><td class="patent-data-table-td patent-date-value">Aug 22, 1989</td><td class="patent-data-table-td ">Ampor, Inc.</td><td class="patent-data-table-td ">Composition for stabilization of diagnostic reagents</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US4902505">US4902505</a></td><td class="patent-data-table-td patent-date-value">Apr 25, 1988</td><td class="patent-data-table-td patent-date-value">Feb 20, 1990</td><td class="patent-data-table-td ">Alkermes</td><td class="patent-data-table-td ">Chimeric peptides for neuropeptide delivery through the blood-brain barrier</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5103233">US5103233</a></td><td class="patent-data-table-td patent-date-value">Apr 16, 1991</td><td class="patent-data-table-td patent-date-value">Apr 7, 1992</td><td class="patent-data-table-td ">General Electric Co.</td><td class="patent-data-table-td ">Radar system with elevation-responsive PRF control, beam multiplex control, and pulse integration control responsive to azimuth angle</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5118666">US5118666</a></td><td class="patent-data-table-td patent-date-value">Jun 1, 1990</td><td class="patent-data-table-td patent-date-value">Jun 2, 1992</td><td class="patent-data-table-td ">The General Hospital Corporation</td><td class="patent-data-table-td ">Insulinotropic hormone</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5120712">US5120712</a></td><td class="patent-data-table-td patent-date-value">Jun 1, 1990</td><td class="patent-data-table-td patent-date-value">Jun 9, 1992</td><td class="patent-data-table-td ">The General Hospital Corporation</td><td class="patent-data-table-td ">Insulinotropic hormone</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5424286">US5424286</a></td><td class="patent-data-table-td patent-date-value">May 24, 1993</td><td class="patent-data-table-td patent-date-value">Jun 13, 1995</td><td class="patent-data-table-td ">Eng; John</td><td class="patent-data-table-td ">Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5493007">US5493007</a></td><td class="patent-data-table-td patent-date-value">Sep 23, 1994</td><td class="patent-data-table-td patent-date-value">Feb 20, 1996</td><td class="patent-data-table-td ">Genentech, Inc.</td><td class="patent-data-table-td ">Oligopeptide</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5545618">US5545618</a></td><td class="patent-data-table-td patent-date-value">Dec 10, 1993</td><td class="patent-data-table-td patent-date-value">Aug 13, 1996</td><td class="patent-data-table-td ">Buckley; Douglas I.</td><td class="patent-data-table-td ">GLP-1 analogs useful for diabetes treatment</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5574008">US5574008</a></td><td class="patent-data-table-td patent-date-value">Aug 30, 1994</td><td class="patent-data-table-td patent-date-value">Nov 12, 1996</td><td class="patent-data-table-td ">Eli Lilly And Company</td><td class="patent-data-table-td ">Antidiabetic agents</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5580853">US5580853</a></td><td class="patent-data-table-td patent-date-value">Mar 22, 1994</td><td class="patent-data-table-td patent-date-value">Dec 3, 1996</td><td class="patent-data-table-td ">New England Deaconess Hospital</td><td class="patent-data-table-td ">Erythropoietin with attached heterobifunctional crosslinking reagent containing cleavable disulfide bond group</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5612034">US5612034</a></td><td class="patent-data-table-td patent-date-value">May 3, 1994</td><td class="patent-data-table-td patent-date-value">Mar 18, 1997</td><td class="patent-data-table-td ">Redcell, Inc.</td><td class="patent-data-table-td ">Super-globuling for in vivo extended lifetimes</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5612458">US5612458</a></td><td class="patent-data-table-td patent-date-value">Dec 22, 1994</td><td class="patent-data-table-td patent-date-value">Mar 18, 1997</td><td class="patent-data-table-td ">Dako/As</td><td class="patent-data-table-td ">Antibody to PNA/nucleic acid complexes</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5614487">US5614487</a></td><td class="patent-data-table-td patent-date-value">May 28, 1993</td><td class="patent-data-table-td patent-date-value">Mar 25, 1997</td><td class="patent-data-table-td ">Genentech, Inc.</td><td class="patent-data-table-td ">Sustained release pharmaceutical composition</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5614492">US5614492</a></td><td class="patent-data-table-td patent-date-value">Nov 23, 1993</td><td class="patent-data-table-td patent-date-value">Mar 25, 1997</td><td class="patent-data-table-td ">The General Hospital Corporation</td><td class="patent-data-table-td ">Diabetes</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5654276">US5654276</a></td><td class="patent-data-table-td patent-date-value">Jun 7, 1995</td><td class="patent-data-table-td patent-date-value">Aug 5, 1997</td><td class="patent-data-table-td ">Affymax Technologies N.V.</td><td class="patent-data-table-td ">Peptides and compounds that bind to the IL-5 receptor</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5705483">US5705483</a></td><td class="patent-data-table-td patent-date-value">Mar 21, 1995</td><td class="patent-data-table-td patent-date-value">Jan 6, 1998</td><td class="patent-data-table-td ">Eli Lilly And Company</td><td class="patent-data-table-td ">Glucagon-like insulinotropic peptides, compositions and methods</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5725804">US5725804</a></td><td class="patent-data-table-td patent-date-value">Jun 6, 1995</td><td class="patent-data-table-td patent-date-value">Mar 10, 1998</td><td class="patent-data-table-td ">Hemosphere, Inc.</td><td class="patent-data-table-td ">Non-crosslinked protein particles for therapeutic and diagnostic use</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5770570">US5770570</a></td><td class="patent-data-table-td patent-date-value">Aug 25, 1995</td><td class="patent-data-table-td patent-date-value">Jun 23, 1998</td><td class="patent-data-table-td ">Paul; Sudhir</td><td class="patent-data-table-td ">Method of delivering a vasoactive intestinal polypeptide, an encapsulated vasoactive intestinal polypeptide, and a method of making the encapsulated vasoactive intestinal polypeptide</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5807827">US5807827</a></td><td class="patent-data-table-td patent-date-value">May 14, 1997</td><td class="patent-data-table-td patent-date-value">Sep 15, 1998</td><td class="patent-data-table-td ">Des-Tyr Dynorphin Partnership</td><td class="patent-data-table-td ">Narcotic analgesic potentiation, narcotic withdrawal</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5840733">US5840733</a></td><td class="patent-data-table-td patent-date-value">Jul 1, 1996</td><td class="patent-data-table-td patent-date-value">Nov 24, 1998</td><td class="patent-data-table-td ">Redcell, Canada, Inc.</td><td class="patent-data-table-td ">Argatroban derivatives which can be covalently linked to various blood components</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5843440">US5843440</a></td><td class="patent-data-table-td patent-date-value">Aug 14, 1996</td><td class="patent-data-table-td patent-date-value">Dec 1, 1998</td><td class="patent-data-table-td ">Redcell Canada, Inc.</td><td class="patent-data-table-td ">Cellular and serum protein anchors for modulating pharmacokinetics</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5855866">US5855866</a></td><td class="patent-data-table-td patent-date-value">Mar 2, 1994</td><td class="patent-data-table-td patent-date-value">Jan 5, 1999</td><td class="patent-data-table-td ">Board Of Regenis, The University Of Texas System</td><td class="patent-data-table-td ">Constructs designed to have a cytotoxic or otherwise anticellular effect against tumor vasculature</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5869602">US5869602</a></td><td class="patent-data-table-td patent-date-value">May 23, 1995</td><td class="patent-data-table-td patent-date-value">Feb 9, 1999</td><td class="patent-data-table-td ">Novo Nordisk A/S</td><td class="patent-data-table-td ">Glucagon having lipophilic substituent on epsilon-amino group of lysine in position 30</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5874408">US5874408</a></td><td class="patent-data-table-td patent-date-value">May 28, 1998</td><td class="patent-data-table-td patent-date-value">Feb 23, 1999</td><td class="patent-data-table-td ">Bayer Corporation</td><td class="patent-data-table-td ">Stabilized albumin-free recombinant factor VII preparation having a low sugar content</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5939390">US5939390</a></td><td class="patent-data-table-td patent-date-value">Sep 9, 1997</td><td class="patent-data-table-td patent-date-value">Aug 17, 1999</td><td class="patent-data-table-td ">Novo Nordisk A/S</td><td class="patent-data-table-td ">Pharmaceutical composition</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5942620">US5942620</a></td><td class="patent-data-table-td patent-date-value">Jul 1, 1998</td><td class="patent-data-table-td patent-date-value">Aug 24, 1999</td><td class="patent-data-table-td ">Conjuchem, Inc.</td><td class="patent-data-table-td ">Methods for producing novel conjugates of thrombin inhibitors</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5958909">US5958909</a></td><td class="patent-data-table-td patent-date-value">Nov 20, 1996</td><td class="patent-data-table-td patent-date-value">Sep 28, 1999</td><td class="patent-data-table-td ">The General Hospital Corporation</td><td class="patent-data-table-td ">Insulinotropic hormones and uses thereof</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5981488">US5981488</a></td><td class="patent-data-table-td patent-date-value">Mar 25, 1998</td><td class="patent-data-table-td patent-date-value">Nov 9, 1999</td><td class="patent-data-table-td ">Eli Lillly And Company</td><td class="patent-data-table-td ">Polypeptide; antidiabetic agent</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6005081">US6005081</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Nov 14, 1997</td><td class="patent-data-table-td patent-date-value">Dec 21, 1999</td><td class="patent-data-table-td ">Genentech, Inc.</td><td class="patent-data-table-td ">Purification of recombinant human neurotrophins</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6006753">US6006753</a></td><td class="patent-data-table-td patent-date-value">Aug 21, 1997</td><td class="patent-data-table-td patent-date-value">Dec 28, 1999</td><td class="patent-data-table-td ">Eli Lilly And Company</td><td class="patent-data-table-td ">Therapy</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6087375">US6087375</a></td><td class="patent-data-table-td patent-date-value">Jun 11, 1999</td><td class="patent-data-table-td patent-date-value">Jul 11, 2000</td><td class="patent-data-table-td ">Conjuchem, Inc.</td><td class="patent-data-table-td ">Methods of treating or preventing thromboses</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6103233">US6103233</a></td><td class="patent-data-table-td patent-date-value">Jun 7, 1995</td><td class="patent-data-table-td patent-date-value">Aug 15, 2000</td><td class="patent-data-table-td ">Conjuchem, Inc.</td><td class="patent-data-table-td ">Cellular and serum protein anchors and conjugates</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6107489">US6107489</a></td><td class="patent-data-table-td patent-date-value">Mar 12, 1999</td><td class="patent-data-table-td patent-date-value">Aug 22, 2000</td><td class="patent-data-table-td ">Conjuchem, Inc.</td><td class="patent-data-table-td ">Chemically reactive tripeptide intermediates which can react with available reactive functionalities on blood components to form covalent linkages, the resulting conjugates have renin inhibition activity for extended periods of time</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6133235">US6133235</a></td><td class="patent-data-table-td patent-date-value">Jul 6, 1999</td><td class="patent-data-table-td patent-date-value">Oct 17, 2000</td><td class="patent-data-table-td ">Eli Lilly And Company</td><td class="patent-data-table-td ">Glucagon-like insulinotropic peptides compositions and methods</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6191102">US6191102</a></td><td class="patent-data-table-td patent-date-value">Oct 30, 1997</td><td class="patent-data-table-td patent-date-value">Feb 20, 2001</td><td class="patent-data-table-td ">Eli Lilly And Company</td><td class="patent-data-table-td ">Glucagon like peptide</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6268343">US6268343</a></td><td class="patent-data-table-td patent-date-value">Feb 26, 1999</td><td class="patent-data-table-td patent-date-value">Jul 31, 2001</td><td class="patent-data-table-td ">Novo Nordisk A/S</td><td class="patent-data-table-td ">Derivatives of GLP-1 analogs</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6277583">US6277583</a></td><td class="patent-data-table-td patent-date-value">Feb 7, 1996</td><td class="patent-data-table-td patent-date-value">Aug 21, 2001</td><td class="patent-data-table-td ">Conjuchem, Inc.</td><td class="patent-data-table-td ">Affinity labeling libraries and applications thereof</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6277819">US6277819</a></td><td class="patent-data-table-td patent-date-value">Aug 21, 1997</td><td class="patent-data-table-td patent-date-value">Aug 21, 2001</td><td class="patent-data-table-td ">Eli Lilly And Company</td><td class="patent-data-table-td ">Use of GLP-1 or analogs in treatment of myocardial infarction</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6277863">US6277863</a></td><td class="patent-data-table-td patent-date-value">Jun 22, 2000</td><td class="patent-data-table-td patent-date-value">Aug 21, 2001</td><td class="patent-data-table-td ">Conjuchem, Inc.</td><td class="patent-data-table-td ">Anticoagulant with reduced side effects</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6284725">US6284725</a></td><td class="patent-data-table-td patent-date-value">Apr 30, 1999</td><td class="patent-data-table-td patent-date-value">Sep 4, 2001</td><td class="patent-data-table-td ">Bionebraska, Inc.</td><td class="patent-data-table-td ">Administering binding compound for glucagon receptor such asglucagon-like peptide</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6329336">US6329336</a></td><td class="patent-data-table-td patent-date-value">May 17, 2000</td><td class="patent-data-table-td patent-date-value">Dec 11, 2001</td><td class="patent-data-table-td ">Conjuchem, Inc.</td><td class="patent-data-table-td ">Glue and crosslinking agent using albumin</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6403324">US6403324</a></td><td class="patent-data-table-td patent-date-value">Mar 13, 1998</td><td class="patent-data-table-td patent-date-value">Jun 11, 2002</td><td class="patent-data-table-td ">Conjuchem, Inc.</td><td class="patent-data-table-td ">Affinity labeling libraries with tagged leaving group</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6437092">US6437092</a></td><td class="patent-data-table-td patent-date-value">Nov 6, 1998</td><td class="patent-data-table-td patent-date-value">Aug 20, 2002</td><td class="patent-data-table-td ">Conjuchem, Inc.</td><td class="patent-data-table-td ">Administering polypeptide with lysine residue derivatized with maleimidopropionic acid; analgesics; narcotic abuse withdrawal</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6440417">US6440417</a></td><td class="patent-data-table-td patent-date-value">Nov 5, 1999</td><td class="patent-data-table-td patent-date-value">Aug 27, 2002</td><td class="patent-data-table-td ">Conjuchem, Inc.</td><td class="patent-data-table-td ">Measuring concentration of therapeutic agent in blood or serum with high specificity; isolated monoclonal antibody produced by hybridoma cell line 9c10 having atcc accession number pta-3772</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6500918">US6500918</a></td><td class="patent-data-table-td patent-date-value">Mar 1, 2001</td><td class="patent-data-table-td patent-date-value">Dec 31, 2002</td><td class="patent-data-table-td ">Conjuchem, Inc.</td><td class="patent-data-table-td ">Conjugate comprising an antinociceptive agent covalently bonded to a blood component</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6506724">US6506724</a></td><td class="patent-data-table-td patent-date-value">Jun 1, 1999</td><td class="patent-data-table-td patent-date-value">Jan 14, 2003</td><td class="patent-data-table-td ">Amylin Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Exendins are peptides that were first isolated from the salivary secretions of the Gila-monster, a lizard found in Arizona and have some sequence similarity to several members of the glucagon-like peptide</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6514500">US6514500</a></td><td class="patent-data-table-td patent-date-value">Sep 7, 2000</td><td class="patent-data-table-td patent-date-value">Feb 4, 2003</td><td class="patent-data-table-td ">Conjuchem, Inc.</td><td class="patent-data-table-td ">Long lasting synthetic glucagon like peptide {GLP-!}</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6528486">US6528486</a></td><td class="patent-data-table-td patent-date-value">Jul 12, 2000</td><td class="patent-data-table-td patent-date-value">Mar 4, 2003</td><td class="patent-data-table-td ">Zealand Pharma A/S</td><td class="patent-data-table-td ">Conjugates which have increased stability, useful in the treatment of excess levels of blood glucose.</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6583111">US6583111</a></td><td class="patent-data-table-td patent-date-value">Jun 1, 2000</td><td class="patent-data-table-td patent-date-value">Jun 24, 2003</td><td class="patent-data-table-td ">Eli Lilly And Company</td><td class="patent-data-table-td ">Use of GLP-1 analogs and derivative adminstered peripherally in regulation of obesity</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6593295">US6593295</a></td><td class="patent-data-table-td patent-date-value">Jun 6, 2001</td><td class="patent-data-table-td patent-date-value">Jul 15, 2003</td><td class="patent-data-table-td ">Conjuchem, Inc.</td><td class="patent-data-table-td ">Long lasting insulinotropic peptides</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6602981">US6602981</a></td><td class="patent-data-table-td patent-date-value">Mar 1, 2001</td><td class="patent-data-table-td patent-date-value">Aug 5, 2003</td><td class="patent-data-table-td ">Conjuchem, Inc.</td><td class="patent-data-table-td ">Antinociceptive agent derivative</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6610825">US6610825</a></td><td class="patent-data-table-td patent-date-value">Mar 1, 2001</td><td class="patent-data-table-td patent-date-value">Aug 26, 2003</td><td class="patent-data-table-td ">Conjuchem, Inc.</td><td class="patent-data-table-td ">Method for alleviating pain or providing an analgesic effect in a patient</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6660716">US6660716</a></td><td class="patent-data-table-td patent-date-value">Jun 6, 2000</td><td class="patent-data-table-td patent-date-value">Dec 9, 2003</td><td class="patent-data-table-td ">Eli Lilly And Company</td><td class="patent-data-table-td ">Method for treating non-insulin dependent diabetes using thiazolidinediones with glucagon-like peptide-1 and agonists thereof</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6703359">US6703359</a></td><td class="patent-data-table-td patent-date-value">Feb 5, 1999</td><td class="patent-data-table-td patent-date-value">Mar 9, 2004</td><td class="patent-data-table-td ">Amylin Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Treating toxic hypervolemia, renal failure, congestive heart failure, nephrotic syndrome, pulmonary edema, and hypertension</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6706689">US6706689</a></td><td class="patent-data-table-td patent-date-value">May 18, 2001</td><td class="patent-data-table-td patent-date-value">Mar 16, 2004</td><td class="patent-data-table-td ">Amylin Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Administering glucagon like peptide-1 (glp-1), where the patient is not suffering from a q-wave myocardial infarction</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6706892">US6706892</a></td><td class="patent-data-table-td patent-date-value">Sep 6, 2000</td><td class="patent-data-table-td patent-date-value">Mar 16, 2004</td><td class="patent-data-table-td ">Conjuchem, Inc.</td><td class="patent-data-table-td ">Adminstering maleimide derivative to covalently bond protein; wound healing, antibiotic, antiinflammatory, anticarcinogenic, hypotensive, and analgesic agents</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6723530">US6723530</a></td><td class="patent-data-table-td patent-date-value">Feb 5, 1998</td><td class="patent-data-table-td patent-date-value">Apr 20, 2004</td><td class="patent-data-table-td ">Amylin Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Polynucleotides encoding proexendin, and methods and uses thereof</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6767887">US6767887</a></td><td class="patent-data-table-td patent-date-value">Jun 5, 1997</td><td class="patent-data-table-td patent-date-value">Jul 27, 2004</td><td class="patent-data-table-td ">Roche Diagnostics Gmbh</td><td class="patent-data-table-td ">Peptides that stimulate release of insulin; treating diabetes</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6821949">US6821949</a></td><td class="patent-data-table-td patent-date-value">Nov 4, 2002</td><td class="patent-data-table-td patent-date-value">Nov 23, 2004</td><td class="patent-data-table-td ">Conjuchem, Inc.</td><td class="patent-data-table-td ">Long lasting synthetic glucagon-like peptide (GLP-1)</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6849714">US6849714</a></td><td class="patent-data-table-td patent-date-value">May 17, 2000</td><td class="patent-data-table-td patent-date-value">Feb 1, 2005</td><td class="patent-data-table-td ">Conjuchem, Inc.</td><td class="patent-data-table-td ">By a modification that enables the peptide to selectively conjugate to blood components, thus protecting the peptide from peptidase activity and increasing the duration of action of the therapeutic peptide for the treatment of various</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6858576">US6858576</a></td><td class="patent-data-table-td patent-date-value">Aug 8, 1997</td><td class="patent-data-table-td patent-date-value">Feb 22, 2005</td><td class="patent-data-table-td ">Amylin Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Methods for regulating gastrointestinal motility</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6861236">US6861236</a></td><td class="patent-data-table-td patent-date-value">Feb 7, 2003</td><td class="patent-data-table-td patent-date-value">Mar 1, 2005</td><td class="patent-data-table-td ">Applied Nanosystems B.V.</td><td class="patent-data-table-td ">Harvesting antibiotic peptides comprising transport protein leader sequences</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6872700">US6872700</a></td><td class="patent-data-table-td patent-date-value">Jan 14, 2000</td><td class="patent-data-table-td patent-date-value">Mar 29, 2005</td><td class="patent-data-table-td ">Amylin Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Methods for glucagon suppression</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6887470">US6887470</a></td><td class="patent-data-table-td patent-date-value">Sep 7, 2000</td><td class="patent-data-table-td patent-date-value">May 3, 2005</td><td class="patent-data-table-td ">Conjuchem, Inc.</td><td class="patent-data-table-td ">Covalently bonding albumin to oligopeptide; biochemical conjugation; analyzing stability</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6887849">US6887849</a></td><td class="patent-data-table-td patent-date-value">Nov 4, 2002</td><td class="patent-data-table-td patent-date-value">May 3, 2005</td><td class="patent-data-table-td ">Conjuchem, Inc.</td><td class="patent-data-table-td ">Long lasting synthetic glucagon-like peptide {GLP-1}</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6894024">US6894024</a></td><td class="patent-data-table-td patent-date-value">Oct 22, 2001</td><td class="patent-data-table-td patent-date-value">May 17, 2005</td><td class="patent-data-table-td ">Amylin Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Administering a therapeutically effective amount of a GLP-1 (glucagon like peptide-1) molecule for therapy of hibernating myocardium</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6902744">US6902744</a></td><td class="patent-data-table-td patent-date-value">Jan 14, 2000</td><td class="patent-data-table-td patent-date-value">Jun 7, 2005</td><td class="patent-data-table-td ">Amylin Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Exendin agonist formulations and methods of administration thereof</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6924264">US6924264</a></td><td class="patent-data-table-td patent-date-value">Apr 28, 2000</td><td class="patent-data-table-td patent-date-value">Aug 2, 2005</td><td class="patent-data-table-td ">Amylin Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">chain extension of polypeptides using polymers selected from polyethylene glycol, polylactams, albumin, gelatin, acrylic polymers, fatty acids, polysaccharides, lipid and/or dextrans; antidiabetic agents</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6956026">US6956026</a></td><td class="patent-data-table-td patent-date-value">Jan 7, 1998</td><td class="patent-data-table-td patent-date-value">Oct 18, 2005</td><td class="patent-data-table-td ">Amylin Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Use of exendins for the reduction of food intake</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6989366">US6989366</a></td><td class="patent-data-table-td patent-date-value">Jun 28, 2002</td><td class="patent-data-table-td patent-date-value">Jan 24, 2006</td><td class="patent-data-table-td ">Amylin Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Exendins, exendin agonists, and methods for their use</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6998387">US6998387</a></td><td class="patent-data-table-td patent-date-value">Mar 16, 1999</td><td class="patent-data-table-td patent-date-value">Feb 14, 2006</td><td class="patent-data-table-td ">Amylin Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Human appetite control by glucagon-like peptide receptor binding compounds</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7090851">US7090851</a></td><td class="patent-data-table-td patent-date-value">Sep 7, 2000</td><td class="patent-data-table-td patent-date-value">Aug 15, 2006</td><td class="patent-data-table-td ">Conjuchem Inc.</td><td class="patent-data-table-td ">Long lasting fusion peptide inhibitors of viral infection</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7105508">US7105508</a></td><td class="patent-data-table-td patent-date-value">Aug 1, 2000</td><td class="patent-data-table-td patent-date-value">Sep 12, 2006</td><td class="patent-data-table-td ">Abbott Gmbh &amp; Co. Kg</td><td class="patent-data-table-td ">Integrin receptors antagonists</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7112567">US7112567</a></td><td class="patent-data-table-td patent-date-value">Feb 15, 2002</td><td class="patent-data-table-td patent-date-value">Sep 26, 2006</td><td class="patent-data-table-td ">Conjuchem Inc.</td><td class="patent-data-table-td ">reactive entity (maleimide) coupled to the peptide conjugated to blood protein such as immunoglobulins, including IgG and IgM, serum albumin, ferritin, steroid binding proteins, transferrin, thyroxin binding protein, alpha -2-macroglobulin, haptoglobin, etc.</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7144854">US7144854</a></td><td class="patent-data-table-td patent-date-value">Sep 7, 2000</td><td class="patent-data-table-td patent-date-value">Dec 5, 2006</td><td class="patent-data-table-td ">Conjuchem, Inc.</td><td class="patent-data-table-td ">Long lasting anti-angiogenic peptides</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7166695">US7166695</a></td><td class="patent-data-table-td patent-date-value">Sep 2, 2004</td><td class="patent-data-table-td patent-date-value">Jan 23, 2007</td><td class="patent-data-table-td ">Conjuchem Biotechnologies Inc.</td><td class="patent-data-table-td ">Affinity markers for human serum albumin</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US20010018421">US20010018421</a></td><td class="patent-data-table-td patent-date-value">Mar 1, 2001</td><td class="patent-data-table-td patent-date-value">Aug 30, 2001</td><td class="patent-data-table-td ">Ezrin Alan M.</td><td class="patent-data-table-td ">Polypeptides</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US20010047084">US20010047084</a></td><td class="patent-data-table-td patent-date-value">Jun 21, 2001</td><td class="patent-data-table-td patent-date-value">Nov 29, 2001</td><td class="patent-data-table-td ">Knudsen Liselotte Bjerre</td><td class="patent-data-table-td ">Extendin derivatives</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US20020009441">US20020009441</a></td><td class="patent-data-table-td patent-date-value">Aug 3, 2001</td><td class="patent-data-table-td patent-date-value">Jan 24, 2002</td><td class="patent-data-table-td ">Philippe Pouletty</td><td class="patent-data-table-td ">Administering mixture of binding agent and active materials</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US20020018751">US20020018751</a></td><td class="patent-data-table-td patent-date-value">Jun 7, 1999</td><td class="patent-data-table-td patent-date-value">Feb 14, 2002</td><td class="patent-data-table-td ">BRIDON Dominique P.</td><td class="patent-data-table-td ">Cellular and serum protein anchors for diagnostic imaging</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US20020039999">US20020039999</a></td><td class="patent-data-table-td patent-date-value">Mar 1, 2001</td><td class="patent-data-table-td patent-date-value">Apr 4, 2002</td><td class="patent-data-table-td ">Ezrin Alan M.</td><td class="patent-data-table-td ">Antinociceptive agent derivative</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US20020049153">US20020049153</a></td><td class="patent-data-table-td patent-date-value">Jun 6, 2001</td><td class="patent-data-table-td patent-date-value">Apr 25, 2002</td><td class="patent-data-table-td ">BRIDON Dominique P.</td><td class="patent-data-table-td ">Modified peptides capable of forming covalent bonds with one or more blood components, especially albumin, to form a conjugate; administered to treat humans with diabetes</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US20030073630">US20030073630</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Feb 1, 2002</td><td class="patent-data-table-td patent-date-value">Apr 17, 2003</td><td class="patent-data-table-td ">BRIDON Dominique P.</td><td class="patent-data-table-td ">Long lasting growth hormone releasing factor derivatives</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US20030108567">US20030108567</a></td><td class="patent-data-table-td patent-date-value">Nov 4, 2002</td><td class="patent-data-table-td patent-date-value">Jun 12, 2003</td><td class="patent-data-table-td ">BRIDON Dominique P.</td><td class="patent-data-table-td ">Antidiabetic agents</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US20030108568">US20030108568</a></td><td class="patent-data-table-td patent-date-value">Nov 4, 2002</td><td class="patent-data-table-td patent-date-value">Jun 12, 2003</td><td class="patent-data-table-td ">BRIDON Dominique P.</td><td class="patent-data-table-td ">Antidiabetic agents</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US20030170250">US20030170250</a></td><td class="patent-data-table-td patent-date-value">May 20, 2002</td><td class="patent-data-table-td patent-date-value">Sep 11, 2003</td><td class="patent-data-table-td ">Ezrin Alan M.</td><td class="patent-data-table-td ">Wound healing agent, antibiotic, antiinflammatory, antioxidant, antiproliferative, immunosuppressant, or anticancer agent linked to an entity covalently reactive with a functionality on fixed blood components</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US20030232754">US20030232754</a></td><td class="patent-data-table-td patent-date-value">Mar 6, 2003</td><td class="patent-data-table-td patent-date-value">Dec 18, 2003</td><td class="patent-data-table-td ">Holst Jens Juul</td><td class="patent-data-table-td ">Use of GLP-1 peptides</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US20040053819">US20040053819</a></td><td class="patent-data-table-td patent-date-value">Dec 7, 2001</td><td class="patent-data-table-td patent-date-value">Mar 18, 2004</td><td class="patent-data-table-td ">Dodd Steven Witt</td><td class="patent-data-table-td ">Normalizing blood glucose levels by maintaining chronic steady state plasma levels of 60-200 picomoles/liter; subcutaneous injection 1-2 times every 24 hours</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US20040127398">US20040127398</a></td><td class="patent-data-table-td patent-date-value">Nov 25, 2003</td><td class="patent-data-table-td patent-date-value">Jul 1, 2004</td><td class="patent-data-table-td ">Conjuchem, Inc.</td><td class="patent-data-table-td ">Long lasting synthetic glucagon like peptide (GLP-1)</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US20040138100">US20040138100</a></td><td class="patent-data-table-td patent-date-value">Nov 25, 2003</td><td class="patent-data-table-td patent-date-value">Jul 15, 2004</td><td class="patent-data-table-td ">Conjuchem, Inc.</td><td class="patent-data-table-td ">biochemical conjugates comprising protein carriers such as albumin complexed with peptides that stimulate the biosynthesis or gene expression of insulin, used as sustained release agents for prophylaxis of metabolic disorders; bioavailability</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US20040156859">US20040156859</a></td><td class="patent-data-table-td patent-date-value">Jan 12, 2004</td><td class="patent-data-table-td patent-date-value">Aug 12, 2004</td><td class="patent-data-table-td ">Conjuchem, Inc.</td><td class="patent-data-table-td ">GP-41 peptides, BBB peptides, anticancer agents, antihistamines, bronchodilators, hypotensive agents, antiangina agents, opioids, analgesics, antidepressants, and hypothyroid agents reactive with amino, hydroxyl or thiol groups</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US20040248782">US20040248782</a></td><td class="patent-data-table-td patent-date-value">Feb 15, 2002</td><td class="patent-data-table-td patent-date-value">Dec 9, 2004</td><td class="patent-data-table-td ">BRIDON Dominique P.</td><td class="patent-data-table-td ">Long lasting glucagon-like peptide2(glp-2)for the treatment of gastrointestinal diseases and disorders</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US20040266673">US20040266673</a></td><td class="patent-data-table-td patent-date-value">Jul 29, 2003</td><td class="patent-data-table-td patent-date-value">Dec 30, 2004</td><td class="patent-data-table-td ">Peter Bakis</td><td class="patent-data-table-td ">Cardiovascular disorders; congestive heart failure</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US20050037974">US20050037974</a></td><td class="patent-data-table-td patent-date-value">Sep 2, 2004</td><td class="patent-data-table-td patent-date-value">Feb 17, 2005</td><td class="patent-data-table-td ">Conjuchem, Inc.</td><td class="patent-data-table-td ">E-Ca R Cb-A, in which E is a diagnostic agent, R is a reactive group, Cb and Ca are optional first and second connecting groups, and A is an affinity group that is any molecule or part of a molecule possessing specific binding determinants for a target molecule</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US20050065075">US20050065075</a></td><td class="patent-data-table-td patent-date-value">May 31, 2002</td><td class="patent-data-table-td patent-date-value">Mar 24, 2005</td><td class="patent-data-table-td ">Erickson John W.</td><td class="patent-data-table-td ">Viricides; respiratory synctia virus; parainfluenza virus; simian immunodeficiency virus; complexing drug to blood component; immobilization; storage stability</td></tr></table><div class="patent-section-footer">* Cited by examiner</div></div><div class="patent-section patent-tabular-section"><a id="npl-citations"></a><div class="patent-section-header"><span class="patent-section-title">Non-Patent Citations</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th colspan="3"class="patent-data-table-th">Reference</th></tr></thead><tr><td class="patent-data-table-td ">1</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Akil et al., "<a href='http://scholar.google.com/scholar?q="Endogenous+Opioids%3A+Biology+and+Function%2C"'>Endogenous Opioids: Biology and Function,</a>" Ann. Rev. Neurosci., 7:223-255 (1984).</td></tr><tr><td class="patent-data-table-td ">2</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Barragan et al., "<a href='http://scholar.google.com/scholar?q="Interactions+of+exendin-%289-39%29+with+the+Effects+of+Glucagon-like+Peptide-1-%287-36%29+Amide+and+of+Exendin-4+on+Arterial+Blood+Pressure+and+Heart+Rate+in+Rats%2C"'>Interactions of exendin-(9-39) with the Effects of Glucagon-like Peptide-1-(7-36) Amide and of Exendin-4 on Arterial Blood Pressure and Heart Rate in Rats,</a>" Regulatory Peptides, 67:63-68 (1996).</td></tr><tr><td class="patent-data-table-td ">3</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Bell et al., "<a href='http://scholar.google.com/scholar?q="Hamster+Preproglucagon+Contains+the+Sequence+of+Glucagon+and+Two+Related+Peptides%2C"'>Hamster Preproglucagon Contains the Sequence of Glucagon and Two Related Peptides,</a>" Nature, 302:716-718 (1983).</td></tr><tr><td class="patent-data-table-td ">4</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Benhar et al., "<a href='http://scholar.google.com/scholar?q="Pseudomonas+Exotoxin+A+Mutants%2C"'>Pseudomonas Exotoxin A Mutants,</a>" J. Biol. Chem., 269(18):13398-13404 (1994).</td></tr><tr><td class="patent-data-table-td ">5</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Bergmann et al., "<a href='http://scholar.google.com/scholar?q="Cationized+Serum+Albumin+Enhances+Response+of+Cultured+Fetal+Rat+Long+Bones+to+Parathyroid+Hormone%2C"'>Cationized Serum Albumin Enhances Response of Cultured Fetal Rat Long Bones to Parathyroid Hormone,</a>" Endocrinology, 116(5):1729-1733 (1985).</td></tr><tr><td class="patent-data-table-td ">6</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Bhargava et al., "<a href='http://scholar.google.com/scholar?q="Immobilization+of+Active+Urokinase+on+Albumin+Microspheres%3A+Use+of+a+Chemical+Dehydrant+and+Process+Monitoring%2C"'>Immobilization of Active Urokinase on Albumin Microspheres: Use of a Chemical Dehydrant and Process Monitoring,</a>" Pharmaceutical Research, 9(6):776-781 (1992).</td></tr><tr><td class="patent-data-table-td ">7</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Breton et al., "<a href='http://scholar.google.com/scholar?q="Prolonged+Half-Life+in+the+Circulation+of+a+Chemical+Conjugate+Between+a+Pro-Urokinase+Derivative+and+Human+Serum+Albumin%2C"'>Prolonged Half-Life in the Circulation of a Chemical Conjugate Between a Pro-Urokinase Derivative and Human Serum Albumin,</a>" Eur. J. Biochem., 231(3):563-569 (1995).</td></tr><tr><td class="patent-data-table-td ">8</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Calara et al., "<a href='http://scholar.google.com/scholar?q="A+Randomized%2C+Open-Label%2C+Crossover+Study+Examining+the+Effect+of+Injection+Site+on+Bioavailability+of+Exentide+%28Synthetic+Exendin-4%29%2C"'>A Randomized, Open-Label, Crossover Study Examining the Effect of Injection Site on Bioavailability of Exentide (Synthetic Exendin-4),</a>" Clin. Ther., 27(2):210-214 (2005).</td></tr><tr><td class="patent-data-table-td ">9</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Davis et al., "<a href='http://scholar.google.com/scholar?q="Reduction+of+immunogenicity+and+Extension+of+Circulating+Half-Life+of+Peptides+Proteins%2C"'>Reduction of immunogenicity and Extension of Circulating Half-Life of Peptides Proteins,</a>" Peptide and Protein Drug Delivery, Lee, V. H. L., ed., Marcel Dekker, Inc., NY, NY; 831-864 (1991).</td></tr><tr><td class="patent-data-table-td ">10</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Delgado et al., "<a href='http://scholar.google.com/scholar?q="The+Uses+and+Properties+of+PEG-Linked+Proteins%2C"'>The Uses and Properties of PEG-Linked Proteins,</a>" Critical Reviews in Therapeutic Drug Carrier Systems, 9(3,4):249-304 (1992).</td></tr><tr><td class="patent-data-table-td ">11</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Dias-Cabral, A.C. et al. (2003) "<a href='http://scholar.google.com/scholar?q="Effect+of+salts+and+temperature+on+the+adsorption+of+bovine+serum+albumin+on+polypropylene+glycol-Sepharose+under+linear+and+overloaded+chromatographic+conditions%2C"'>Effect of salts and temperature on the adsorption of bovine serum albumin on polypropylene glycol-Sepharose under linear and overloaded chromatographic conditions,</a>" Journal of Chromatography, 1018: 137-153.</td></tr><tr><td class="patent-data-table-td ">12</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Drucker, "<a href='http://scholar.google.com/scholar?q="Perspectives+in+Diabetes%2C"'>Perspectives in Diabetes,</a>" Diabetes, 47(2):159-169 (Feb. 1998).</td></tr><tr><td class="patent-data-table-td ">13</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Edwards et al., "<a href='http://scholar.google.com/scholar?q="Exendin-4+Reduces+Fasting+and+Postprandial+Glucose+and+Decreases+Energy+Intake+in+Healthy+Voluneers%2C"'>Exendin-4 Reduces Fasting and Postprandial Glucose and Decreases Energy Intake in Healthy Voluneers,</a>" Am. J. Physiol. Endocrinol. Metab., 281:E155-E161 (2001).</td></tr><tr><td class="patent-data-table-td ">14</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Edwards et al., "<a href='http://scholar.google.com/scholar?q="Glucagon-like+Peptide+1+Has+a+Physiological+Role+in+the+Control+of+Postprandial+Glucose+in+Humans%2C"'>Glucagon-like Peptide 1 Has a Physiological Role in the Control of Postprandial Glucose in Humans,</a>" Diabetes, 48:86-93 (1999).</td></tr><tr><td class="patent-data-table-td ">15</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Eng et al., "<a href='http://scholar.google.com/scholar?q="Prolonged+Effect+of+Exendin-4+on+Hyperglycemia+of+db%2Fdb+Mice%2C"'>Prolonged Effect of Exendin-4 on Hyperglycemia of db/db Mice,</a>" J. Biol. Chem., 267(11):7402-7405 (1992).</td></tr><tr><td class="patent-data-table-td ">16</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Eng, "<a href='http://scholar.google.com/scholar?q="Isolation+and+Characterization+of+Exendin-4%2C+an+Exendin-3+Analogue%2C+from+Heloderma+suspecum+Venom%2C"'>Isolation and Characterization of Exendin-4, an Exendin-3 Analogue, from Heloderma suspecum Venom,</a>" Diabetes, 45:152A (abstract 554) (1996).</td></tr><tr><td class="patent-data-table-td ">17</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Foa et al., "<a href='http://scholar.google.com/scholar?q="Glucagon+and+Other+Products+of+the+Proglucagon+Gene%3A+Physiology+and+Possible+Role+in+the+Pathogenesis+of+Disease%2C"'>Glucagon and Other Products of the Proglucagon Gene: Physiology and Possible Role in the Pathogenesis of Disease,</a>" Giomale Italiano Di Diabetologia, 11:(Supplemental)1-42 (1991).</td></tr><tr><td class="patent-data-table-td ">18</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Francis et al., "<a href='http://scholar.google.com/scholar?q="PEGylation+of+Cytokines+and+other+Therapeutic+Proteins+and+Peptides%3A+The+Importance+of+Biological+Optimisation+of+Coupling+Techniques%2C"'>PEGylation of Cytokines and other Therapeutic Proteins and Peptides: The Importance of Biological Optimisation of Coupling Techniques,</a>" International Journal of Hematology, 68:1-18 (1998).</td></tr><tr><td class="patent-data-table-td ">19</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Gombotz et al., "<a href='http://scholar.google.com/scholar?q="Biodegradable+Polymers+for+Protein+and+Peptide+Drug+Delivery%2C"'>Biodegradable Polymers for Protein and Peptide Drug Delivery,</a>" Bioconjug. Chem., 6:332-351 (1995).</td></tr><tr><td class="patent-data-table-td ">20</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Goodson et al., "<a href='http://scholar.google.com/scholar?q="Site-Directed+Pegylation+of+Recombinant+Interleukin-2+at+Its+Glycosylation+Site%2C"'>Site-Directed Pegylation of Recombinant Interleukin-2 at Its Glycosylation Site,</a>" Bio/Technology, 8:343-346 (1990).</td></tr><tr><td class="patent-data-table-td ">21</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Goosen, "<a href='http://scholar.google.com/scholar?q="Optimization+of+Microencapsulation+Parameters%3A+Semipermeable+Microcapsules+as+a+Bioartificial+Pancreas%2C"'>Optimization of Microencapsulation Parameters: Semipermeable Microcapsules as a Bioartificial Pancreas,</a>" Biotechnology and Bioengineering, XXVII:146-150 (1985).</td></tr><tr><td class="patent-data-table-td ">22</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Heinrich et al., "<a href='http://scholar.google.com/scholar?q="Pre-proglucagon+Messenger+Ribonucleic+Acid%3A+Nucleotide+and+Encoded+Amino+Acid+Sequences+of+the+Rat+Pancreatic+Complementary+Deoxyribonucleic+Acid%2C"'>Pre-proglucagon Messenger Ribonucleic Acid: Nucleotide and Encoded Amino Acid Sequences of the Rat Pancreatic Complementary Deoxyribonucleic Acid,</a>" Endocrinology, 115:2176-2181 (1984).</td></tr><tr><td class="patent-data-table-td ">23</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Hirai et al., "<a href='http://scholar.google.com/scholar?q="A+New+Mast+Cell+Degranulating+Peptide+%22mastoparan%22+in+the+Venom+of+Vespula+lewisii%2C"'>A New Mast Cell Degranulating Peptide "mastoparan" in the Venom of Vespula lewisii,</a>" Chem. Pharm. Bull., 27(8):1942-1944 (1979).</td></tr><tr><td class="patent-data-table-td ">24</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Holmes, Darren L. et al. (2000) "<a href='http://scholar.google.com/scholar?q="Site+Specific+1%3A1+Opoid%3AAlbumin+conjugate+with+in+Vitro+Activity+and+Long+in+Vivo+Duration%2C"'>Site Specific 1:1 Opoid:Albumin conjugate with in Vitro Activity and Long in Vivo Duration,</a>" Bioconjugate Chemistry, 11(4): 439-444.</td></tr><tr><td class="patent-data-table-td ">25</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Hupe-Sodmann et al., "<a href='http://scholar.google.com/scholar?q="Endoproteolysis+of+Glucagon-like+Peptide+%28GLP%29-1%287-36%29+amide+by+Ectopeptidases+in+RINm5F+Cells%2C"'>Endoproteolysis of Glucagon-like Peptide (GLP)-1(7-36) amide by Ectopeptidases in RINm5F Cells,</a>" Peptides, 18(5):625-632 (1997).</td></tr><tr><td class="patent-data-table-td ">26</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Ishikawa et al., "<a href='http://scholar.google.com/scholar?q="Enzyme-Labeling+with+Maleimides+and+Its+Application+to+the+Immunoassay+of+Peptide+Hormones%2C"'>Enzyme-Labeling with Maleimides and Its Application to the Immunoassay of Peptide Hormones,</a>" Enzyme-Labeled Immunoassay of Hormones and Drugs, Walter deGruyter &amp; Co., Berlin, New York, pp. 43-57 (Oct. 7, 1978).</td></tr><tr><td class="patent-data-table-td ">27</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Isoai et al., "<a href='http://scholar.google.com/scholar?q="A+Potent+Anti-Metastatic+Activity+of+Tumor+Invasion-Inhibiting+Factor-2+and+Albumin+Conjugate%2C"'>A Potent Anti-Metastatic Activity of Tumor Invasion-Inhibiting Factor-2 and Albumin Conjugate,</a>" Biochem. Biophys. Res. Commun., 192(1):7-14 (1993).</td></tr><tr><td class="patent-data-table-td ">28</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Jette, Lucie et al. (2005) "<a href='http://scholar.google.com/scholar?q="Human+Growth+Hormone-Release+Factor+%28hGRF%291-29-+Albumin+Bioconjugates+Activate+the+GRF+Receptor+on+the+Anterior+Pituitary+in+Rats%3A+Indentification+of+CJC-1295+as+a+Long-Lasting+GRF+Analog%2C"'>Human Growth Hormone-Release Factor (hGRF)1-29- Albumin Bioconjugates Activate the GRF Receptor on the Anterior Pituitary in Rats: Indentification of CJC-1295 as a Long-Lasting GRF Analog,</a>" Endocrinilogy, 146(7): 3052-3058.</td></tr><tr><td class="patent-data-table-td ">29</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Kapas et al., "<a href='http://scholar.google.com/scholar?q="Cloning+and+Expression+of+cDNA+Encoding+a+Rat+Adrenomedullin+Receptor%2C"'>Cloning and Expression of cDNA Encoding a Rat Adrenomedullin Receptor,</a>" J. Biol. Chem., 270(43):25344-25347 (1995).</td></tr><tr><td class="patent-data-table-td ">30</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Knusli et al., "<a href='http://scholar.google.com/scholar?q="Polyethylene+Glycol+%28PEG%29+Modification+of+Granulocyte+Macrophage+Colony+Stimulating+Factor+%28GM-CSF%29+Enhances+Neutrophil+Priming+Activity+but+not+Colony+Stimulating+Activity%2C"'>Polyethylene Glycol (PEG) Modification of Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Enhances Neutrophil Priming Activity but not Colony Stimulating Activity,</a>" British Journal of Haematology, 82:654-663 (1992).</td></tr><tr><td class="patent-data-table-td ">31</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Kolodny et al., "<a href='http://scholar.google.com/scholar?q="A+Conjugation+of+Synthetic+Peptides+to+Proteins%3A+Quantitation+from+S-Carboxymethylcysteine+Released+Upn+Acid+Hydrolysis%2C"'>A Conjugation of Synthetic Peptides to Proteins: Quantitation from S-Carboxymethylcysteine Released Upn Acid Hydrolysis,</a>" Analytical Biochemistry, 187:136-140 (1990).</td></tr><tr><td class="patent-data-table-td ">32</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Leger, Roger et al. (2003) "<a href='http://scholar.google.com/scholar?q="Synthesis+and+in+Vitro+Analysis+of+Atrial+Natriuretic+Peptide-Albumin+Conjugates%2C"'>Synthesis and in Vitro Analysis of Atrial Natriuretic Peptide-Albumin Conjugates,</a>" Bioorganic &amp; Medicinal Chemistry Letters 13: 3571-3575.</td></tr><tr><td class="patent-data-table-td ">33</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Leger, Roger et al. (2004) "<a href='http://scholar.google.com/scholar?q="Identification+of+CJC-1131-albumin+bioconjugate+as+a+stable+and+bioactive+GLP-1%287-36%29+analog%2C"'>Identification of CJC-1131-albumin bioconjugate as a stable and bioactive GLP-1(7-36) analog,</a>" Bioorganic &amp; Medicinal Chemistry Letters, 14: 4395-4398.</td></tr><tr><td class="patent-data-table-td ">34</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Lopez et al., "<a href='http://scholar.google.com/scholar?q="Mammalian+Pancreatic+Preproglucagon+Contains+Three+Glucagon-related+Peptides%2C"'>Mammalian Pancreatic Preproglucagon Contains Three Glucagon-related Peptides,</a>" Proc. Natl. Acad. Sci. USA, 80:5485-5489 (1983).</td></tr><tr><td class="patent-data-table-td ">35</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Mao et al., "<a href='http://scholar.google.com/scholar?q="Superoxide+Dismutase%3A+Improving+Its+Pharmacological+Properties+by+Conjugation+with+Human+Serum+Albumin%2C"'>Superoxide Dismutase: Improving Its Pharmacological Properties by Conjugation with Human Serum Albumin,</a>" Biomat. Art. Cells, Art. Org., 17(3):229-244 (1989).</td></tr><tr><td class="patent-data-table-td ">36</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Marburg et al., "<a href='http://scholar.google.com/scholar?q="Introduction+of+the+Maleimide+Function+onto+Resin-Bound+Peptides%3A+A+Simple%2C+High+Yield+Process+Useful+for+Discriminating+among+Several+Lysines%2C"'>Introduction of the Maleimide Function onto Resin-Bound Peptides: A Simple, High Yield Process Useful for Discriminating among Several Lysines,</a>" Bioconjug. Chem., 7:612-616 (1996).</td></tr><tr><td class="patent-data-table-td ">37</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Mariani, Massimo et al. (Sep. 1998) "<a href='http://scholar.google.com/scholar?q="A+Competitive+Enzyme-Linked+Immunosorbent+Assay+for+Measuring+the+Levels+of+Serum+Antibody+to+Haemophilus+influenzae+Type+b%2C"'>A Competitive Enzyme-Linked Immunosorbent Assay for Measuring the Levels of Serum Antibody to Haemophilus influenzae Type b,</a>" Clinical and Diagnostic Laboratory Immunology, 5(5): 667-674.</td></tr><tr><td class="patent-data-table-td ">38</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Meurer et al., "<a href='http://scholar.google.com/scholar?q="Properties+of+Native+and+In+Vitro+Glycosylated+Forms+of+the+Glucagon-like+Peptide-1+Receptor+Antagonist+Exendin+%289-39%29%2C"'>Properties of Native and In Vitro Glycosylated Forms of the Glucagon-like Peptide-1 Receptor Antagonist Exendin (9-39),</a>"Metabolism, 48(6):716-724 (1999).</td></tr><tr><td class="patent-data-table-td ">39</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Mumby et al., "<a href='http://scholar.google.com/scholar?q="Antisera+of+Designed+Specificity+for+Subunits+of+Guanine+Nucleotide-binding+Regulatory+Proteins%2C"'>Antisera of Designed Specificity for Subunits of Guanine Nucleotide-binding Regulatory Proteins,</a>" Proc. Natl. Acad. Sci., 83:265-269 (1986).</td></tr><tr><td class="patent-data-table-td ">40</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Oren et al., "<a href='http://scholar.google.com/scholar?q="Mode+of+Action+of+Linear+Amphipathic+alpha-Helical+Antimicrobial+Peptides%2C"'>Mode of Action of Linear Amphipathic alpha-Helical Antimicrobial Peptides,</a>" Biopolymers (Peptide Science), 47:451-463 (1998).</td></tr><tr><td class="patent-data-table-td ">41</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Paige et al., "<a href='http://scholar.google.com/scholar?q="Prolonged+Circulation+of+Recombinant+Human+Granulocyte-Colony+Stimulating+Factor+by+Covalent+Linkage+to+Albumin+Through+a+Heterobifunctional+Polyethylene+Glycol%2C"'>Prolonged Circulation of Recombinant Human Granulocyte-Colony Stimulating Factor by Covalent Linkage to Albumin Through a Heterobifunctional Polyethylene Glycol,</a>" Pharm. Res., 12(12): 1883-1888 (1995).</td></tr><tr><td class="patent-data-table-td ">42</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Patrias et al., "<a href='http://scholar.google.com/scholar?q="Trimethylaminuria+%28Fish-Malodor+Syndrome%29+and+the+Flavin+Monooxygenases%2C"'>Trimethylaminuria (Fish-Malodor Syndrome) and the Flavin Monooxygenases,</a>" Biotech Report, 106-107 (1994/1995).</td></tr><tr><td class="patent-data-table-td ">43</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Poznansky et al., "<a href='http://scholar.google.com/scholar?q="Growth+Hormone-Albumin+Conjugates+Reduced+Renal+Toxicity+and+Altered+Plasma+Clearance%2C"'>Growth Hormone-Albumin Conjugates Reduced Renal Toxicity and Altered Plasma Clearance,</a>" FEBS Letters, 239(1):18-22 (1988).</td></tr><tr><td class="patent-data-table-td ">44</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Poznansky, "<a href='http://scholar.google.com/scholar?q="Enzyme-Protein+Conjugates%3A+New+Possibilities+for+Enzyme+Therapy%2C"'>Enzyme-Protein Conjugates: New Possibilities for Enzyme Therapy,</a>" Pharmac. Ther., 21:53-76 (1983).</td></tr><tr><td class="patent-data-table-td ">45</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Qu et al., "<a href='http://scholar.google.com/scholar?q="A+Role+for+Melanin-Concentrating+Hormone+in+the+Central+Regulation+of+Feeding+Behaviour%2C"'>A Role for Melanin-Concentrating Hormone in the Central Regulation of Feeding Behaviour,</a>" Nature, 380:243-247 (1996).</td></tr><tr><td class="patent-data-table-td ">46</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Raufman, "<a href='http://scholar.google.com/scholar?q="Bioactive+Peptides+from+Lizard+Venoms%2C"'>Bioactive Peptides from Lizard Venoms,</a>" Regulatory Peptides, 61:1-18 (1996).</td></tr><tr><td class="patent-data-table-td ">47</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Reubi et al., "<a href='http://scholar.google.com/scholar?q="Specific+High+Affinity+Binding+Sites+for+Somatostatin-28+on+Pancreatic+beta-Cells%3A+Differences+with+Brain+Somatostatin+Receptors%2C"'>Specific High Affinity Binding Sites for Somatostatin-28 on Pancreatic beta-Cells: Differences with Brain Somatostatin Receptors,</a>" Endocrinology, 110(3):1049-1051 (1982).</td></tr><tr><td class="patent-data-table-td ">48</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Ringsdorf, "<a href='http://scholar.google.com/scholar?q="Structure+and+Properties+of+Pharmacologically+Active+Polymers%2C"'>Structure and Properties of Pharmacologically Active Polymers,</a>" J. Polymer Sci. Symposium No. 51, pp. 135-153 (1975).</td></tr><tr><td class="patent-data-table-td ">49</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Ritzel et al., "<a href='http://scholar.google.com/scholar?q="A+Synthetic+Glucagon-like+Peptide-1+Analog+with+Improved+Plasma+Stability%2C"'>A Synthetic Glucagon-like Peptide-1 Analog with Improved Plasma Stability,</a>" Journal of Endocrinology, 159:93-102 (1998).</td></tr><tr><td class="patent-data-table-td ">50</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Robberecht et al., "<a href='http://scholar.google.com/scholar?q="Immunoreactive+Helodermin-like+Peptides+in+Rat%3A+A+New+Class+of+Mammalian+Neuropeptides+Related+to+Secretin+and+VIP%2C"'>Immunoreactive Helodermin-like Peptides in Rat: A New Class of Mammalian Neuropeptides Related to Secretin and VIP,</a>" Biochem. Biophys. Res. Commun., 130(1):333-342 (1985).</td></tr><tr><td class="patent-data-table-td ">51</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Ruiz-Grande et al., "<a href='http://scholar.google.com/scholar?q="Lipolytic+Action+of+Glucagon-like+Peptides+in+Isolated+Rat+Adipocytes%2C"'>Lipolytic Action of Glucagon-like Peptides in Isolated Rat Adipocytes,</a>" Peptides, 13(1)13-16 (1992).</td></tr><tr><td class="patent-data-table-td ">52</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Santiago, "<a href='http://scholar.google.com/scholar?q="Incidence+of+IDDM+and+Frequency+of+the+DQbeta1+and+DQalpha1%2C"'>Incidence of IDDM and Frequency of the DQbeta1 and DQalpha1,</a>" Diabetes, Abstract book, 56&lt;SUP&gt;th &lt;/SUP&gt;Annual Meeting and Scientific Sessions, 847 (Jun. 8-11, 1996).</td></tr><tr><td class="patent-data-table-td ">53</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Schirra et al., "<a href='http://scholar.google.com/scholar?q="Exendin%289-39%29amide+is+an+Antagonist+of+Glucagon-like+Peptide-1%287-36%29amide+in+Humans%2C"'>Exendin(9-39)amide is an Antagonist of Glucagon-like Peptide-1(7-36)amide in Humans,</a>" J. Clin. Invest., 101(7):1421-1430 (1998).</td></tr><tr><td class="patent-data-table-td ">54</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Selkoe, "<a href='http://scholar.google.com/scholar?q="Physiological+Production+of+the+beta-Amyloid+Protein+and+the+Mechanism+of+Alzheimer%27s+Disease%2C"'>Physiological Production of the beta-Amyloid Protein and the Mechanism of Alzheimer's Disease,</a>" TINS, 16(10):403-409 (1993).</td></tr><tr><td class="patent-data-table-td ">55</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Siegel et al., "<a href='http://scholar.google.com/scholar?q="Biological+Activity+of+GLP-1+Analogues+with+N-Terminal+Modifications%2C"'>Biological Activity of GLP-1 Analogues with N-Terminal Modifications,</a>" Regulatory Peptides, 79(23):93-102 (1999).</td></tr><tr><td class="patent-data-table-td ">56</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Smith et al., "<a href='http://scholar.google.com/scholar?q="Atrial+Natriuretic+Factor+During+Fetal+and+Postnatal+Life%3A+A+Review%2C"'>Atrial Natriuretic Factor During Fetal and Postnatal Life: A Review,</a>" J. Dev. Physiol., 12:55-62 (1989).</td></tr><tr><td class="patent-data-table-td ">57</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Stehle et al., "<a href='http://scholar.google.com/scholar?q="The+Loading+Rate+Determines+Tumor+Targeting+Properties+of+Methotrexate-Albumin+Conjugates+in+Rats%2C"'>The Loading Rate Determines Tumor Targeting Properties of Methotrexate-Albumin Conjugates in Rats,</a>" Anti-Cancer Drugs, 8:677-685 (1997).</td></tr><tr><td class="patent-data-table-td ">58</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Syed et al., "<a href='http://scholar.google.com/scholar?q="Potent+Antithrombin+Activity+and+Delayed+Clearance+from+the+Circulation+Characterize+Recombinant+Hirudin+Genetically+Fused+to+Albumin%2C"'>Potent Antithrombin Activity and Delayed Clearance from the Circulation Characterize Recombinant Hirudin Genetically Fused to Albumin,</a>" Blood, 89(9):3243-3252 (1997).</td></tr><tr><td class="patent-data-table-td ">59</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Thibaudeau, Karen et al. (2005) "<a href='http://scholar.google.com/scholar?q="Synthesis+and+Evaluation+of+Insulin-Human+Serum+Albumin+Conjugates%2C"'>Synthesis and Evaluation of Insulin-Human Serum Albumin Conjugates,</a>" Bioconjugate Chem., 16: 1000-1008.</td></tr><tr><td class="patent-data-table-td ">60</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Thim et al., "<a href='http://scholar.google.com/scholar?q="Molecules+in+Focus%3A+CART%2C+a+New+Anorectic+Peptide%2C"'>Molecules in Focus: CART, a New Anorectic Peptide,</a>" Int. J. Biochem. Cell. Biol., 30:1281-1284 (1998).</td></tr><tr><td class="patent-data-table-td ">61</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Turton et al., "<a href='http://scholar.google.com/scholar?q="A+Role+for+Glucagon-like-Peptide-1+in+the+Central+Regulation+of+Feeding%2C"'>A Role for Glucagon-like-Peptide-1 in the Central Regulation of Feeding,</a>" Nature, 379:69-72 (1996).</td></tr><tr><td class="patent-data-table-td ">62</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">U.S. Appl. No. 09/623,533, filed Sep. 5, 2000, Boudjellab et al.</td></tr><tr><td class="patent-data-table-td ">63</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">U.S. Appl. No. 09/623,533, filed Sep. 5, 2000, Bridon et al.</td></tr><tr><td class="patent-data-table-td ">64</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">U.S. Appl. No. 09/623,543, filed Sep. 5, 2000, Beliveau et al.</td></tr><tr><td class="patent-data-table-td ">65</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">U.S. Appl. No. 09/623,543, filed Sep. 5, 2000, Bridon et al.</td></tr><tr><td class="patent-data-table-td ">66</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">U.S. Appl. No. 09/657,336, filed Sep. 7, 2000, Boudjellab et al.</td></tr><tr><td class="patent-data-table-td ">67</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">U.S. Appl. No. 09/657,431, filed Sep. 7, 2000, Beliveau et al.</td></tr><tr><td class="patent-data-table-td ">68</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">U.S. Appl. No. 11/040,810, filed Jan. 21, 2005, Bakis et al.</td></tr><tr><td class="patent-data-table-td ">69</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">U.S. Appl. No. 11/066,697, filed Feb. 25, 2005, Bridon et al.</td></tr><tr><td class="patent-data-table-td ">70</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">U.S. Appl. No. 11/067,556, filed Feb. 25, 2005, Bidon et al.</td></tr><tr><td class="patent-data-table-td ">71</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Vilaseca et al., "<a href='http://scholar.google.com/scholar?q="Proteins+Conjugates+of+Defined+Structure%3A+Synthesis+and+Use+of+a+New+Carrier+Molecule%2C"'>Proteins Conjugates of Defined Structure: Synthesis and Use of a New Carrier Molecule,</a>" Bioconjug. Chem., 4:515-520 (1993).</td></tr><tr><td class="patent-data-table-td ">72</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Yeh et al., "<a href='http://scholar.google.com/scholar?q="Design+of+Yeast-Secreted+Albumin+Derivatives+for+Human+Therapy%3A+Biological+and+Antiviral+Properties+of+a+Serum+Albumin-CD4+Genetic+Conjugate%2C"'>Design of Yeast-Secreted Albumin Derivatives for Human Therapy: Biological and Antiviral Properties of a Serum Albumin-CD4 Genetic Conjugate,</a>" Proc. Natl. Acad. Sci. USA, 89:1904-1908 (1992).</td></tr><tr><td class="patent-data-table-td ">73</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Young et al., "<a href='http://scholar.google.com/scholar?q="Glucose-Lowering+and+Insulin-Sensitizing+Actions+of+Exendin-4%2C"'>Glucose-Lowering and Insulin-Sensitizing Actions of Exendin-4,</a>" Diabetes, 48:1026-1034 (1999).</td></tr><tr><td class="patent-data-table-td ">74</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Zalipsky, "<a href='http://scholar.google.com/scholar?q="Functionalized+Poly%28ethylene+glycol%29+for+Preparation+of+Biologically+Relevent+Conjugates%2C"'>Functionalized Poly(ethylene glycol) for Preparation of Biologically Relevent Conjugates,</a>" Bioconjug. Chem., 6:150-165 (1995).</td></tr><tr><td class="patent-data-table-td ">75</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Zegers et al., "<a href='http://scholar.google.com/scholar?q="An+Improved+Conjugation+Method+for+Controlled+Covalent+Coupling+of+Synthetic+Peptides+to+Proteins+Using+Glutaraldehyde+in+a+Dialysis+Method%2C"'>An Improved Conjugation Method for Controlled Covalent Coupling of Synthetic Peptides to Proteins Using Glutaraldehyde in a Dialysis Method,</a>" Journal of Immunological Methods, 130:195-200 (1990).</td></tr></table><div class="patent-section-footer"></div></div><div class="patent-section patent-tabular-section"><a id="forward-citations"></a><div class="patent-section-header"><span class="patent-section-title">Referenced by</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th class="patent-data-table-th">Citing Patent</th><th class="patent-data-table-th">Filing date</th><th class="patent-data-table-th">Publication date</th><th class="patent-data-table-th">Applicant</th><th class="patent-data-table-th">Title</th></tr></thead><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7601691">US7601691</a></td><td class="patent-data-table-td patent-date-value">Feb 25, 2005</td><td class="patent-data-table-td patent-date-value">Oct 13, 2009</td><td class="patent-data-table-td ">Conjuchem Biotechnologies Inc.</td><td class="patent-data-table-td ">PYY peptide or a functional derivative, coupled to a reactive group( michael acceptor, maleimides or succnimides) capable of reacting on a blood component so as to form a stable covalent bond</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7608692">US7608692</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Apr 11, 2008</td><td class="patent-data-table-td patent-date-value">Oct 27, 2009</td><td class="patent-data-table-td ">Amylin Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">or exendin-4 agonists covalently bonded to albumin, polyethylene glycol, gelatin, (hydroxypropyl)-methacrylamide, a polyamino acid, fatty acid, polysaccharide, dextran to increase molecular size; diabetes, postprandial dumping syndrome, postprandial hyperglycemia, dyslipidemia, obesity; renal filtration</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7737251">US7737251</a></td><td class="patent-data-table-td patent-date-value">Dec 23, 2005</td><td class="patent-data-table-td patent-date-value">Jun 15, 2010</td><td class="patent-data-table-td ">Conjuchem Biotechnologies Inc.</td><td class="patent-data-table-td ">conjugates comprising blood proteins covalently coupled to a gastrointestinal tissue growth promoter derivatives, having an extended in vivo half-life, for the treatment or prevention of gastrointestinal disorders</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7741286">US7741286</a></td><td class="patent-data-table-td patent-date-value">Feb 8, 2006</td><td class="patent-data-table-td patent-date-value">Jun 22, 2010</td><td class="patent-data-table-td ">Conjuchem Biotechnologies Inc.</td><td class="patent-data-table-td ">kringle peptides; peptidase stabilized</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7741453">US7741453</a></td><td class="patent-data-table-td patent-date-value">May 31, 2002</td><td class="patent-data-table-td patent-date-value">Jun 22, 2010</td><td class="patent-data-table-td ">Conjuchem Biotechnologies, Inc.</td><td class="patent-data-table-td ">Viricides; respiratory synctia virus; parainfluenza virus; simian immunodeficiency virus; complexing drug to blood component; immobilization; storage stability</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7982018">US7982018</a></td><td class="patent-data-table-td patent-date-value">Oct 16, 2007</td><td class="patent-data-table-td patent-date-value">Jul 19, 2011</td><td class="patent-data-table-td ">Conjuchem, Llc</td><td class="patent-data-table-td ">conjugate urocortin polypeptide complexing with serum protein; increased in vivo half-life; cardiovascular disorder, stress or anxiety disorder, memory or learning disorder, obesity or anorexia eating disorder, decreasing body weight, glycemic control in gastrointestinal, modulating muscle mass</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8080516">US8080516</a></td><td class="patent-data-table-td patent-date-value">Jun 29, 2005</td><td class="patent-data-table-td patent-date-value">Dec 20, 2011</td><td class="patent-data-table-td ">Conjuchem, Llc</td><td class="patent-data-table-td ">Long lasting synthetic exendin-4 peptide conjugates</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8084414">US8084414</a></td><td class="patent-data-table-td patent-date-value">Aug 30, 2005</td><td class="patent-data-table-td patent-date-value">Dec 27, 2011</td><td class="patent-data-table-td ">Conjuchem, Llc</td><td class="patent-data-table-td ">Methods involving long lasting synthetic exendin-4-peptide conjugates</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8093206">US8093206</a></td><td class="patent-data-table-td patent-date-value">Dec 14, 2005</td><td class="patent-data-table-td patent-date-value">Jan 10, 2012</td><td class="patent-data-table-td ">Conjuchem, Llc</td><td class="patent-data-table-td ">Methods involving long lasting synthetic exendin-4 peptide conjugates</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2011064316A2?cl=en">WO2011064316A2</a></td><td class="patent-data-table-td patent-date-value">Nov 25, 2010</td><td class="patent-data-table-td patent-date-value">Jun 3, 2011</td><td class="patent-data-table-td ">Paolo Botti</td><td class="patent-data-table-td ">Mucosal delivery of peptides</td></tr></table><div class="patent-section-footer">* Cited by examiner</div></div><div class="patent-section patent-tabular-section"><a id="classifications"></a><div class="patent-section-header"><span class="patent-section-title">Classifications</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th class="patent-data-table-th"> </th><th class="patent-data-table-th"> </th></tr></thead><tr><td class="patent-data-table-td ">U.S. Classification</td><td class="patent-data-table-td "><span class="nested-value"><a href="http://www.google.com/url?id=F_Z_BAABERAJ&q=http://www.uspto.gov/web/patents/classification/uspc530/defs530.htm&usg=AFQjCNEOd3srpZKCSH0W93D5fiJ4_0S25w#C530S364000">530/364</a></span></td></tr><tr><td class="patent-data-table-td ">International Classification</td><td class="patent-data-table-td "><span class="nested-value"><a href="http://www.google.com/url?id=F_Z_BAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=B01D0015320000">B01D15/32</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=F_Z_BAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=B01D0015080000">B01D15/08</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=F_Z_BAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=C07K0014765000">C07K14/765</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=F_Z_BAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=C07K0001200000">C07K1/20</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=F_Z_BAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=C07K0014760000">C07K14/76</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=F_Z_BAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0047480000">A61K47/48</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=F_Z_BAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=C07K0019000000">C07K19/00</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=F_Z_BAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=B01D0015160000">B01D15/16</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=F_Z_BAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0047420000">A61K47/42</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=F_Z_BAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=C07K0001000000">C07K1/00</a></span></td></tr><tr><td class="patent-data-table-td ">Cooperative Classification</td><td class="patent-data-table-td "><span class="nested-value"><a href="http://www.google.com/url?id=F_Z_BAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=A61K47/48284">A61K47/48284</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=F_Z_BAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=B01D15/327">B01D15/327</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=F_Z_BAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=C07K14/76">C07K14/76</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=F_Z_BAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=C07K1/20">C07K1/20</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=F_Z_BAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=B01D15/166">B01D15/166</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=F_Z_BAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=C07K14/765">C07K14/765</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=F_Z_BAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=C07K1/303">C07K1/303</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=F_Z_BAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=B01D15/426">B01D15/426</a></span></td></tr><tr><td class="patent-data-table-td ">European Classification</td><td class="patent-data-table-td "><span class="nested-value">C07K1/20</span>, <span class="nested-value">C07K1/30A</span>, <span class="nested-value">C07K14/765</span>, <span class="nested-value">A61K47/48R2L</span>, <span class="nested-value">C07K14/76</span>, <span class="nested-value">B01D15/32R2</span></td></tr></table><div class="patent-section-footer"></div></div><div class="patent-section patent-tabular-section"><a id="legal-events"></a><div class="patent-section-header"><span class="patent-section-title">Legal Events</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th class="patent-data-table-th">Date</th><th class="patent-data-table-th">Code</th><th class="patent-data-table-th">Event</th><th class="patent-data-table-th">Description</th></tr></thead><tr><td class="patent-data-table-td patent-date-value">May 22, 2012</td><td class="patent-data-table-td ">B1</td><td class="patent-data-table-td ">Reexamination certificate first reexamination</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">CLAIMS 10, 13 AND 22 ARE CANCELLED. CLAIMS 1, 2, 11, 12, 14, 18, 23-25 AND 28 ARE DETERMINED TO BE PATENTABLE AS AMENDED. CLAIMS 3-9, 15-17, 19-21, 26 AND 27, DEPENDENT ON AN AMENDED CLAIM, ARE DETERMINED TO BE PATENTABLE. NEW CLAIMS 29-46 ARE ADDED AND DETERMINED TO BE PATENTABLE.</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Jun 13, 2011</td><td class="patent-data-table-td ">FPAY</td><td class="patent-data-table-td ">Fee payment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Year of fee payment: </span><span class="nested-value">4</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Apr 20, 2011</td><td class="patent-data-table-td ">AS</td><td class="patent-data-table-td ">Assignment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">CONJUCHEM, LLC, CALIFORNIA</span></div><div class="nested-key-value"><span class="nested-key">Effective date: </span><span class="nested-value">20110218</span></div><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ADVANCED DIAGNOSTICS AND DISCOVERY;REEL/FRAME:026157/0022</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Oct 26, 2010</td><td class="patent-data-table-td ">AS</td><td class="patent-data-table-td ">Assignment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">ADVANCED DIAGNOSTICS AND DISCOVERY, CALIFORNIA</span></div><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:CONJUCHEM BIOTECHNOLOGIES INC.;REEL/FRAME:025198/0735</span></div><div class="nested-key-value"><span class="nested-key">Effective date: </span><span class="nested-value">20100823</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Jul 12, 2010</td><td class="patent-data-table-td ">AS</td><td class="patent-data-table-td ">Assignment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Effective date: </span><span class="nested-value">20100707</span></div><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">4523482 CANADA INC. (CANADIAN CORPORATION NUMBER 4</span></div><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:CONJUCHEM BIOTECHNOLOGIES INC. (CANADIAN CORPORATION NUMBER 6513590);REEL/FRAME:24662/694</span></div><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">CHANGE OF NAME;ASSIGNOR:4523482 CANADA INC. (CANADIAN CORPORATION NUMBER 4523482);REEL/FRAME:24662/758</span></div><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">CONJUCHEM BIOTECHNOLOGIES INC.,CANADA</span></div><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:CONJUCHEM BIOTECHNOLOGIES INC. (CANADIAN CORPORATION NUMBER 6513590);REEL/FRAME:024662/0694</span></div><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">CONJUCHEM BIOTECHNOLOGIES INC., CANADA</span></div><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">CHANGE OF NAME;ASSIGNOR:4523482 CANADA INC. (CANADIAN CORPORATION NUMBER 4523482);REEL/FRAME:024662/0758</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">May 25, 2010</td><td class="patent-data-table-td ">RR</td><td class="patent-data-table-td ">Request for reexamination filed</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Effective date: </span><span class="nested-value">20100315</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">May 13, 2008</td><td class="patent-data-table-td ">CC</td><td class="patent-data-table-td ">Certificate of correction</td><td class="patent-data-table-td "></td></tr><tr><td class="patent-data-table-td patent-date-value">Aug 1, 2006</td><td class="patent-data-table-td ">AS</td><td class="patent-data-table-td ">Assignment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">CONJUCHEM BIOTECHNOLOGIES INC., CANADA</span></div><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:CONJUCHEM INC.;REEL/FRAME:018039/0669</span></div><div class="nested-key-value"><span class="nested-key">Effective date: </span><span class="nested-value">20060523</span></div><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:CONJUCHEM INC.;REEL/FRAME:18039/669</span></div><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">CONJUCHEM BIOTECHNOLOGIES INC.,CANADA</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Apr 22, 2005</td><td class="patent-data-table-td ">AS</td><td class="patent-data-table-td ">Assignment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">CONJUCHEM, INC., CANADA</span></div><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BUSQUET-GAGNON, NATHALIE;QURAISHI, OMAR;BRIDON, DOMONIQUE P.;REEL/FRAME:016498/0738;SIGNING DATES FROM 20050419 TO 20050420</span></div></td></tr></table><div class="patent-section-footer"></div></div><div class="modal-dialog" id="patent-images-lightbox"><div class="patent-lightbox-controls"><div class="patent-lightbox-rotate-controls"><div class="patent-lightbox-rotation-text">Rotate</div><div class="rotate-icon rotate-ccw-icon"></div><div class="rotate-icon rotate-cw-icon"></div></div><div class="patent-lightbox-index-counter"></div><a class="patent-lightbox-fullsize-link" target="_blank">Original Image</a><div class="patent-drawings-control patent-drawings-next"><img class="patent-drawings-button-img"src="/googlebooks/images/kennedy/page_right.png" alt="Next page"width="21" height="21" /></div><div class="patent-drawings-control patent-drawings-prev"><img class="patent-drawings-button-img"src="/googlebooks/images/kennedy/page_left.png" alt="Previous page"width="21" height="21" /></div></div><div class="modal-dialog-content"><div class="patent-lightbox-image-holder"><div class="patent-lightbox-placeholder"></div></div></div></div><script>_OC_initPatentsAtb({image_not_available_html: " Image not available"});</script></div></div></div></td></tr></table><script>(function() {var href = window.location.href;if (href.indexOf('?') !== -1) {var parameters = href.split('?')[1].split('&');for (var i = 0; i < parameters.length; i++) {var param = parameters[i].split('=');if (param[0] == 'focus') {var elem = document.getElementById(param[1]);if (elem) {elem.focus();}}}}})();</script><script>_OC_addFlags({LockSrc:"/books/javascript/lock_8a2b04e7bf975d5171d8e4c0b6365c7a.js", Host:"http://www.google.com/", IsBooksRentalEnabled:1, IsWebstoreDisplayCaseEnabled:1, IsObfuscationEnabled:1, IsBrowsingHistoryEnabled:1, IsWebReaderSvgEnabled:0, IsGeoLayerEnabled:1, IsImageModeNotesEnabled:1, IsCopyMenuItemEnabled:1, IsGiftingEnabled:0, IsWebReaderUniversalPaginatorEnabled:0, IsOfflineBubbleEnabled:1, IsReaderEnabledForPlayRequests:1, IsFutureOnSaleVolumesEnabled:1, IsOfflineRestrictedCopyEnabled:1, IsBooksUnifiedLeftNavEnabled:1, IsRestrictedCopyEnabled:1, IsZipitFolderCollectionEnabled:1, IsEndOfSampleRecommendationsEnabled:1, IsRatingsOnBookcardsEnabled:1, IsAdsDisabled:0, IsIframePageDisplayEnabled:0, IsEmbeddedMediaEnabled:1, IsImageModeAnnotationsEnabled:1, IsMyLibraryGooglePlusEnabled:1, IsImagePageProviderEnabled:0, IsBookcardListPriceSmall:0, IsInternalUser:0, IsBooksShareButtonEnabled:0, IsPreOrdersEnabled:0, IsDisabledRandomBookshelves:0, WebstoreDisplayCasePosition:3});_OC_Run({"enable_p13n":false,"add_vol_to_collection_base_url":"http://www.google.com/patents?op=add\u0026sig=ACfU3U1UVWw4enjwxDBcxsr9x0a1cCvdeg\u0026id=F_Z_BAABERAJ","remove_vol_from_collection_base_url":"http://www.google.com/patents?op=remove\u0026sig=ACfU3U0JdiUQ3w3Cu9A9l3cL04qLmC9TxQ\u0026id=F_Z_BAABERAJ","logged_in":false,"p13n_save_user_settings_url":"http://www.google.com/patents?op=edit_user_settings\u0026sig=ACfU3U1sCMdgPpuAH2-sdb3n5m7XBRUYEA","is_cobrand":false,"sign_in_url":"https://www.google.com/accounts/Login?service=\u0026continue=http://www.google.com/patents%3Fhl%3Den\u0026hl=en","is_play_enabled":true}, {"volume_id":"","is_ebook":true,"volumeresult":{"has_flowing_text":false,"has_scanned_text":true,"can_download_pdf":false,"can_download_epub":false,"is_pdf_drm_enabled":false,"is_epub_drm_enabled":false,"download_pdf_url":"http://www.google.com/patents/download/Method_for_purification_of_albumin_conju.pdf?id=F_Z_BAABERAJ\u0026output=pdf\u0026sig=ACfU3U1Mou26KfcJct5J9mvhM5DU1jsavQ"},"sample_url":"http://www.google.com/patents/reader?id=F_Z_BAABERAJ\u0026printsec=frontcover\u0026output=reader\u0026source=gbs_atb_hover","is_browsable":true,"is_public_domain":true}, {});</script><div id="footer_table" style="font-size:83%;text-align:center;position:relative;top:20px;height:4.5em;margin-top:2em"><div style="margin-bottom:8px"><a href=http://www.google.com/><nobr>Google&nbsp;Home</nobr></a> - <a href=//www.google.com/patents/sitemap/><nobr>Sitemap</nobr></a> - <a href=http://www.google.com/googlebooks/uspto.html><nobr>USPTO Bulk Downloads</nobr></a> - <a href=/intl/en/privacy/><nobr>Privacy Policy</nobr></a> - <a href=/intl/en/policies/terms/><nobr>Terms of Service</nobr></a> - <a href=https://support.google.com/faqs/answer/2539193?hl=en><nobr>About Google Patents</nobr></a> - <a href="http://www.google.com/tools/feedback/intl/en/error.html" onclick="try{_OC_startFeedback({productId: '72792',locale: 'en'});return false;}catch(e){}"><nobr>Send Feedback</nobr></a></div><span>Data provided by IFI CLAIMS Patent Services</span><br><span >&copy;2012 Google</span></div> <script type="text/javascript">var gaJsHost = (("https:" == document.location.protocol) ? "https://ssl." : "http://www.");document.write(unescape("%3Cscript src='" + gaJsHost + "google-analytics.com/ga.js' type='text/javascript'%3E%3C/script%3E"));</script><script type="text/javascript">var pageTracker = _gat._getTracker("UA-27188110-1");pageTracker._setCookiePath("/patents/");pageTracker._trackPageview();</script> </body></html>